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ABSTRACT
In silico approaches to nucleic acid targeted drug discovery have been used in order to 
study duplex DNA, in complexes with proteins as well as more unusual form of G-rich 
DNA folded into higher-order structures termed as G-quadruplexes, in complexes with 
therapeutic small molecules. The overall aim of this work has been to provide insight 
into the stability, recognition, energetics of binding and dynamic behavior of these 
DNAs in complexes with the STAT3βtc homodimer:DNA complex and with therapeutic 
small molecules in G-quadruplex/pyridostatin and G-quadruplex/fragment complexes 
by means of combined in silico approaches. The techniques of explicit solvent molecu-
lar dynamics (MD) simulations, and subsequent calculations of the free energies of 
binding, molecular docking, and 3D-pharmacophore modeling have been applied to 
study STAT3 and G-quadruplex DNA, promising targets for anticancer therapeutic in-
tervention.
 Analysis of the data obtained from multiple 50-ns MD simulations of the 
STAT3-DNA complexes has suggested how the transcription factor STAT3 interacts 
with duplex DNA, the nature of the conformational changes, and ways in which func-
tion may be affected. A majority of known pathologic mutations affecting the DNA-
biding region of the STAT3 have been found at the protein-DNA interface, and they 
have been mapped in detail. The STAT3 conformations obtained from these MD simula-
tions have been subsequently used as a basis for a comparative multiple-target molecu-
lar docking study with an in-house library  of potential STAT3 inhibitors, providing a 
rational of their binding in the absence of structural data.
 A novel “dynamic docking” approach (robust platform of numerous MD simula-
tions) has been developed to address the G-quadruplex receptor and ligand flexibility 
issue, and subsequent conformational change upon binding. The strength of binding at 
different regions and both sites of the G-quadruplex were then closely examined. An in 
silico study of a fragment-based approach towards G-quadruplex stabilizing ligands has 
also been explored, in parallel with experimental studies, to assess whether this could 
provide a reliable rapid approach to finding hit fragments in the case of the c-MYC 
promoter quadruplex.
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INTRODUCTION
 
“ D N A n e i t h e r  c a r e s  n o r  k n o w s .  D N A j u s t  i s .  A n d  w e  a l l  d a n c e  t o  i t s  m u s i c . ”
( R i c h a r d  D a w k i n s ) 
1
Watson and Crick with their DNA helix model in 1953
adapted from http://biologyinculture.wordpress.com
‘Overture’
The work described in this thesis is principally  focused on in silico studies of nucleic 
acid complexes with proteins, and therapeutic small molecules. Whereas the fundamen-
tal role of proteins in biological processes has been recognized for many years (as most 
human diseases have a protein-related foundation), the importance of folded DNA 
within the framework of these processes is only more recently coming into prominence.
Despite being relatively  young, both fields of molecular modeling (computational), and 
biomolecular structure determination (experimental) have undergone tremendous pro-
gress, since molecular mechanics developed around the same time that protein crystal-
lography  was coming to prominence, and the structure of the DNA was discovered by 
Watson, Crick, Franklin and Gosling.1-3 The discovery  of the elegant, yet simple DNA 
helix gave rise to molecular biology, and can be also seen as an imaginary  cross-
disciplinary  connection, that has led to the completion of the human genome sequencing 
project in 2007. Additionally, in silico simulations have provided even more details of 
the structures of DNA and its complexes. Consequently, biomolecular simulations are 
now viewed as essential aspects of the modern drug discovery process. 
So it follows that this work should be introduced by  a concise literature review of the 
rich field of biomolecular modeling and its techniques, as well as the vast field of DNA 
as a molecular target for anticancer therapy. Only the most relevant aspects of the mo-
lecular targets of interest, and their “computation” will be discussed, describing the un-
derlying principles of in silico approaches applied here.
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==============================================================
CHAPTER 1:
DNA structure and recognition
==============================================================
Nucleic acids, in addition to forming the well-known DNA double helix, can form a va-
riety of different (canonical and non-canonical) structures. Interestingly, the double he-
lix is largely  independent of its sequence, whereas the stability  and form of other struc-
tures of DNA are often dictated by their sequence, and in particular by  the different 
chemical properties of their nucleobases.4
1.1 STRUCTURAL DIVERSITY OF DNA AND ITS FUNDAMENTAL   
 BUILDING BLOCKS
1.1.1 Essential components of DNA architecture
The elementary building block of nucleic acid polymers, the mononucleotide, is com-
posed of a 5-membered, typically  non-planar, sugar ring (deoxyribose in DNA and ri-
bose in RNA), a phosphate group, and a purine (adenine and guanine) or pyrimidine 
(cytosine and thymine) base. Thymine is replaced by uracil in RNA. Nucleosides, the 
units formed from the sugar and base only, are then linked together via a phosphate 
group, forming a polynucleotide chain. Subsequently, (upon polymerization into DNA 
chains) a sugar/phosphate backbone is formed via a phosphodiester bridge joining the 
C3’-hydroxyl group of n-th nucleotide sugar with C5’-hydroxyl of the (n+1)-th nucleo-
tide (3’ to 5’ phosphodiester bond) (Figure 1.1). In the classical DNA double helix, two 
opposite- (anti-parallel) direction (5’→ 3’) polynucleotide chains form a flexible 
“ladder-like” structure with an imaginary central axis. 
            INTRODUCTION
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The conformational space of a nucleotide is specified by  six backbone torsion angle ro-
tations (α, β, γ, δ, ε, and ζ) and one glycosidic torsion angle χ, together with sugar 
pucker flexibility. There is a standard atomic numbering scheme in place for DNA. The 
DNA backbone, with the charged phosphate groups of the backbone exposed to the ex-
ternal environment (i.e. solvent), is specified by the following sequence: P → O5’→ 
C5’→ C4’ → C3’ → O3’ (→ P) (Figure 1.1).
Figure 1.1: Structural features of a DNA chain with standard atom labeling.
The chain runs from the 5’ (C5’) to 3’ (C3’) end, with the nucleotide phosphodiester bonds linking the 
C3’-hydroxyl group of one nucleotide sugar with C5’-hydroxyl group of the next one.  Nucleic acid tor-
sion angles are labeled as α (O3’-P-O5’-C5’),  β (P-O5’-C5’-C4’), γ (O5’-C5’-C4’-C3’),  δ (C5’-C4’-C3’-
O3’), ε (C4’-C3-O3’-P), ζ (C3’-O3’-P-O5’) and χ (O4’-C1’-N1/N9-C2/C4 pyrimidine/purine).  C2’-endo 
sugar pucker, and a distance between two consecutive P atoms ~ 6 Å are features typical for B-DNA.
 
 Non-covalent interactions, in particular hydrogen bonding and stacking interac-
tions, determine the structure of biomolecules5,6 (such as nucleic acids and proteins). 
While it is understood that hydrogen bonding is essential for the specificity  of base pair-
ing, π-π stacking interactions between planar aromatic rings of nucleobases are equally 
important contributions to the final stability of nucleic acid structures.6,7 Although indi-
vidually weak, the additive power of these interactions has large cooperative stabilizing 
effects (π-π stacking  ~ “deus ex machina”). 
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1.1.2 Duplex DNA versus G-quadruplex DNA
The most prevalent form of DNA is the canonical anti-parallel double-helical duplex, 
linked together by Watson-Crick hydrogen bonding pairs; A:T (two hydrogen bonds), 
and G:C (three hydrogen bonds). The asymmetry  in the base pairs gives rise to two par-
allel types of grooves (major and minor), whose dimensions reflect base pair (bp) dis-
tances from the central axis, and their orientation. There are a number of biologically-
relevant helix forms (A-DNA, B-DNA or Z-DNA), however the right-handed B-form is 
dominant under physiological conditions8,9 (Figure 1.2 a). B-DNA is 20 Å wide, and has 
10 bp  per turn, with the major groove 11.6 Å wide and 8.5 Å deep, while the minor 
groove is 6 Å wide and 8.2 Å deep. Both major- and in particular minor grooves have 
been extensively targeted with small-molecules for therapeutic intervention, with the 
aim of disrupting the transcription of specific genes at the DNA level.10-13
 An alternative arrangement of DNA into “four-stranded” structures, called 
G-quadruplexes, is built from G-rich sequences of telomeric (and also genomic) DNA, 
around two or more π-π stacked quartets of hydrogen-bonded guanine bases (i.e G-
quartets, G4), via Hoogsteen pairings, with an essential alkali metal ion (and an order of 
preference K+ > Na+) positioned in the interior channel of each G-quartet. The ions co-
ordinate to O6 atoms of the guanine bases (Figure 1.2 b) resulting in a significant stabi-
lizing effect to the structure. The G-quartets are linked together by intervening variable-
length sequences, loops, arranged on the outside of the relatively rigid and stable G4 
core. The flexible loops are thus the key determinants of G-quadruplex structural vari-
ability. Unlike duplex DNA, G-quadruplexes may adopt parallel, anti-parallel or mixed 
strand orientation, depending on the sequence, and experimental conditions.14,15 
There are three principal categories of quadruplex arrangements, that are possible:  
(1) tetramolecular, (2) bimolecular or (3) intramolecular (i.e unimolecular, where all 
guanine bases involved in G-tetrad formation originate from single strand of DNA). 
Depending on the G-quartet  arrangement and the sequence length, the loops intervening 
between successive G-quartets can then adopt different conformations (lateral, propeller 
or diagonal).16 
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Figure 1.2: Essentials of duplex and G-quadruplex DNA.
(a) duplex DNA helix is formed by two anti-parallel right-handed strands, linked together by Watson-
Crick base-pairing between A:T and C:G (i.e hydrogen bonding),  together with π-π stacking interactions, 
that strongly contribute to the overall duplex stability. A base-pair is then the motif repeated 10-times 
within one helical turn. Two types of non-equivalent asymmetrical grooves are typical for duplex DNA; 
(b) G-quadruplex DNA, despite being often described as “four-stranded”, it can be formed from four (te-
tramolecular), two (bimolecular) or one (unimolecular) G-rich strand,  organized into parallel,  anti-parallel 
or mixed right-handed structures of π-π stacked G-quartets with an essential monovalent alkali ion lo-
cated in the central channel. Hoogsteen base-pairing involves different face of the aromatic ring of nu-
cleobases for hydrogen bonding. All G-quadruplex structures have four grooves, defined as the cavities 
bounded by the phosphodiester backbone.16  
 Conformation and properties of nucleic acids are directly influenced by solva-
tion, with water molecules (well organized around bases and phosphates) being an inte-
gral part of nucleic acid structure.17 DNA conformational type and base identity is re-
flected in hydration patterns (hydration sites), which represent sites of preferred polar 
binding to DNA. Calculated hydration sites can then be translated into predictions of 
amino acids binding to DNA in protein-DNA complexes.18 
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1.2 DNA IN COMPLEXES WITH PROTEINS
Interactions of nucleic acids with a wide range of DNA-binding proteins (such as regu-
latory, replication, recombination proteins etc.), are at the core of essential biological 
processes. There are a number of factors (structural features) that are of key  importance 
in terms of nucleic acid recognition by  other molecules; phosphate-phosphate distances 
in canonical DNA helices, minor/major groove dimensions which are directly related to 
their electron density  (T:A pairs are electron poor compared to C:G), or stereochemical 
repulsion.18 However, it is the specificity of these interactions that is fundamentally im-
portant in all aspects of gene regulation.19,20 Thus large areas of research have evolved 
around protein-DNA complexes, with focus on their biomedical importance and sys-
tematic classification.21
1.2.1 Targeting transcription factors for therapeutic intervention
Transcription factors (TF) are DNA-binding proteins that, usually in combination with 
other proteins form the pre-initiation complex, regulate the synthesis of complementary 
RNA copies (messenger RNA, mRNA) of their target genes (i.e transcription) by  con-
trolling the recruitment of RNA polymerase II. Through subsequent translation into pro-
teins, they determine the cellular phenotype. Interconnected signaling cascades are initi-
ated upon binding their ligands (by cell surface receptors), involving mostly kinases and 
phosphatases that act on transcription factors, leading to activation of transcription ma-
chinery upon its recruitment. 
 Constitutive activation of transcription factors, however, can lead to various can-
cers. In particular three signaling pathways, namely the JAK/STAT pathway,22 the Ras/
Raf/MAP/ERK pathway23 and the Hedgehog pathway,24 have been found upregulated in 
a range of human cancers, making them of great interest for the development of new 
chemotherapeutic agents.25 Molecularly-targeted therapies are fast becoming a real op-
tion for the treatment of cancers and other diseases. In malignant cancer growth, intra-
cellular signaling pathways are dysregulated, which causes abnormal cell proliferation, 
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resistance to cell death (apoptosis), altered differentiation, and cytotoxic stress. Altering 
transcription factor activity can have significant consequences, since a multiple signal-
ing pathway may converge on a single transcription factor, which can modulate a gene 
expression program that leads to oncogenic alteration.26 Assessing and validating the 
druggability  of molecular targets, and in particular transcription factors (they typically 
have both protein-protein and protein-DNA interfaces) has proven to be challenging. 
27,28 However a number of transcription factors, such as STAT3 are viewed as suitable 
therapeutic - druggable - targets.29 
1.2.2 Signal Transducer and Activator of Transcription 3 (STAT3)
Signal Transducers and Activators of Transcription (STATs) are a group of latent tran-
scription factors in cytokine signaling, discovered in the early 1990’s. These factors are 
unique due their ability to transduce signals from the cell membrane to the nucleus, 
where they activate gene transcription, bypassing secondary messengers.30 Seven TF 
members of the STAT family have been identified, i.e. STAT1, 2, 3, 4, 5a, 5b and 6, and 
their activation is an essential event for the mediation of cytokines and growth-factor 
induced cellular and biological processes, such as proliferation, differentiation, survival, 
development and inflammation.31,32 
 STAT3 is the key mediator of interleukin 6 (IL-6)-type cytokine signaling.33 
Structurally, STAT3 is similar to other STAT proteins (closely related is STAT1), having 
the N-terminal domain involved in tetramerization,34 while the coiled-coil domain plays 
a role in STAT3 activation.35,36 The DNA-binding domain with sequence specificity for 
a palindromic IFN-γ-activated sequence (GAS) element37 is also involved in nuclear 
translocation, and mediates co-regulatory  interactions with other TF such as NF-κB.38 
The Src-homology 2 (SH2) domain is  generally  the most structurally conserved domain 
among STATs, and it is involved in receptor recruitment and also in STAT 
dimerization.31 In contrast, the transactivation domain is the least  preserved domain, and 
it is associated in PPI (for instance with CREB-binding protein).39 The transactivation 
domain also accommodates Y705 and S727 (STAT3α only), the sites of tyrosine/serine 
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phosphorylation respectively, associated with STAT3 activation and dimerization.40 
Further post-translational modifications of STATs, such as lysine acetylation (K685),41 
or ubiquitination, modulate the transcriptional activity  and significantly contribute to 
STAT-induced gene response.31
 STAT3 exists in two isoforms of different properties42: the full-length STAT3α 
(~92 kDa) and the truncated STAT3β (~83 kDa), which lacks ~50 residues of the 
C-terminal transactivation domain. STAT3β is often considered as the dominant nega-
tive form, because its over-expression can suppress specific STAT3 functions43,44 (Fig-
ure 1.3 a). However, STAT3β has been shown to activate specific STAT3 genes, demon-
strating a unique function for the STAT3 isoforms.45
 STAT3 is a well-recognised and important mediator of tumour-induced immuno-
suppression at many levels.46,47 STAT3 is activated by numerous cytokine signaling 
pathways (i.e IL-6), and also by  abnormal signalling of various growth factor receptors, 
together with oncoproteins such as Src and BCR-ABL.48 As a key molecule in linking 
oncogenic pathways with immunosuppression, activated STAT3 not only down-
regulates Th1 cytokines (critical mediators of anti-tumour immune response), but also 
directs malignant progression via the aberration of key proteins such as the cell survival 
(anti-apoptotic) proteins Bcl-xL and Mcl-1, the cell-cycle regulators cyclin D1/D2 and 
c-MYC, and inducers of angiogenesis (i.e VEGF).22,30 As a result, cancer cells with 
aberrantly  active STAT3 show greater resistance to the initiation of apoptotic processes 
from the environment and apoptosis-initiating chemotherapeutics.49 According to the 
original canonical view, multiple distinct steps are involved within the STAT3 signalling 
pathway (Figure 1.3 b). Upon extracellular receptor stimulation by growth factors or 
cytokines (e.g. IL-6), the receptor (gp130) becomes dimerized, and subsequently acti-
vated, which triggers the activation of the Janus protein tyrosine kinases JAK1 and 
JAK2, that are associated with the cytoplasmic tail of the receptor. This phosphorylation 
of the cytoplasmic tail provides a docking site for the recruitment of monomeric30 or 
dimeric50 un-activated STAT3 proteins via reciprocal interaction of their SH2 domains. 
Activated JAK tyrosine kinases phosphorylate recruited STAT3 proteins at a specific 
tyrosine within the C-terminus (Y705), and the phosphorylated STAT3 monomers dis-
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sociate from the receptor to form STAT3-STAT3 homodimers. These then translocate 
from the cytoplasm to the nucleus, where they bind to target DNA motifs,22 promoting 
the expression of proteins crucial for cell growth and survival. Normal STAT3 activa-
tion is relatively brief and regulated by  a number of deactivation mechanisms, but hu-
man cancer cells express constitutively active STAT3 at high concentrations.46 There is 
a mounting body of evidence51 suggesting that tumour formation can be caused by ab-
normally active STAT3. Thus inhibition of aberrant STAT3 activity induces growth ar-
rest and apoptosis of tumour cells in vitro as well as in vivo, validating STAT3 as a suit-
able molecular target for anticancer drug discovery.22,51,52 Due to the complexity  of the 
signalling pathway (as described above), targeting STAT3 in order to suppress is aber-
rant function in cancer cells can be approached (1) indirectly, by targeting the upstream 
components of the STAT3 pathway, or (2) directly  targeting the STAT3 protein by 
means of SH2 domain inhibitors (dimerization inhibitors), the DNA-binding domain 
inhibitors or the N-terminal domain inhibitors.51 Inhibitors targeting the STAT3 SH2 
domain are the most explored and reported on strategy.
Figure 1.3: Functional domains of STAT3 protein; and canonical STAT3 signalling pathway.
(a) the full length STAT3α, and its isoform STAT3β; (b) Canonical view of STAT3 signalling cascade; 
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1.2.3 STAT3 inhibitors: from peptides to small molecules
For the first time, STAT3 dimerization was directly inhibited by Turkson et al, employ-
ing a truncated peptide sequence derived from the native STAT3-binding phosphopep-
tide (PpYLKTK).53 A number of research groups have since developed (and patented) 
short peptides54,55 and peptidomimetics56-58 designed to block the SH2 domain of 
STAT3. However, membrane permeability and stability  are the two  main challenges 
facing a peptidic approach to drug discovery.51 Other classes of therapeutic molecules 
designed to inhibit STAT3 function are oligonucleotides59,60 (and even G-quartet oligo-
nucleotides61), platinum-based compounds62 and a large field of small molecule-
inhibitors, mostly  discovered via in silico screening an/or rational drug design.49 
However, only five classes of small molecule inhibitors,63-67 and their second generation 
compounds,68-72 have been patented so far (summarized in Figure 1.4) with only one 
inhibitor, BP-1-102, being reported as orally bioavailable.72
Figure 1.4: Patented small molecule inhibitors of STAT3 and their analogues, discovered via in silico 
approaches and/or rational structure based drug design.
(1) natural product STA-2163 identified by VS (DOCK) of 429.000 compounds at the NCI, and its related 
compounds CLT-00568 (patented for retinal disease treatment),  LLL-369 and LLL-1270; (2) salicylic acid-
based inhibitor S31-20164 identified by VS (GLIDE) optimized to leading dimerization-disruptive agent 
S31-201.1066,71 that was further optimized into BP-1-102,72 a first orally bioavailable STAT3 inhibitor; 
(3) CPD-18865 identified by in silico screen (~1.5 million compounds, MolSoft) employing complemen-
tary screens against STAT1; (4) STX-011966 identified by employing 3 different scoring techniques; (5) 
rationally-designed substituted oxazole S31-M2001,67 based on structure of peptidomimetic ISS610.56 
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1.3 G-QUADRUPLEX DNA AS A THERAPEUTIC TARGET
G-quadruplex DNAs are involved in a wide range of biological and biochemical proc-
esses and have been located throughout the human genome.73 Furthermore, they may 
have a significant promise as pharmacological targets in anticancer therapy. The thera-
peutic strategy for targeting G-quadruplexes initially  emerged for telomeric DNA (and 
telomerase inhibition),74,75 and within the past decade, interest in therapeutic signifi-
cance of G-quadruplexes has increased, and now targets G-quadruplexes in gene 
promoters (i.e c-KIT, c-MYC, b-RAF).76 Over the past decade, the conformational vari-
ance of G-quadruplex nucleic acid structures (both DNA and RNA) has been effectively 
studied by NMR and X-ray  crystallography, and in particular in the last two years, 
nearly a third of the currently  known quadruplex structures have been solved. To this 
date, there are over 150 quadruplex structures deposited in the Protein Data Bank 
(www.rcsb.org/pdb), both native and in complexes with ligands (i.e BRACO-19, 77 the 
porphyrin TMPyP4,78 or several tetrasubsituted naphthalene diimide compounds79). The 
structural data provide a solid basis for rational drug design of new G-quadruplex inter-
acting compounds, whose presence has been numerously shown to cause rearrange-
ments of the bases within the loops, forming new ligand binding scaffolds.79
1.3.1 G-quadruplexes in human telomeres 
Telomeres are nucleoprotein complexes located at the terminal regions of eukaryotic 
chromosomes, and in mammals, they are composed of non-coding tandem repeats of the 
sequence d(TTAGGG), together with associated telomeric proteins (six-protein com-
plex) known as shelterin.80 Telomeres play a major role in protecting telomeric region 
from degradation and genomic instability.81 The terminal 100-200 nucleotides at the 
3’-end of telomeres are single-stranded (overhang), and able to form G-quadruplex 
structures. Stabilization of G-quadruplexes in human telomeric DNA with small mole-
cules is a promising anticancer strategy, as that has been shown to inhibit the activity  of 
telomerase, which is over-expressed  in ~ 80-85% of cancer cells and primary  tumors, 
acting as a tumor promoter.82 
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1.3.2 Computational methods employed in studying G-quadruplex/ligand complexes
A number of computational studies, carried out to date, have employed biomolecular 
simulation methods to obtain a superior insight into the structure and interactions of 
both telomeric and genomic G-quadruplex nucleic acids. Dynamic behavior,83,84 con-
formational properties85 and energetics,86,87 have been addressed, as well as plausible 
higher order structures,88,89 cation binding,90-92 or the behavior of existing G-quadruplex 
ligands.93,94 A growing number of complementary molecular docking and ligand-based 
pharmacophore modeling studies have been regularly employed in parallel to experi-
mental biophysical assays, in order explore plausible binding modes of the studied 
G-quadruplex ligands, to optimize the lead compounds, and to rationalize their selectiv-
ity. For instance, selectivity of a group of naphthalene diimide ligands for telomeric 
G4-RNA over the G4-DNA was explained by  Collie95 et al using the docking method in 
the AFFINITY program (Accelrys; http://accelrys.com/). 
 With respect to ligand-based pharmacophore modeling, two quadruplex-
stabilizing alkaloid compounds, obtained by  screening a Chinese herbal medicine com-
pounds database (10,000 compounds) with previously  generated pharmacophores (Cata-
lyst software, Accelrys) have been described;96 a ligand-based pharmacophore model, 
devised on the basis of acridine derivatives, was employed in the identification of 
triaryl-substituted imidazole derivative TSIZ01.97 However, obtaining the most favour-
able binding poses of the compounds in silico has been challenging due to the specific 
features of quadruplex nucleic acid molecules. The highly charged backbones, the pres-
ence of stabilizing alkali metal cations, the basic quadruplex architecture and in particu-
lar the flexibility of the G-quadruplex structures are all important issues to be consid-
ered within the framework of in silico screening of G-quadruplex ligands by molecular 
docking. The quality  of G-quadruplex docking results, and subsequently the binding 
affinity of potential G-quadruplex ligands, might be strongly affected by the flexibility 
of the loop regions.98 To address the receptor and ligand flexibility issue, and subse-
quent conformational change upon binding, a novel form of fully “dynamic docking” 
method has been developed (described in CHAPTER 6). 
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 Consequently, virtual screening of large chemical libraries to aid the selection of 
new G-quadruplex-binding ligands has not  yet been extensively explored and, until 
recently, rarely  used.99 Two examples of G-quadruplex binding ligands are shown in 
Figure 1.5, both using the human telomeric quadruplex structure (PDB id 1KF1) as a 
starting point, and employing the ICM method of molecular docking software (Mol-
soft100); a synthetic substituted indole101 identified by in silico screening of ~100,000 
drug-like compound, and the naphthopyrone natural product fonsecin B102 identified by 
screening over 20,000 compounds in natural product database. The use of molecular 
docking in virtual screening for the identification of bioactive molecules from natural 
product databases has recently been reviewed by Ma103 et al.
Figure 1.5:  Two G-quadruplex-binding compounds identified by virtual screening. 
(a) a synthetic substituted indole101 ; (b) the naphthopyrone natural product fonsecin B102 
 
 In silico studies combined with NMR experiments in tandem provide more de-
tailed understanding of the interactions between the ligands and G4-DNA.104 A rela-
tively small, but structurally very diverse commercially available database (6,000 com-
pounds) was screened against the parallel structure of the simple quadruplex 
[d(TGGGGT)4] (PDB id 1S45) by means of AutoDock v. 4. Subsequent NMR screening 
of the top 30 hits identified six G4-groove-binding molecules, that were further studied 
in detail by NMR, Isothermal Titration Calorimetry (ITC) measurements and molecular 
docking with modified quadruplexes, identifying the most potent G-quadruplex  groove-
binders to date.105 
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Truly large-scale integrated in silico and in vitro screening platforms for the purpose of 
discovering novel small molecules binding to specific nucleic acids were described by 
the Chaires' group, using the analogy of a “funnel”.106  The ZINC “drug-like” virtual 
database of 11.3 million compounds was screened against the antiparallel quadruplex 
target (PDB id 2HY9) employing the Surflex-Dock molecular docking software. An 
array  of potential nucleic acids competing sites, as well as all possible binding sites on 
the target  nucleic acid itself were considered for the virtual screening, which was per-
formed on a grid of more than 10,000 computer processors. This approach, as well as 
the  appropriate choice of the software, were previously  validated.107,108 The top  160 hits 
that emerged after scoring, for selective binding to the quadruplex target, were tested by 
a high-throughput melting assay followed by  a secondary screening of the top com-
pounds. A characterization of their binding behavior with the quadruplex target, by 
means of rigorous binding studies using calorimetry, spectroscopy, competition dialysis, 
molecular dynamics simulations and functional assays, identified a substantially stabi-
lizing quadruplex-binder, which in turn suggests that the proposed in silico and in vitro 
platform may be used to discover new G-quadruplex binding scaffolds.106 
 At present, virtual screening alone is unable to adequately predict the selectivity 
of a particular ligand for different G-quadruplexes, because of the inherent inaccuracies 
in comparing binding energies between multiple G-quadruplex structures.98 However 
G-quadruplex structures display  a high degree of diversity  in their loop and grooves 
geometries, which in particular could be used to enhance the selectivity of ligands, 
allowing for their excellent structure-specific recognition, affinity and specificity. For 
instance, in the case of the promoter KIT1 quadruplex structure (the NMR structure109 
or the X-ray structure110) the presence of a distinct  cleft may be suitable for ligand bind-
ing and virtual HTS.76
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==============================================================
CHAPTER 2:
Molecular modeling and computational approaches to biomolecular 
structure and drug design
==============================================================
‘Molecular modeling is the science and art of studying molecular structure and function 
through model building and computation‘.111 The “model” is defined by the Oxford 
English Dictionary as ‘a simplified and idealized description of a system or process, 
often in mathematical terms, devised to facilitate calculations and predictions’. The 
computations then include ab initio and semi-empirical quantum mechanics, empirical 
(molecular) mechanics, molecular dynamics, Monte Carlo, free energy  and solvation 
methods, structure/activity relationships (SAR), chemical/biochemical information and 
databases, and a number of other established procedures. Furthermore, the refinement of 
experimental data, such as from X-ray crystallography or nuclear magnetic resonance 
(NMR), is also regarded as part of biomolecular modeling.
‘The key  in modeling is to develop and apply models that  are appropriate for the ques-
tions being examined with them’.111
2.1 THE CONCEPTS AND PRINCIPLES OF MOLECULAR MODELING
Since starting in the 1960s, and progressing rapidly since the 1980s, together with the 
ever-increasing access to supercomputers the burgeoning field of biomolecular model-
ing  has been in continuous development. Many ongoing methodological and techno-
logical improvements have provided a robust platform for in silico biomolecular stud-
ies, and computational chemistry/biology. Among those of key  importance are: 
advances in instrumental and experimental techniques; novel models and improved 
algorithms for molecular simulations; and the availability  of increasingly fast super-
computers, parallel processors and GPU computing.112 However, communication, both 
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at  the personal (i.e multidisciplinary  collaborations between theoreticians and experi-
mentalists), as well as virtual level (fast ubiquitously  present Internet and web 
resources), play a pivotal role in facing the challenges of biomolecular modeling and  in 
silico drug design. 
 Molecular modeling may also be classified as a division of science focused on 
applying the fundamental laws of physics and chemistry to the study of molecules, and 
biological macromolecules. Currently, it  is one of the most-widely  applied techniques in 
biological chemistry, biophysics and drug discovery.113 The ultimate aspect enabling the 
widespread and interdisciplinary application of molecular modeling is the continuing 
growth of computing power. This has made it possible to analyze, compare and charac-
terize large and complex data sets obtained from biomolecular systems experiments.114 
In the case of drug discovery, the principal aim is to create models and simulations, 
which can assist in the individual stages of a discovery pipeline by  predicting, rational-
izing and estimating the properties of molecules and their interactions, leading to more 
rational approach to the drug discovery and development process.115 Rational drug 
design is then based on a fundamental assumption that drug activity  is obtained via 
molecular binding of a ligand molecule to the pocket of a macromolecular target. Their 
chemical and geometrical complementarity in their active state is then essential for 
successful drug activity.116 
 The importance of molecular modeling and simulation methods has grown in the 
past decade due to their exquisitely detailed contributions to the study  and function of 
biomacromolecules; e.g protein folding and conformational changes, modeling the 
dynamics of ion channels and transport  across membranes, modeling and analysis of 
enzyme mechanisms, computation of binding free energies for ligands, structure-based 
drug design etc.117 However, experimental data plays an key role in biomacromolecular 
modeling. For instance, development of the classical molecular mechanics force fields 
would not have been possible with such data, since quantum-chemical theoretical data 
alone would not be sufficient to develop a force field.114 
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2.2 MOLECULAR MECHANICS: A FOUNDATION FOR FORCE FIELDS
The notion that  molecular geometry, energy, and various molecular properties may be 
calculated from mechanical-like models subjected to basic physics forces, underlines 
the basis of molecular modeling. A molecule, represented as a mechanical system in 
which the particles are connected by springs, rotates, translates and vibrates in order to 
adopt favourable conformations in space upon inter- and intra-molecular forces acting 
on it. The forces are depicted as a sum of harmonic-like (from Hooke’s law) terms for 
bond-length and bond-angle deviations from equilibrium (ideal) values; trigonometric 
dihedral (torsional) terms to account for molecule’s internal rotation; and non-bonded 
van der Waals and electrostatic potentials.111 
2.2.1 Underlying principles of molecular mechanics
The term molecular mechanics (MM) refers to the use of  simple potential energy func-
tions (i.e. harmonic oscillators or Coulombic potentials) to model molecular systems.118 
As an alternative simplified approach to quantum mechanics (QM), the MM method 
ignores the electronic motions (electrons are treated implicitly) and calculates the 
energy of a system as a function of the nuclear position only, with the assumption of the 
Born-Oppenheimer approximation to the potential energy.
There are three underlying principles, originating from quantum-mechanical roots 
(i.e the Schrödinger equation), which determine the overall effectiveness of MM: 
• The thermodynamic hypothesis, which assumes that a strong thermodynamic force 
drives “scrambled” conformations of high free energy to the native state of low free en-
ergy.
• The principle of additivity, assuming that the effective molecular energy  can be 
expressed as a sum of potentials derived from simple physical forces (i.e bonded and 
non-bonded terms)
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• The principle of transferability, which assumes that potentials can be developed to in-
clude all experimental data for representative structures, and subsequently be success-
fully applied to predict large biomolecules formed of adequate chemical subgroups.
 MM  approaches are generally  applied in energy minimization, dynamic simula-
tions (i.e molecular dynamics or Monte Carlo simulations), or ligand docking/scoring 
simulations, hence both effective formulation of the potential energy function as well as 
the suitable search algorithm are key aspect of a successful MM simulation.
2.2.2 Force field: functional form of potential energy function
‘An empirical force field is a recipe for reproducing a potential energy surface’.119 
Potential energy is a component of the total energy of the system based on the position 
of the atoms (usually expressed in terms of Cartesian coordinates). Atoms are approxi-
mated as Lennard-Jones spheres with constant point charges localized within the atomic 
centers,120 while force is the negative derivative of the potential, with respect to posi-
tion. The equation for potential energy is known as the functional form of a force field. 
Each force field utilizes a slightly different  functional form, however the equation al-
ways comprises bonded (bonds, angles, dihedrals, and improper dihedrals) and non-
bonded (Lennard-Jones and Coulombic) terms (Figure 2.1, equation 2.1, 2.2 and 2.3).
Figure 2.1: Representation of the key components to a molecular mechanics force field.
(a) bond stretching, (b) angle bending, (c) bond rotation (torsion), (d) non-bonded van der Waals interac-
tions and (e) non-bonded electrostatic interactions.
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Etotal&=&Ebonded&&+&Enonbonded            (2.1)
Etotal&=&&∑bonds&Eibonds&(bi)&+&∑angles&Eibond&angles&(θi)&&+&∑dihedrals&Eitor&(φi)&+ 
 ∑nonbonded&pairs&Ei<j&r(rij)              (2.2)
                  
 
 The total energy (E) of a molecule is then defined as a sum of contributions aris-
ing from “ideal” bond length and bond angle distortions (bi,& θi) and internal torsion 
flexibility (φi) along with contributions from non-bonded (van der Waals and electro-
static) interactions (rij). One very  typical and widely applied force field is AMBER (an 
acronym for Assisted Model Building with Energy Refinement). Like other widely  ap-
plied force fields in consists of several discrete terms in simple functional form, describ-
ing an intra- and inter-molecular force within the system as follows (equation 2.3):
           (2.3)
The first two terms of the above equation are harmonic potentials representing the inter-
action between two (bonds) and three (angles) atoms, separated by  one (bonds) or two 
(angles) covalent bonds respectively. They are an approximation to the energy of a 
bond/angle, as a function of displacement from the reference (ideal) bond length b0 or 
bond angle θ0 respectively. The force constants Kb and Kθ then determine the strength of 
the bond/angle. The third term is periodic (i.e cosine function) torsion angle potential 
function, which models the presence of steric  barriers between four atoms separated by 
three covalent bonds. The associated rotational motion is described in Fourier terms, 
where each rotational sequence described by a torsion (dihedral) angle ϕ, multiplicity n 
(i.e coefficients of symmetry), which denote the periodicity  of the rotational barrier, and 
force constant Kϕ  which is the associated barrier height (magnitude). A reference phase 
angle (phase shift) γ denotes where the torsion angle passes through its minimum value. 
Additionally, improper torsion term potentials are used to describe out-of-plane bending 
frequencies, i.e to keep four atoms properly planar (hence the atoms involved are not 
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serially bonded but rather branched). Improper dihedrals can be expressed in terms of 
harmonic potentials, but  in case of AMBER force field, they are reproduced in corre-
sponding way as proper dihedrals, with the phase angle γ always equal to 180 degrees 
(π radians). Collectively, these three terms represent the internal or intramolecular pa-
rameters. 
 The non-bonded interactions (the fourth term of equation 2.3) contain a repul-
sion term and a dispersion term, describing the interactions (balance) between neutral 
atoms; and a Coulomb term, dealing with the electrostatic interactions. The repulsive 
and attractive terms (i.e. van der Waals interactions) are combined in the Lennard-Jones 
(12-6) potential, where the attractive and repulsive coefficients C and A depend on the 
chemical nature of the two interacting atoms (they  are atom-pair specific). The 
attractive/repulsive effects become significant with decreasing inter-atomic distance r, 
thus positioning the atoms at the optimal distance stabilizes the system, giving rise to a 
minimum in the energy  (Figure 2.2). The measure of how strongly  two non-bonded par-
ticles attract each other (i.e the depth of the potential energy well) is referred to as 
‘epsilon’ (ε), while ‘sigma’ (σ) is referred to as the van der Waals (atomic) radius. 
Figure 2.2: A graph of Lennard-Jones 12-6 potential.
Lennard-Jones 12-6 potential describes the attraction and repulsion forces between nonionic particles. ε 
and σ characterize the strength of the non-bonded interaction, and the atomic radius respectively. These 
atom pair parameters  are then used to calculate the C and A attractive/repulsive coefficients.
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Lastly, the electrostatic interaction between fully or partially charged groups (atoms) is 
represented by a Coulombic potential term, where two atoms (i and j) have point 
charges qi and qj. The magnitude of the electrostatic energy  varies inversely  with the 
distance between the atoms rij. The dielectric constant ε is typically set  to 1, correspond-
ing to permitivity in a vacuum (in explicit solvent simulations).
 As mentioned earlier, the total energy of the system is calculated as the sum of 
all bonded and non-bonded interactions. However, the direct evaluation of the long-
range electrostatic interactions would be computationally very  complex, time consum-
ing and expensive, therefore the non-bonded intermolecular distances are typically trun-
cated at a cut-off distance (any interaction past the cutoff distance is ignored), which 
could potentially lead to an accumulation of errors. Use of the Particle Mesh Ewald 
(PME)121,122 treatment of electrostatics, a technique that calculates the electrostatic en-
ergy of a system on a lattice with periodic boundary  condition, can mostly eliminate the 
problem. 
 Electrostatics effects are long-range, and their influence on polar and charged 
molecules (water, ions, amino and nucleic acids) makes them of a special importance in 
terms of determining the structure, motion and function of many biomolecular systems 
(such as protein-DNA binding, biomolecule-ligand binding), as they are ubiquitous. 
Electrostatic interactions are also essential in determining the thermodynamics of bind-
ing123 (i.e binding affinity), discussed later in the text.
 Theoretical methods based on empirical force fields are often applied to biomo-
lecular systems (i.e nucleic acids and their complexes) in the context of molecular 
dynamics (MD) simulations, that can further provide their atomic details, as well as free 
energies related to conformational changes of the studied biomolecular system.
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2.3 MOLECULAR DYNAMICS SIMULATIONS OF BIOMOLECULES
In molecular dynamics (MD) simulations, the motion of a biomolecular system under 
the effect of a “force” (i.e a specified force field) is simulated by following its molecu-
lar configurations in time, according to Newton’s equation of motion (the second law). 
In terms of individual atoms (particles), mathematically, the net force is equal to the 
time derivative (dt) of the particle’s momentum (p), which is defined by its mass (m) 
and velocity (v), as shown in equation 2.4:
F&=&ma&=&m&dv/dt&=&d(mv)/dt&=&dp/dt      (2.4)
However for a large biomolecular system of N atoms, the Newtonian equation of mo-
tion is written in terms of first-order differential equations (equation 2.5):  
MV(t)&=&F(X)&=&C∇E(X(t))&+&...,Ẋ(t)&=&V(t)          (2.5)
where X ∈ R3N indicates the collective Cartesian vector of the system (i.e the x, y  and z 
components of each atom); V& is the corresponding collective velocity vector; M is the 
diagonal mass matrix, and the dot superscript indicates differentiation with respect to t. 
The total force (F) comprises the systematic force, which is the negative gradient of the 
potential energy  (E) and, possibly, additional terms that mimic the environment.124 Each 
gradient component i, i = 1,... 3N, is then given by equation 2.6:
 ∇E(X)i&=&∂E(X)/∂αi,         (2.6)
where αi indicates the x, y  or z component of the atom. These equations must be then 
integrated numerically (by means of MD integrators such as Verlet or the leap-frog al-
gorithm), providing a sequence of solutions and velocity  pairs, {Xn, Vn}, for integers n 
that represent discrete times t&=&n∆t&at intervals (i.e timesteps) ∆t. The initial atomic 
velocities are generated with a Maxwell-Boltzman distribution at given temperature.124 
Thus in summary, the resulting MD trajectories are then defined by both position and 
velocity vectors and they describe the evolution of the system in phase space.
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As a consequence of Newton’s law application, the total energy of the system is con-
served, thus MD simulations naturally form a micro-canonical ensemble (NVE). Algo-
rithms that introduce a thermostat or barostat to the system allow the sampling of the 
canonical (constant NVT) or isothermal-isobaric (conserved NPT) ensemble. MD fol-
lows the time evolution of a system, enabling us to study  its dynamic properties, as all 
the degrees of freedom of the system are subjected to a force, hence move. It is often 
necessary  to constrain some degrees of freedom using constraints algorithms to bonds 
such as the SHAKE125 or LINCS126 method. The latter method (LINCS, an acronym for 
Linear Constraint Solver) was employed in the molecular dynamics simulations de-
scribed in this thesis.
 MD simulations applied to biomolecular systems are a powerful technique that 
can provide us with valuable insight into important features of studied systems, where 
experimental data is not accessible. However, it is necessary to carefully  consider their 
current limitations (i.e the sampling algorithms and time-scale limitations, force field 
approximation and polarization effects) of simulations in order to avoid over-
interpretation of the results. 
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2.4  FREE ENERGY CALCULATIONS AS POST-PROCESSING METHODS
Biomolecular association events can be predicted by thermodynamics, i.e the extent of 
biochemical reactions, as well as the direction of spontaneous processes and stability. 
“Thermodynamics quantifies equilibrium, phase changes and stability  using unmeasur-
able quantities like enthalpy and entropy; these are coupled to experimentally 
measurable quantities like temperature and pressure, through mathematical 
relationships”.127 In such a way, physicochemical transformations in micro- and macro-
molecular systems can be explained. 
2.4.1 The basic concept of  “free-energy”
The perception of “free energy” as a key  criterion behind many important thermody-
namic phenomena (such as equilibrium in chemical reactions), has been extensively 
studied for several decades now. Free energy is essentially  “the factor that determines 
how a process will proceed and the probability  that a system will adopt given state”.128 
In terms of theoretical predictions, the expression for the free energy (Helmholtz free 
energy) in canonical ensemble (i.e NVT is constant) is directly related to its partition 
function, and is given by (equation 2.7):
F&=&&CkBT&lnQNVT where  Q&=&∑i&eCβEi    && (2.7)
where kB& & is Boltzmann’s constant and QNVT is the partition function of the system (i.e 
describing its statistical properties in thermodynamic equilibrium), and β is the inverse 
temperature divided by Boltzmann’s constant. The absolute free energy (equation 2.7) 
can only by  directly calculated for small simple systems governed by a simple Hamilto-
nian, where an analytical expression for the partition function is obtainable.128 
 For most biomolecular systems, the aim is to determine relative free energies; 
for instance, the difference in binding of two ligands with the same receptor, or a com-
plex formation (bound/unbound state). Because free energy is a state function, free 
            INTRODUCTION
25
energy differences between distinct  sub-states can indeed be evaluated without simu-
lating the transition. Thus free energy  differences between two states (A and B) are the 
ratios of partition functions (equation 2.8):
∆F&=&FA&C&FB&=&CkBT&ln(QA/QB)       (2.8)
The ratios of partition functions (that are also directly related to chemical equilibrium) 
can be computed by means of different techniques (a compromise between accuracy 
and efficacy). Thus the quality of free energy difference calculations is reflected by  the 
choice of:• a reliable molecular model (i.e Hamiltonian) describing the system’s thermodynamics 
employed in energy and force calculations; more CPU time-demanding, and exact, is 
quantum-mechanical description (such as Free Energy  Perturbation i.e FEP, Thermody-
namic Integration i.e TI, or the non-equilibrium statistical mechanics approach by 
Jarzynski129), whereas more approximate approaches employ  empirical force fields 
(such as Linear Interaction Energy i.e LIE130, or the Molecular Mechanics Poisson-
Boltzman/Generalized-Born Surface Area i.e MM/PB(GB)SA approach).• a sampling method that is employed to generate an ensemble of representative con-
figurations (such as MD or Monte Carlo methods)
2.4.2 MM/PBSA and MM/GBSA method: 
The key objective of the approximate binding free energy MM/PBSA method,131 and its 
complimentary  MM/GBSA method,132 is to calculate the free energy difference between 
two states which generally represent the bound and unbound state of two solvated mole-
cules, or eventually to compare free energy of two different solvated conformations of 
the same molecule. Representative snapshots from an ensemble of conformations ob-
tained via MD simulation are used for the calculation (stripped from the explicit sol-
vent), yielding an average of the energies. The binding free energies of macromolecular 
association are computed by the means of a thermodynamic cycle (Figure 2.3), combin-
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ing molecular mechanics energies (so-called gas phase energy contributions that  are in-
dependent of the chosen solvent model) with implicit solvent approaches.
Figure 2.3: MM/PB(GB)SA thermodynamic cycle.
Molecular mechanics energies (gas phase energy contributions) that are independent of the chosen solvent 
model, are combined with implicit solvent approaches.  The calculations are performed for all three sys-
tems: the receptor, ligand and the complex.
The free energy of binding is then calculated as given by equations 2.9, 2.10, which can 
be further broken down into individual energy terms (equation 2.11, 2.12, 2.13):
ΔGbind&=&∆H&C&T∆S        (2.9)&ΔGbind&=&(∆EMM&+&∆GSOL)&C&T∆S      (2.10)ΔEMM&=&(EMMcomplex&C&&EMMreceptor&C&EMMligand)     (2.11)∆GSOL&=&(∆GSOLcomplex&C&∆GSOLreceptor&&C&∆GSOLligand)    (2.12)∆S&=&(Scomplex&C&Sreceptor&C&&Sligand)      (2.13)
where ∆H& is the enthalpic contribution to binding energy, ∆EMM is the difference in av-
erage molecular mechanics energy, while the ΔGSOL term accounts for the solvation free 
energy (comprising both polar and non-polar component); T is the temperature and ∆S 
is a change in entropy. Thus the binding free energy of two molecules can be declared 
as the sum of an intermolecular energy (evaluated using a MM  force field), a solvation 
free energy energy term and an entropic term.
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Solvation free energies are calculated by either solving the linear, more accurate, Pois-
son Boltzman (PB) equation, or more approximate, and computationally more effective 
Generalized Born (GB) equation. The calculations performed for each of the three states 
(complex, receptor and ligand) provide the electrostatic contributions to the solvation 
free energy, while the hydrophobic contributions are calculated by means of an 
empirical term (i.e surface tension energy is related to the solvent accessible surface 
area, SASA). Entropy contributions to the total free energy may be estimated either by 
quasi-harmonic analysis133 or by  using normal mode analysis. However, while the 
enthalpic contribution to binding free energy  (i.e the change in enthalpy ∆H) is easily 
obtained from the molecular mechanics forcefield itself, together with the complex sol-
vation effects that can be accounted for by an implicit solvation model, the entropic 
contribution to binding free energy (i.e the change in configurational entropy) has been 
more challenging to calculate.133 
The Poisson-Boltzmann (PB) equation is the core of one of the most popular implicit 
solvent models, as continuum electrostatic approximations are based on numerical solu-
tions to the non-linear PB equation (equation 2.14), which comprises the Gauss’ law (or 
Poisson equation) for electrostatic potential with the Boltzmann charge density. A line-
arized approximation to the PB equation is employed within the MM/PBSA method to 
represent the ionic nature of a biomacromolecule (solute) immersed in aqueous solution 
with counter-ions.
∇&∙&[ε(x)&∇Φ(x)]&=&C4πρsolute(x)&C&4π∑n=i&qi&ci&exp&[Cqi&Φ(x)/kBT]  (2.14)
The Generalized Born (GB) model is then an approximation to the linearized PB equa-
tion. MM/PBSA (and MM/GBSA) methods have recently  been widely  employed in 
binding free energy calculations of various protein-ligand systems,134 as well as probing 
protein interfaces for binding affinity.135 They have been exploited in the ranking of 
ligand binding affinities, which is important in particular in the drug discovery field. 
However limitations of the method have been reported in terms of MM/PBSA perform-
ance for structurally-diverse structures136 or poor approximation of the entropy loss 
which has been challenging to compute in a number of cases, or often simply ignored. 
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2.5 VIRTUAL SCREENING TECHNIQUES: MOLECULAR DOCKING
The expression virtual screening (VS), which emerged in the late 1990s as an alterna-
tive to experimental high-throughput screening (HTS), describes the use of computa-
tional algorithms and models for the identification of novel bioactive molecules. Over 
the years, it has become an important component of the in silico search for hit and lead 
compounds and their optimization. Numerous such methods and applications have been 
described and widely reviewed.137,138 VS can be broadly  divided into two main catego-
ries, namely structure-based VS (i.e molecular docking, structure-based pharmacophore 
modeling), which utilizes the 3D structure of a biological target, and ligand-based 
(similarity-based) VS, where the structure-activity data from a set of known active 
compounds are employed.139
Molecular docking is a term used for a large-scale computational plan that  aims to find 
the ‘best’ matching between two molecules: a receptor and a ligand. Given the atomic 
coordinates of two molecules, docking predicts their “correct” bound association  (bind-
ing pose),140 and estimates the strength of the interaction. There are three crucial com-
ponents in docking: 
(1) representation of the system
(2) conformational space search via a search algorithm
(3) ranking of potential solutions using the scoring function/energy function.  
Molecular surfaces can be described by either a mathematical model (e.g. geometrical 
shape descriptors) or by  a grid; but they can also be described by a molecular frame 
treatment - rigid or flexible. Incorporation of ligand and receptor flexibility  to some ex-
tent, is currently  required for accurate docking since the simplistic rigid ‘lock-and-key’ 
model of ligand receptor interaction is not adequate.141 Thus rotational, translational and 
conformational degrees of freedom of the ligand are sampled at each docking run, and 
in some cases, further conformational degrees of freedom of residues within the ligand 
binding site are taken into account. The search algorithm generates a set of candidate 
geometries for a particular ligand, and then the configurations are evaluated (ranked) 
against each other using scoring functions, proposing the top-scoring pose at the global 
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minimum. The complexes are eventually  re-scored in the end of the search to rank the 
hits in terms of their binding energy (affinity) for the receptor of interest. Despite 
significant progress that  has been made in the generation of potential ligand poses by 
automated molecular docking, and the experimental poses can be predicted with reason-
able accuracy,142 there are still a number of pitfalls in the existing virtual screening 
methods (described in recent reviews by Schneider143 or Scior144 et al), that need to be 
addressed. These are related to the scoring functions used for binding affinity  predic-
tions for a diverse set of molecules, followed by ranking their binding potencies;142 
namely oversimplification of the energy terms usually  employed in the scoring func-
tions, such as entropy contributions,145 specific non-covalent  interactions that are not 
commonly included in the scoring functions,146 water-mediated hydrogen bonds,147 or 
the target flexibility  upon ligand binding. Thus more alternative approaches to docking 
are desirable, and will be discussed as a part of the work described here 
(CHAPTER 5 & 6).
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‘INTERMEZZO’
 
“ I  d o n ’ t  d e m a n d  t h a t  a  t h e o r y  c o r r e s p o n d  t o  r e a l i t y  b e c a u s e  I  d o n ’ t  k n o w  w h a t 
i t  i s .  R e a l i t y  i s  n o t  a  q u a l i t y  y o u  c a n  t e s t  w i t h  l i t m u s  p a p e r.  A l l  I ’ m  c o n c e r n e d 
w i t h  i s  t h a t  t h e  t h e o r y  s h o u l d  p r e d i c t  t h e  r e s u l t s  o f  e x p e r i m e n t . ”
( S t e p h e n  H a w k i n g )
3 1
‘Overture’
A key  aspect of many biological processes involving nucleic acids and their complexes, 
directly  relates to their sequence-specific structure and motion. This motion (sequence-
dependent flexibility and dynamics), brings an additional level of complexity beyond 
structure, that  is essential for interpreting the function of nucleic acids (and their com-
plexes). Molecular dynamics (MD) simulations with empirically-derived force fields is 
a technique, that can in principal, provide a complete theoretical description of a struc-
ture in motion. A critical aspect of such MD simulation is the choice of potential energy 
function (i.e its functional form, force field), that directly affects the modeling efficacy, 
as the the accuracy of modeling depends on the correctness of the potential.148 Nucleic 
acids are very complex and flexible systems (with particular charge distribution along 
the backbone). DNA backbone conformation is defined by six different torsion angles, 
and as a result, the conformational space of nucleic acids is significantly more complex 
than the conformational space of proteins, hence requiring longer simulation times for 
the system relaxation.149 Further consideration for simulations of DNA complexes, lies 
in the force field, which needs to be balanced in terms of pair interactions involving all 
combinations of solvent and the solute atoms.150 
Over the past decade or so, there has been a massive improvement in the empirically-
derived molecular mechanics force fields, tremendous gain in computational power, and 
hence in parallelization of the the simulation programs. This in turn, has contributed to 
great increase in reliability  of MD simulations applied to nucleic acids and their com-
plexes, and to the ability of not only reproducing the experimentally-obtained data, but 
also providing an insight beyond the experiment (i.e duplex,151 triplex,152 quadru-
plex83,84 or supercoiled DNA153 simulations). However, as outlined above, the reliability 
of simulations of DNA complexes, is directly  related to the careful choice of the most 
advanced/improved force field parameters (and their combinations) that are currently 
available, together with an effective MD code, that will allow optimal choice of simu-
lated conditions and reasonable cost of computational time.
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==============================================================
CHAPTER 3:
Porting AMBER force field parameters for nucleic acids, parmbsc0,  
into GROMACS and their validation, and introducing parameters for 
phosphorylated tyrosine residue
==============================================================
3.1 BACKGROUND:
There is a good diversity  in the software packages that may be used today for MD simu-
lations of biomolecular systems. Each widely  used and reviewed MD code features cer-
tain specific advantages over the others, which need to be considered prior to starting 
the MD simulation. However, the majority of these codes can employ force field, 
structure, and trajectory  file formats that were originally introduced and/or produced in 
other programs. The choice of a force field to be used for the MD simulation should 
also be thought of, reflecting the nature of the simulated system. 
3.1.1 Using GROMACS to simulate DNA complexes
GROMACS154,155 an acronym for GROningen MAchine for Chemical Simulation, is 
presented as a versatile suite for molecular dynamics simulations of biomolecules, sys-
tems with complicated bonded interactions. GROMACS does not  have a force field of 
its own, but it supports force fields such as GROMOS96,156 OPLS-AA,157 or 
AMBER.158 Like AMBER, GROMACS has evolved from the initial version of 
CHARMM,159 but it has since been fully developed and distributed as a free software, 
under the terms of the GNU (General Public License, http://www.gnu.org/). A great 
emphasis on algorithmic optimization has been introduced into GROMACS, resulting 
in its exceptional performance with respect to the other MD programs; with the ability 
to run efficiently on desktop  computers, and in parallel employing standard MPI com-
munication (both CPUs and GPU-accelerated MD simulations are supported). All 
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GROMACS file formats are plain-text based, so they are human-readable and editable 
in a situation when new residue/parameters need to be added to an existing force field. 
There are three different types of topology files utilized by GROMACS:
(I)  top system topology; defines the entire system topology, either directly or by 
including .itp files.
(II)   itp include topology; defines individual, or multiple, components of a topology as 
a separate file, and it is force field-specific
(III)  rtp residue topology; the file contains the default interaction type for the bonded 
interactions and residue entries (i.e atoms). 
Such files are needed to define a GROMACS topology for a macromolecule contained 
in a PDB file. Furthermore, each force field has a defined set of atom types with 
characteristic static properties, such as name/number, and mass (atomtypes.atp file). The 
charge is then listed in the residue topology file.
 AMBER stands for Assisted Model Building with Energy Refinement, and it 
refers to two assets: a suite of separate programs that are designed to work together 
throughout the three main steps of a system preparation, molecular dynamics 
simulation, and trajectory  analysis; and a set of molecular mechanical force fields for 
the simulation of biomolecules.160 Being continuously improved/developed since  the 
1980s, AMBER (together with CHARMM) is one of the more established and respected 
MD packages.118 PMEMD code, a recent addition to AMBER, provides scaling on pro-
foundly parallel platforms (up  to 64 cores), as a response to the massively increasing 
computer resources currently available.
3.1.2 Force field choice for MD simulations of DNA complexes
The force fields implemented in AMBER and CHARMM are the most widely used and 
reviewed force fields. In particular, AMBER force fields have proven to be the best 
choice for nucleic acid (both canonical and noncanonical) MD simulations  in terms of 
accuracy  of reproduction of their structural and dynamic properties. It  also successfully 
reproduced hydrogen bond and stacking interactions which were hypothesized by 
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high-level QM data. Moreover, a number of systematic studies suggest  that the AMBER 
force field is physically meaningful and retains a proper balance between intramolecular 
and intermolecular forces, and they also demonstrated good performance in extreme 
environments.161 However, in MD simulations of DNA extended beyond the time-scale 
of 10-ns, tremendous α/γ transitions to the gauche+, trans geometry, which subsequently 
introduced serious distortions in DNA at 50-ns trajectories, were reported.162 This 
disturbing effect, was later confirmed by other research groups, as a general sequence-
independent issue of parm94163 and parm99164 simulations. Since the α/γ torsional is 
important for the description of the low-twist conformations, which in turn may be criti-
cal during the protein-DNA recognition processes, there was a need for the correction 
(with perspective to the longer explicit MD simulation time that are currently possible).
 Full reparametrization of the α/γ torsional term in nucleic acids was carried out 
by Perez and co-workers, leading to a new AMBER force field for nucleic acids, known 
as parmbsc0.161 Based on AMBER-parm99,164 this force field  improves the representa-
tion of the α/γ conformational space of nucleic acids. In principle, the standard nomen-
clature employing the O3’-P-O5’-C5’ (i.e. α torsion) and O5’-C5’-C4’-C3‘ (i.e γ tor-
sion) to represent the α and γ dihedrals is retained as in the original parm99 force field 
(Figure 3.1), and a new atom type (CI) was introduced, and assigned to C5’ carbon (in 
order to prevent alteration of the other conformational profiles).
Figure 3.1: α and γ dihedral term representation as defined in AMBER parmbsc0.161
Schematic representation of the molecular model of the sugar-phosphate component of the nucleotide, 
that was used to define α and γ  torsions and port them into to GROMACS. The atom-type definition is 
also displayed.
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3.2 AIMS
In its simple form, a biomolecular force field is composed of two distinct constituents, 
which describe the interaction between particles (i.e atoms); 
(1) the set of equations (i.e the potential functions) employed to generate the potential 
energies and their derivatives, the forces
(2) the parameters, that are used in this set of equations
Exceptions can be found, but it is typical for a force field to be purely  additive, and 
transferable between the simulation programs, provided that the code may be slightly 
modified due to the discrete differences in torsions, units etc.  
Here, the ultimate goal is to
• successfully port AMBER parmbsc0161 parameters for nucleic acids into GROMACS 
v 4.5, for the subsequent molecular dynamics simulations of protein-DNA complexes 
and G-quadruplex nucleic acids complexes with small-molecule ligands, that are the 
scope of the following chapters described in ‘PART 1’ (protein-DNA MD simulations) 
and ‘PART 2’ (G-quadruplex/ligand MD simulations) respectively. 
• additionally introduce AMBER parameters for phosphorylated tyrosine residue, re-
ported by Homeyer165 et al,  into GROMACS v 4.5,154,155 which was employed for MD 
simulations of phosphorylated STAT3-DNA complex, discussed within the chapters in 
‘PART 1’.
It should be noted, that  while the MD simulations described in this thesis, were carried 
out between 2010 and 2012 (July), ACPYPE,169 a tool based on ANTECHAMBER170 
for generating automatic topologies and parameters in different formats was released 
and published. The ACPYPE tool was then employed here, in order to verify the repro-
ducibility of the parmbsc0 parameters that were previously manually ported into 
GROMACS.
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3.3 CONVERSION AND VERIFICATION OF parmbsc0  IN GROMACS
A detailed description of AMBER parmbsc0161 parameters implementation into 
GROMACS, and its validation is demonstrated here. Reparametrized nucleic acid pa-
rameters of the AMBER parm99164 force field, parmbsc0161 parameters, were obtained 
from the frcmod file (parmbsc0.frcmod), which comprises all the specifications regard-
ing the atom types, atom mass, and bonded (bonds, angles, dihedrals, improper dihe-
drals) and non-bonded terms. These parameters were then manually converted to 
GROMACS-accommodated AMBER-port parm99SB-ILDN, an improved protein side-
chain torsion potential force field developed at Shaw’s166 research group  (based on 
parm99SB,167 a modification of parm99), by replacing the distinct nucleic acids parame-
ters with parmbsc0 parameters. The principles by which GROMACS accommodates the 
potential energy functions used in force fields were carefully followed, and subsequent 
validation of successful parameter conversion was carried out.
3.3.1 Introducing new atom types and parameters into an existing force field
Introduction of a new residue to an existing forcefield into GROMACS, or modification 
of an existing forcefield, such as this case, requires an alteration of several topology and 
parameter files, with respect to the following steps:
• A novel residue, or a modification to an existing residue, is added to the *.rtp file (i.e. 
dna.rtp) of the chosen force field, and to the residuetypes.dat file with the appropriate 
specification.
• If hydrogens are added with the new residue, a relevant entry should be made within 
the *.hdb file.
• New atom types need to be added into the atomtypes.atp and ffnonbonded.itp files
• If new bonded types (bonds, angles and/or torsions) are required, they need to be 
added into the ffbonded.itp.
• specbond.dat file needs to be updated, if the added residue involves special connec-
tivity to other residues.
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Prior to any modifications, the parm99SB-ILD AMBER-port forcefield directory  (with 
all its parameter and topology files) implemented within GROMACS v 4.5.3154,155 was 
copied from its original location to the working directory (preventing any accidental 
modifications to the original AMBER port) and saved using an alternate name.
The equation used for the potential energy, known as a functional form of a force field 
is outlined here in its simplified form (equation 3.1), as a summation of the bonded 
(bonds, angles, torsions) and non-bonded (Lennard-Jones and Coulombic) terms (equa-
tions 3.2 and 3.3):
 V(r)&=&Ebonded&&+&EnonCbonded        (3.1)  
 Ebonded&&=&&Ebonds&&+&Eangles&+&Etorsions                   (3.2)
 EnonCbonded&pairs&=&EVdW&+&Eelectrostatic       (3.3)  
The following sections discuss the conversion of: (i) van der Waals non-bonded parame-
ters; (ii) the bonded parameters conversion, with emphasis on the 4-body interactions; 
and (iii) subsequent verification of the successful conversion of parmbsc0161 parame-
ters.
3.3.2 Conversion of non-bonded parameters
In order for the new parmbsc0 parameters to be recognized in GROMACS when topol-
ogy files for the simulated DNA molecules are generated; a new entry for the CI atom 
type (assigned to C5’), together with its atom mass specification, was introduced into 
the atomtypes.itp  file. Also the CT atom types assigned to C5’ in the dna.rtp  file were 
changed to CI. Subsequently the CI atom type parameter, and its atomic mass of 12.01, 
was introduced into the ffnonbonded.itp  file, together with two required and atom type-
specific van der Waals parameters; sigma (σ; i.e. van der Waals atomic radius) and epsi-
lon (ε; i.e. the depth of potential energy well). 
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In the original AMBER parmbsc0161 frcmod file the CI atom is given the following ra-
dius and well depth parameters, where the first  number is the atomic radius in Ang-
strom, and the second term is the well depth in kcal/mol.
 CI  1.9080  0.1094
Since the CI atom type retained the Van der Waals parameters as defined in parm99, 
where any sp3 aliphatic carbon, such as C5’ (Figure 3.1), is assigned as CT atom type, a 
line with CT atom type specifications was duplicated in GROMACS ffnonbonded.itp 
file, and the duplicate was renamed as CI, with the following parameters:
[ atomtypes ]
; name    at.num  mass  charge    ptype  sigma             epsilon
CI           6          12.01   0.0000   A        3.39967e-01  4.57730e-01 
where ‘ptype’ is the particle type (atom), sigma is the radius in nm, and epsilon is in 
kJ/mol. Sigma and epsilon values are directly used in this instance of using AMBER 
force field in GROMACS; they  (epsilon and sigma values) are combined to provide pa-
rameters for all pairs of atom types in the system, and subsequently  Cij(12) (i.e. constant 
A) and  Cij(6) (i.e constant C) atom pair-dependent parameters, which are employed in 
GROMACS internal Lennard-Jones potential equation for two atoms are calculated and 
used in the program’s internal version of the LJ potential equation (details given in 
CHAPTER 2).
   
3.3.3 Conversion of bonded parameters - bonds and angles
Bonded interactions are based on a fixed list of atoms; those are not exclusively pair 
interactions, such as bonds (1-2 interactions), but they  comprise angles (1-3 interac-
tions), and torsions (1-4 interactions) as well, and they are represented/modeled via 
combination of  potentials with specific parameters. Description of the overall “Class I” 
potential energy function (i.e force field), and its energy components and their parame-
ters, is given in detail in CHAPTER 2. However in practice there is a close relation be-
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tween the force fields and the simulation programs (codes) that implement them, in 
terms of distinct differences of force constant expressions, units, or the functional forms 
of the individual equations.168 Hence the mathematical shapes of the individual AMBER 
force field bonded energy terms are outlined here,  both in their ‘native’ AMBER, and 
‘adapted’ GROMACS format, to demonstrate the discrete features  and differences that 
need to be considered for successful  parmbsc0161 parameters conversion.
 The harmonic potential representing bond length stretching between atomic 
pairs, where atoms are separated by one covalent bond, is outlined in its functional 
shape as implemented in AMBER and GROMACS in Table 3.1; while the harmonic 
potential term describing the alteration of bond angles from their ideal values is outlined 
in Table 3.2. The forms of the 2-body  and 3-body interaction terms are corresponding 
between each other, and also between AMBER and GROMACS. However, there is a 
difference in the default  units used by the two codes, and also  AMBER does not use the 
factor ½ in harmonic potentials, which was accounted for in the parmbsc0161 parameters 
conversion to GROMACS.  
Table 3.1: Bond (1-2 interactions) potential function term, as implemented in AMBER and GROMACS.
FF Energy term - BONDS b0 units Kb units
AMBER Ebond&=&∑Kb&(b&+&b0)2& Å kcal.mol-1.Å-2
GROMACS Vb(bij)&=&½&Kb&(b&+&b0)2 nm kJ.mol-1.nm-2
Table 3.2: Angle (1-3 interaction) potential function term, as implemented in AMBER and GROMACS.
FF Energy term - ANGLES θ0 units Kθ units
AMBER Eangle&=&∑Kθ&(θ&+&θ0)2& ° kcal.mol-1.rad-2
GROMACS Va(θijk)&=&½&Kθ&(θ&+&θ0)2& ° kJ.mol-1.rad-2
AMBER parmbsc0161 ideal (i.e reference) bond length (b0) and ideal bond angle (th0) 
values, and their respective force constants Kb and Kθ are listed in Table 3.3 and 3.4, 
together with their corresponding values for the specific bonds/angles upon parameter 
conversion into GROMACS.  
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Table 3.3: Force field parameters describing the bonds in parmbsc0161 force field.
               
BOND
AMBER GROMACS
Kb b0 Kb r0
[kcal.mol-1.Å-2] [Å] [kJ.mol-1.nm-2] [nm]
CI-H1
CI-CT
OS-CI
OH-CI
340.0 1.090 284512.0 0.10900
310.0 1.526 259408.0 0.15260
320.0 1.410 267776.0 0.14100
320.0 1.410 267776.0 0.14100
The ideal bond length values (b0) were multiplied by 10-1 to convert them from default 
Ångstrom to nm units (which are used by  GROMACS); while the bond force constants 
(Kb) were multiplied by (i) 4.184, to convert  kcal. mol-1 to kJ. mol-1, then by (ii) 100 to 
convert Å-2 to nm-2 and finally  by (iii) 2 to account for the force constant factor used by 
GROMACS. 
Table 3.4: Force field parameters describing the angles in parmbsc0161 force field.
 
               
ANGLE
AMBER GROMACS
Kθ th0 Kθ th0
[kcal.mol-1.rad-2] [ ° ] [kJ.mol-1.rad-2] [ ° ]
H1-CI-CT
H1-CI-H1
CI-CT-H1
CI-CT-OS
CI-CT-CT
OS-CI-H1
OS-CI-CT
P-OS-CI
OH-CI-H1
OH-CI-CT
HO-OH-CI
50.0 109.50 418.400 109.50
35.0 109.50 292.880 109.50
50.0 109.50 418.400 109.50
50.0 109.50 418.400 109.50
40.0 109.50 334.720 109.50
50.0 109.50 418.400 109.50
50.0 109.50 418.400 109.50
100.0 120.50 836.800 120.50
50.0 109.50 418.400 109.50
50.0 109.50 418.400 109.50
55.0 108.50 460.240 108.50
The AMBER values for ideal (i.e equilibrium) bond angle (th0) were kept identical since 
both codes use  degrees for angle units, and subsequently the angle force constants were 
multiplied by  4.184 (kcal. mol-1 to kJ. mol-1), and by a factor of 2 to obtain correspond-
ing angle force constants in GROMACS format. 
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3.3.4 Conversion of bonded parameters - dihedrals
The term describing dihedral (torsion) angle twisting is represented by  a cosine function 
(periodic potential), to model the steric barriers (i.e rotation barrier height) between 
atoms I-J-K-L, separated by three covalent bonds. The related rotational motion is then 
described by a dihedral angle, hence the dihedral parameters, together with the atomic 
charges van der Waals parameters, are the primary determinants of the relative confor-
mational energies of  a molecule.    
In AMBER, torsion potential formula parameters PK (one half of the rotation barrier 
magnitude), IDIVF (total number of torsions about a single bond that the potential 
applies to), PN (periodicity of a particular topology  about the dihedral of interest, i.e the 
number of potential barriers) and PHASE (phase shift), are used to define the dihedral 
potential energy  function. They are typical for each bonded series of atoms I-J-K-L. The 
torsional energy terms as implemented in AMBER and GROMACS codes are outlined 
in Table 3.5.
Table 3.5: Torsion angle potential function term, as implemented in AMBER and GROMACS.
FF Energy term - TORSIONS units
AMBER Edihedral = ∑Vn/2 [1 + cos(nϕ - γ)] Vn/2 [kcal.mol-1]
formula Etors = (PK/IDIVF) * [1 + cos(PNϕ - PHASE)]
GROMACS Vd(ϕijkl) = Kϕ (1 + cos( nϕ - ϕs) Kϕ [kJ.mol-1]
 To illustrate the nature of dihedral parameters in AMBER, and their subsequent 
conversion to GROMACS, we will use the first dihedral in Table 3.6 as an example. In 
case of the X-CI-OS-X dihedral, two “wild-cards” X are used for atoms attached to the 
central C-O atoms connected by a single bond. The IDIVF=3 suggests how many  times 
the dihedral would be defined, if all the atoms had been expressed explicitly, without 
the wildcard X (if all dihedral atoms were explicitly expressed), IDIVF=1. PK is equal 
to one-half of the barrier (magnitude) height, which corresponds to the term Vn/2 that is 
used in the primary AMBER dihedral potential term (Table 3.5), and is subsequently 
divided by IDIVF factor, to represent a torsional barrier for a specific dihedral case. In 
GROMACS, this is represented by force constant Kϕ. Periodicity  (multiplicity) n=3 
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defines the number of potential barriers as the C-O bond (CI-OS) is rotated from -180 to 
180 degrees, and PHASE=0 suggest that there is an energy  maximum at 0 degrees 
(while for energy minimum at 0 degrees PHASE=180), and that the potential energy 
barriers  can be reproduced by the truncated Fourier series with no phase shift needed. 
Based on the principles outlined above, the AMBER dihedral parameters conversion to 
GROMACS was done by dividing the PK (i.e Vn/2) value by  factor IDIVF, and subse-
quent multiplication by 4.184 (kcal. mol-1 to kJ. mol-1) to obtain Kϕ value; the phase 
angles (γ, ϕ0 respectively) and absolute periodicity values (n) remained the same. 
Table 3.6: Force field parameters describing the α/γ torsions in parmbsc0161 force field.
The X-CI-CT-X AMBER dihedral (highlighted in cyan) was replaced by four explicit dihedrals (high-
lighted by dark grey) to be used in GROMACS.
               
DIHEDRAL
AMBER GROMACS
  tor # 
(IDIVF)
Vn/2 (~PK) γ (~PHASE) n     
(PN)
torsion fn ϕs Kϕ n
[kcal.mol-1] [ ° ] [ ° ] [kJ.mol-1]
X-CI-OS-X 
X-CI-OH-X 
X-CI-CT-X 
OH-CI-CT-OS
OS-CI-CT-OS 
H1-CI-CT-H1 
H1-CI-CT-CT
CT-OS-CT-CI
CT-OS-CT-CI
H1-CI-CT-OS
H1-CI-CT-OH
H1-CT-CI-OS
H1-CT-CI-OH
CI-CT-CT-CT
CI-CT-CT-CT
CI-CT-CT-CT
OS-P -OS-CI
OS-P -OS-CI
OS-P -OS-CI
OH-P -OS-CI
OH-P -OS-CI
OH-P -OS-CI
CT-CT-CI-OS
CT-CT-CI-OS
CT-CT-CI-OS
CT-CT-CI-OH
CT-CT-CI-OH
CT-CT-CI-OH
3 1.150 0.0 3.0 9 0.0 1.60387 3
3 0.500 0.0 3.0 9 0.0 0.69733 3
9 1.400 0.0 3.0 9 0.0 0.65084 3
9 0.0 0.65084 3
9 0.0 0.65084 3
9 0.0 0.65084 3
9 0.0 0.65084 3
1 0.383 0.0 -3.0 9 0.0 1.60247 3
1 0.100 180.0 2.0 9 180.0 0.41840 2
1 0.250 0.0 1.0 9 0.0 1.04600 1
1 0.250 0.0 1.0 9 0.0 1.04600 1
1 0.250 0.0 1.0 9 0.0 1.04600 1
1 0.250 0.0 1.0 9 0.0 1.04600 1
1 0.180 0.0 -3.0 9 0.0 0.75312 3
1 0.250 180.0 -2.0 9 180.0 1.04600 2
1 0.200 180.0 1.0 9 180.0 0.83680 1
1 0.185181 31.79508 -1.0 alpha 9 31.79508 0.774797 1
1 1.256531 351.95960 -2.0 alpha 9 351.95960 5.257326 2
1 0.354858 357.24748 3.0 alpha 9 357.24748 1.484726 3
1 0.185181 31.79508 -1.0 alpha 9 31.79508 0.774797 1
1 1.256531 351.95960 -2.0 alpha 9 351.95960 5.257326 2
1 0.354858 357.24748 3.0 alpha 9 357.24748 1.484726 3
1 1.178040 190.97653 -1.0 gamma 9 190.97653 4.928919 1
1 0.092102 295.63279 -2.0 gamma 9 295.63279 0.385355 2
1 0.962830 348.09535 3.0 gamma 9 348.09535 4.028481 3
1 1.178040 190.97653 -1.0 gamma 9 190.97653 4.928919 1
1 0.092102 295.63279 -2.0 gamma 9 295.63279 0.385355 2
1 0.962830 348.09535 3.0 gamma 9 348.09535 4.028481 3
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The one exception of the converted AMBER dihedrals was a dihedral defined around 
the CI-CT bond using two “wild cards” X (highlighted in cyan, Table 3.6). Upon nu-
merous unsuccessful attempts to reproduce the dihedral potential energy employing the 
X-CI-CT-X dihedral, this dihedral was replaced by four explicitly defined dihedrals1. 
Namely: (1) OH-CI-CT-OS, (2) OS-CI-CT-OS, (3) H1-CI-CT-H1, and (4) H1-CI-CT-
CT, with the phase angle and barrier height values corresponding to the original X-CI-
CT-X dihedral. This was done to prevent a misinterpretation of other explicitly defined 
dihedrals with corresponding CI-CT single bond at positions J-K that were further de-
fined by AMBER (such as H1-CI-CT-H1 and H1-CI-CT-CT), and their confusion with 
X-CI-CT-X dihedral options. All parmbsc0161 dihedrals in GROMACS were assigned as 
type 9 function types, which allow multiple potential functions to be applied automati-
cally to a single dihedral (as defined in the system topology file for bonded interactions 
ffbonded.itp).
3.3.5 Testing and validation of the parmbsc0 force field ported into GROMACS
The AMBER parmbsc0161  parameters conversion to GROMACS was tested and veri-
fied by running a single point energy (SPE) molecular dynamics simulations of 9-bp 
DNA helix, both in AMBER and GROMACS, employing the new improved parmbsc0 
force field (i.e the parmbsc0161 parameters, frcmod and lib files, loaded into 
parm99SB), and the standard AMBER parm99SB167 force field (used as a control). A 
flowchart demonstrating the testing of parmbsc0161 force field ported into GROMACS, 
carried out to validate the ability  of the newly created parmbsc0-port to reproduce the 
“original” AMBER test  simulation results, is graphically outlined in Figure 3.2. Three 
sets of corresponding test SPE simulations were performed as follows:
• in SANDER, (AMBER main program for MD simulations)
• in GROMACS, with AMBER topologies ‘translated’ into GROMACS topologies by 
ACPYPE,169 a tool based on ANTECHAMBER170 for generating automatic topologies 
and parameters in different formats 
• in GROMACS, employing the AMBER-ports
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1 I acknowledge a helpful discussion with Dr. Ondrej Kroutil regarding the X-CI-CT-X dihedral.
Figure 3.2: Flowchart demonstrating the testing and validation of the parmbsc0-port for GROMACS.
9-bp DNA helix topologies and coordinates were obtained through xleap, to be used for SPE test simula-
tions in AMBER, ACPYPE169 via GROMACS, and GROMACS itself,  employing parm99SB,167 
parmbsc0161 and parmbsc0-port manually created for GROMACS.
A model of dsDNA helix was obtained from the STAT3-DNA complex, by  extracting 
the 9-bp STAT3 consensus sequence,37 and saving it as a new PDB entry. This “test 
structure” was then processed through the xleap utility in AMBER, to obtain the topol-
ogy and coordinate files, which were generated by employing the parm99SB167 force 
field, and subsequently parmbsc0161 force field, that was previously loaded into xleap in 
separate ‘frcmod’ and ‘lib’ files. Two sets of force field-specific topologies were ob-
tained and saved in AMBER prmtop files; also coordinates (which are force field inde-
pendent) in AMBER inpcrd file, and standard PDB file were output. The individual 
x-y-z coordinate entries within the AMBER coordinates file (inpcrd) were rounded to 
three decimal points, to match the coordinate entries of the PDB file, and ensure the 
consistency of the results, since these particular coordinate files were used for all the 
subsequent test simulations (including those in GROMACS). Corresponding input files 
for the SPE MD simulations were generated both for AMBER (sander) and 
GROMACS, with no constraints, no cutoff values for non-bonded interactions, and no 
solvent models applied. Three sets of SPE test simulations were then carried out  accord-
ing to the following scenarios, with their results summarized in Table 3.7.
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(I) Two SPE simulations were completed in sander (AMBER), using the parm99SB and 
parmbsc0 -generated topologies. Individual components of their bonded and nonbonded 
energy terms, such as bonds, angles, dihedrals (both proper and improper), Lennard-
Jones and Coulomb interactions (both long-range and short-range), as well as the over-
all potential energy were extracted from the resulting output files and compared. 
(II) The AMBER parm99SB and parmbsc0 topology and coordinate files were proc-
essed via the ACPYPE tool, which “translated” them into GROMACS topology file 
formats, for the subsequent four SPE test simulations carried out in GROMACS v 4.5. 
The numerous ACPYPE-employing simulations were used mainly for understanding the 
effects of using different function types for the dihedral parameters, as the AMBER 
improper dihedrals are treated as proper dihedrals in GROMACS. Specifically, the 
dihedral functions explored were: (1) for proper dihedrals, Ryckaert-Bellemans func-
tion,171 a type 3 function (which is internally used by GROMACS to compute Fourier 
dihedrals) was applied, together with a standard periodic proper dihedral type 1155 func-
tion used to compute the AMBER improper dihedrals contribution. In case of 
parmbsc0161 parameters, the parmbsc0 dihedral contribution were also computed by 
function type 1 here; (2) then variant of the standard periodic type dihedral type 1, 
type 9155 function (which is suggested by  the GROMACS manual as useful when multi-
ple potential functions are applied to a single dihedral), was combined with an improper 
dihedral periodic type 4, which is identical to type 1, but also distinguishes improper 
from proper dihedrals in the parameter section and in the output; (3) at last, both proper 
and improper dihedrals were assigned the type 1 function for the calculation. As for the 
AMBER simulations, individual components of their bonded and nonbonded energy 
terms, and the overall potential energy  were extracted from the resulting output  files and 
compared.
(III)  Two SPE test simulations of the 9-bp  DNA helix were carried out in GROMACS 
v 4.5, with the topologies generated by pdb2gmx GROMACS tool, employing the 
AMBER-port force fields. First, the parm99SB AMBER port, which is by default a part 
of GROMACS v 4.5 suite, was used; secondly, the customized AMBER-port compris-
ing the parmbsc0 parameters manually  introduced into parm99SB-port, previously 
copied into the working directory, was employed. As in the previous two cases, the 
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individual energy components were compared between the two GROMACS simula-
tions, but also among each other within all of the eight test simulations.
All test simulation results may then suggest the following conclusions:
•  parmbsc0161 parameters do indeed improve the treatment of  α/γ torsions in nucleic 
acids simulations. As expected, the values of the energy  components were correspond-
ing between parm99SB and parmbsc0 with the exception of dihedrals, and hence the 
overall potential energy. Improved dihedral potential and the total potential energy 
values were observed for the parmbsc0 force field compared to the standard parm99SB.
•  From the four simulations based on  the ACPYPE-translated topologies from AMBER 
to GROMACS, a number of observations were made regarding the dihedral function 
types 1, 3, 4 and 9, which are by default implemented in GROMACS; (1) in terms of 
the summarized dihedral potential energy, using the dihedral function type 3 (Ryckaert-
Bellemans function171), together with the periodic dihedral type 1, led to corresponding 
results, as when function types 9 and 4 were employed. However, when types 3 and  1 
were combined their dihedral potential energy outputs within the Ryckaert-Bellemans 
and proper dihedral  sections were found to be in the same proportion as the outputs of 
types 9 and 4  within the proper and improper dihedrals section. Applying the type 1 
function solely, to both proper and improper dihedrals, led to a single dihedral potential 
energy output within the proper dihedral section. In general, replacing dihedral function 
types 3 and 1 with 9 and 4, or replacing them by type 1 only, did not  make a difference 
with respect to the summarized dihedral potential energy (comprising proper, improper 
and Ryckaert-Bellemans functions). Furthermore, the total potential energy remained 
unchanged when the corresponding force fields were compared. This suggests that there 
is a variability in the individual user’s preferences for the output choice, without affect-
ing the total dihedral and total potential energy. 
• Excellent agreement was achieved between the outcomes of the SPE test simulations 
with respect to the ‘native’ AMBER, ACPYPE-translated topologies for GROMACS, 
and also GROMACS, using the parmbsc0-port with the manually introduced parmbsc0 
force field. 
• In summary, the parmbsc0 parameter conversion for the use in AMBER-port in 
GROMACS v. 4.5 was successful.
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3.4 CONVERSION OF AMBER PARAMETERS FOR PHOSPHORYLATED  
 TYROSINE RESIDUE INTO GROMACS
Structural properties of phosphorylated proteins are important with respect to molecular 
recognition and regulatory processes, since protein phosphorylation is an important 
process governing key steps in cellular regulatory  networks. Protein phosphorylation is 
a very specific process, affecting only side chains of particular protein residues (such as 
serine, tyrosine or threonine), leading to a formation of phosphodiester linkage between 
hydroxyl group oxide of amino acid residues, and phosphate group.172 A phosphate 
group bound to an amino acid side chain has either a single- or double-negative charge, 
with respect to the surrounding environment. Understanding of the role played by  this 
group in terms of protein structure formation (or catalytic events) is directly linked to 
the knowledge of whether the phosphate group is mono- or di-anionic.173 
 For the in silico studies  of STAT3βtc:homodimer complexed with DNA, that are 
described in detail in CHAPTERS 4 and 5, introduction of additional AMBER force 
field parameters for phosphorylated tyrosine residue was required. A consistent set of 
publicly available AMBER force field parameters designed for phospho-amino acids 
was developed by Homeyer165 et al, from which the parameters for phospho-Tyr with 
unprotonated phosphate group were employed here (Figure  3.3). The choice of diani-
onic charge for  phospho-Tyr in  STAT3 was based both on literature survey173,174 and 
on biological experiments via personal communication.
Figure 3.3: Schematic representation of the phospho-Tyr (Y2P) model with atom-types definition.
This model of Y2P165 was used to introduce new parameters for phosporylated Tyr into to GROMACS
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3.4.1 Introducing phospho-Tyr residue into AMBER-port in GROMACS
The dianionic phospho-Tyr (Y2P) parameters165 were obtained in the form of two AM-
BER force field parameters files; (1) frcmod file with the bonded parameters specifica-
tions, and (2) OFF library  file, where atom names, atom types, and charges of the 
phospho-Tyr atoms were stored. The converted Y2P parameters were transferred into 
the AMBER-port of parm99SB-ILDN166 in GROMACS (into a copy of the port saved 
in the working directory). Several distinct steps (principles) for converting/introducing 
new residue to AMBER-port in GROMACS v. 4.5, that are described above, were ap-
plied and followed here too. First, the new phosphotyrosine residue with dianionic 
charge, abbreviated as Y2P, was introduced into the residue topology file within the 
parm99SB-ILDN AMBER port. Individual atoms and their corresponding atom types 
were listed explicitly, together with their respective charges (Table 3.8) into the [atoms] 
section of the [Y2P] residue.  
Table 3.8: Y2P residue atom name, atom type, and partial charges specification.
Atom names, and charges are corresponding between the original Y2P.frcmod file and the GROMACS 
residue topology file within the AMBER-port.
Y2P
atom name atom type charge [e] atom # atom type definition
N
H
CA
HA
CB
HB2
HB3
CG
CD1
HD1
CE1
HE1
CZ
CE2
HE2
CD2
HD2
OG
P
O1P
O2P
O3P
C
O
N -0.516300 1 N -sp2 nitrogen in amides
H 0.293600 2 H -H attached to N
CT 0.141279 3 CT -any sp3 carbon
H1 0.027982 4 H1 -H attached to aliphatic carbon with
CT -0.251171 5 one electron-withdrawing substituent
HC 0.081930 6 HC -H attached to aliphatic carbon with 
HC 0.081930 7 no electron-withdrawing substituents
CA 0.073446 8 CA -any aromatic sp2 carbon
CA -0.198084 9
HA 0.112503 10 HA -H attached to aromatic carbon
CA -0.254266 11
HA 0.161606 12
C 0.477009 13 C -any carbonyl sp2 carbon
CA -0.254266 14
HA 0.161606 15
CA -0.198084 16
HA 0.112503 17
OS -0.557944 18 OS -sp3 oxygen in ethers
P 1.380672 19 P -phosphorus in phosphates
O2 -0.943550 20 O2 -sp2 oxygen in anionic acids
O2 -0.943550 21
O2 -0.943550 22
C 0.536600 23
O -0.581900 24 O -sp2 oxygen in amides
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Bonds within the Y2P residue were further explicitly specified in the [bonds] section, 
followed by  seven Y2P improper torsions in the [impropers] section. Angles and dihe-
drals were not explicitly listed here, as those are defined for all amino acids in the sys-
tem topology file for bonded interactions (ffbonded.itp). Furthermore, all hydrogens 
within Y2P, together with their connectivity to other atoms, was specified in the hydro-
gen database file (aminoacids.hdb).
 The newly-defined bonded parameters, one new bond, two angles, and one im-
proper torsion angle (Table 3.9), were manually entered into the system topology file for 
bonded interactions, into the [bondtypes], [angletypes], and [dihedraltypes] sections.
Table 3.9: Bonded parameters for Y2P residue in AMBER, and upon conversion to GROMACS.
AMBER GROMACS
BOND
P-OS
ANGLE
C-OS-P
CA-C-OS
IMPROPER
CA-CA-C-OS
Kb b0 Kd r0
[kcal.mol-1.Å-2] [Å] [kJ.mol-1.nm-2] [nm]
525.0 1.610 439320.0 0.16100
Kθ th0 Kθ th0
[kcal.mol-1.rad-2] [ ° ] [kJ.mol-1.rad-2] [ ° ]
100.0 120.50 836.800 120.50
70.0 120.00 585.760 120.00
Vn/2 (~PK) γ (~PHASE) n      
(PN)
fn Kϕ ϕs n
[kcal.mol-1] [ ° ] [kJ.mol-1] [ ° ]
1.100 180.0 2.0 4 4.60240 180.0 2
Since the ffbonded.itp topology file contains bonded interactions for both protein and 
nucleic acid systems, a P-OS bond for nucleic acids (r0 = 0.16100 nm; Kd = 192464.0 
kJ/mol) was already defined there. Despite the corresponding value of equilibrated bond 
length between the NA-specific and Y2P-specific P-OS bond,  there is a real difference 
in their force constant values, where Y2P-specific Kd corresponds to the force constant 
value of P-O2 bond (Kd = 439320.0 kJ/mol). Hence a Y2P-specific flag for the P-OS 
bond (bond_Y2P_P_OS) was introduced at the relevant section of the residue topology 
file, and a corresponding bond flag was also used in the system topology file for bonded 
interactions (#define bond_Y2P_P_OS), together with the r0 and Kd values. An 
explicitly-defined bond flag then ensured the use of correct parameters when the topol-
ogy files of a simulated system were created. There were no identical angle entries for 
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the C-OS-P and CA-C-OS Y2P-specific angles in the ffbonded.itp topology file, so they 
were entered within the [angletypes] section. Lastly, the improper torsion specification 
with parameters were included into the [dihedraltypes] section, corresponding to the 
improper torsion listed for [Y2P] in the residue topology file (CA-CA-C-OS). The im-
proper torsion was distinguished from proper dihedrals by assignment of  the dihedral 
function 4, which was designed by GROMACS for this purpose.
The customized parm99SB-ILDN166 AMBER-port with previously introduced 
parmbsc0161 parameters for nucleic acids, and parameters for phosphorylated tyrosine 
residue165 was then employed for all subsequent MD simulations of the STAT3-DNA 
complexes (CHAPTERS 4 and 5), and G-quadruplex DNA (CHAPTERS 6 and 7). The 
protein residue parameters did not interfere with the G-quadruplex DNA MD simula-
tions, since only residues present in the PDB file of the molecular model are regarded 
for the system topology generation by GROMACS.
3.4.2 Retrospective testing and Y2P parameters validation in GROMACS v. 4.5
Following the force field parameters testing and validation procedure described above 
for parmbsc0,  the phospho-Tyr parameters conversion from ‘native’ AMBER format 
(frcmod and lib files), and their subsequent administration into parm99SB-ILDN, and 
parm99SB AMBER-ports in GROMACS v 4.5, was retrospectively  performed (with the 
latter being used as a control). A short tripeptide from the STAT3 sequence with the 
phosphorylated tyrosine residue (pTyr, pY), Pro-pTyr-Leu, and a control unphosphory-
lated sequence of Pro-Tyr-Leu, were used for the SPE test simulations. 
Three sets of corresponding test SPE simulations were performed (Figure 3.4) :
• in SANDER, (AMBER main program for MD simulations) with Y2P parameters 
loaded into parm99SB and parm99SB-ILDN
• in GROMACS, with AMBER topologies ‘translated’ into GROMACS by ACPYPE169
• in GROMACS, employing the parm99SB167 and parm99SB-ILDN166 AMBER-ports, 
with manually introduced Y2P parameters
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Figure 3.4: Flowchart demonstrating the testing and validation of Y2P parameters for AMBER-ports in 
GROMACS.
Tripeptide PpYL and PYL (control) topologies and coordinates were obtained through xleap, to be used 
for SPE test simulations in AMBER, ACPYPE via GROMACS, and GROMACS itself,  employing 
parm99SB and parm99SB-ILDN force field with Y2P parameters.  The individual potential energy com-
ponents were then compared among each other.
The test  SPE simulations, whose results are summarized in Table 3.10, were initially 
performed only for the Pro-pTyr-Leu tripeptide treated by parm99SB-ILDN force field 
with Y2P parameters, since that was the force field employed for the STAT3-DNA com-
plex MD simulations. However, the comparison of the individual potential energy 
components displayed an inconsistency of ~ 3 kJ/mol in terms of the dihedral torsions, 
and the total potential energy, between the AMBER and GROMACS (i.e pdb2gmx) 
results (Table 3.10 a). This ~ 3 kJ/mol difference was not observed within the ACPYPE-
employed simulations. To confirm or refute whether this inconsistency was due to faulty 
Y2P parameters conversion into GROMACS, a subsequent SPE test simulations were 
performed for the unphosphorylated Pro-Tyr-Leu tripeptide, also treated by the 
parm99SB-ILDN force field166 (Table 3.10 b). 
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Even here, the corresponding ~3 kJ/mol inconsistency was observed, suggesting a 
GROMACS AMBER-port-specific error rather than faulty Y2P parameters conversion. 
A third round of corresponding SPE test simulations was carried out, with both tripep-
tides treated by parm99SB force field with Y2P parameters. The subsequent analysis 
revealed an agreement between AMBER, ACPYPE and GROMACS simulations, in 
terms of all explored potential energy  components. Thus these three sets of SPE test 
simulations carried out in AMBER, ACPYPE and GROMACS revealed that the 
parm99SB-ILDN AMBER port implemented in GROMACS v 4.5 did not correctly 
reproduce AMBER dihedral parameters, leading to inconsistencies in the dihedral 
potential energy component and subsequently the total potential energy. 
 Further test SPE simulations were then performed, using a phosphorylated pen-
tapeptide Pro-pTyr-Leu-Lys-Thr (also obtained from the STAT3 sequence). As with the 
tripeptides, a corresponding ~ 3 kJ/mol difference in the dihedral potential energy  and 
total potential energy was observed between AMBER and GROMACS simulations, but 
not between AMBER and ACPYPE simulations (data not shown). This finding 
suggested that it might be tyrosine/phospho-tyrosine dihedrals not being correctly  con-
verted by  AMBER-port parm99SB-ILDN in GROMACS v 4.5. To get a deeper insight 
into that problem, topologies for both the tyrosine and phospho-tyrosine residue 
(i.e bonds, angles, dihedrals and impropers) were extracted from their respective topol-
ogy files generated by GROMACS and ACPYPE and compared. ACPYPE topology 
represents the AMBER topology  as generated by sander, and it is in a human-readable 
format (unlike the original AMBER topology). All the bond, angle and improper torsion 
entries were corresponding between GROMACS and ACPYPE topology in terms of the 
Tyr and pTyr residue respectively. However, when comparing the individual dihedral 
torsions, one extra proper dihedral connecting atoms CZ-CE2-CD2-CG (i.e atom types 
C-CA-CA-CA; defined in GROMACS system topology file ffbonded.itp  as X-CA-CA-
X dihedral with  Kd = 15.16700 kJ/mol) was found in the GROMACS-generated 
topology  file for both phosphorylated and unphosphorylated tyrosine residues. This 
CZ-CE2-CD2-CG dihedral was not found in the ACPYPE topologies, so we may  specu-
late, that this particular dihedral is causing the ~ 3kJ/mol discrepancy  in parm99SB-
ILDN AMBER-port compared to the parm99SB AMBER-port, and compared to the 
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original AMBER-generated topologies. Even though the parm99SB-ILDN166 was 
assessed as the most suitable choice of force field for the protein part of the STAT3-
DNA complex due to the improved parameters of amino acid side chains, namely Ile, 
Leu, Asp and Asn, there is a real requirement of improvement of its correct implementa-
tion within GROMACS v 4.5.
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PART I
EXPLICIT SOLVENT MOLECULAR DYNAMICS STUDIES OF 
THE STAT3βtc-HOMODIMER:DNA COMPLEX
 
“ E v e r y t h i n g  t h a t  l i v i n g  t h i n g s  d o  c a n  b e  u n d e r s t o o d  i n  t e r m s  o f 
t h e  j i g g l i n g  a n d  w i g g l i n g  o f  a t o m s  “
( R i c h a r d  F e y n m a n ,  1 9 6 3 )
5 7
‘Overture’
Signal Transducers and Activators of Transcription (STAT) proteins are a group of latent 
cytoplasmic transcription factors that relay signals from the plasma membrane (in 
response to stress, cytokines and growth factor signalling) to the nucleus.30 The 
inappropriate activation of STAT is linked to various inflammatory diseases (i.e Hyper-
IgE Syndrome,175-176 HIES) and cancers;46 - In particular, the STAT3 transcription factor 
is of  key importance to, and is over-expressed and constitutively activated in, a number 
of human cancers, including pancreatic cancer, melanoma, head and neck cancer, gastric 
cancer and breast cancer. The persistent activation of STAT3 plays a major role in up-
regulating protooncogenes, resulting in survival and proliferation of cancer cells. Hence 
STAT3 is now a validated target for anticancer drug discovery.22,52,177
 According to the original paradigm, cytokines (such as IL-6 and interferon) 
stimulate the phosphorylation of a specific tyrosine residue (Y705) in STAT3, which 
confers on it  the ability to dimerize, subsequently translocate to the nucleus and bind to 
its consensus DNA sequences.30 However, it  has previously been reported that 
phosphorylation is not a pre-requisite for nuclear transport of STAT3 (which is 
dependent on Ran and importin α3 and β1), and a novel mechanism, where 
unphosphorylated STAT3 might  have significant transcriptional control over the 
expression of genes that do not directly  respond to phosphorylated STAT3 was 
suggested.50,178 Furthermore, direct binding of the unphosphorylated STAT3 core 
directly  to M67 (i.e the high affinity STAT3 target DNA sequence) was recently 
reported.179 
 
 The transcriptionally  active STAT3-STAT3 homodimer has been extensively  
targeted (both directly and indirectly)49,51 by  many research groups with the ultimate 
goal of suppressing the aberrant STAT3 function in human cancer cells. In silico 
screening techniques and structure-based drug design have been employed in a number 
of studies aimed at the discovery of small-molecule inhibitors of the STAT3-STAT3 
dimerisation, since the prevention of dimerisation reflects directly  into the downstream 
signalling thus avoiding blocking upstream signalling and reducing the side effect. 
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However, to date, only  five categories of inhibitors have been reported.63-67 This may be 
due to the inherent challenges of targeting protein-protein interactions (i.e lack of 
distinct binding sites); and in the case of inhibition of transcription factors, such as 
STAT3, the protein-DNA interaction may further increase the free energy of the 
associated protein-protein part, hence escalating the challenge of the latter’s disruption 
by small molecules.180 
 There are currently two crystal structures of STAT3 deposited in the Protein Data 
Bank (PDB). Both these structures, of the phosphorylated STAT3β-DNA complex181 
(PDB id 1BG1) and the unphosphorylated STAT3 core fragment182 (PDB id 3CWG), 
have regions of tertiary structure missing in the STAT3 protein-protein interaction 
domains. In particular, a flexible loop of residues containing the tyrosine residue Tyr 
705, which is substantially  enhancing the dimer stabilisation and the interaction surface, 
is missing from the structural data currently  available. This flexible loop of residues that 
can reach across and interact with the partner SH2 domain, stabilise the association and 
bind the phosphorylated tyrosine into a specific binding site on the partner SH2 domain, 
and so uncertainty of the structural arrangement at this key region makes virtual 
screenings even more challenging. Furthermore, X-ray crystal structures are spatially 
and temporally-averaged, thus providing only limited information on dynamic 
properties.
     
 In this part of the thesis, explicit solvent molecular dynamics simulations of the 
STAT3βtc homodimer:DNA complex will be addressed, in both its phosphorylated and 
unphosphorylated form, as well as in complex-bound and latent monomeric form, to 
gain a valuable insight into the aspects of the recognition at  both protein-DNA (CHAP-
TER 4) and protein-protein (CHAPTER 5) level.  These results will directly  aid in silico 
approaches to the discovery of novel STAT3-STAT3 inhibitors for chemotherapeutic 
intervention.
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==============================================================
CHAPTER 4:
Relationships between STAT3 mutations and protein-DNA recognition
==============================================================
4.1 BACKGROUND:
Recent molecular dynamics studies of the STAT3 complex183 and the STAT3 SH2 
domain with docked ligands184 have focused on protein-protein interactions. However, 
understanding the protein-DNA recognition process is of importance for a complete 
insight into the dynamic nature of the STAT3 homodimer:DNA complex which is in 
turn critical for structure-based design of STAT3-STAT3 inhibitors. Water molecules 
often play  a role in molecular recognition and association185,186 and especially in protein 
stability,187,188 protein-protein interactions, protein-ligand recognition,185 and protein-
DNA recognition.189,190 Protein-DNA contacts at the atomistic level can be explained in 
terms of hydrogen bonds (direct readout), water-mediated hydrogen bonds, van der 
Waals, electrostatic and hydrophobic contacts.190 Electrostatic charge interactions are 
considered to be a major determinant of protein-DNA interactions, contributing to 
indirect readout, depending on the distance between the charge groups. However, 
(weaker) hydrogen bonding contributes both to direct read-out (via contacts with base-
pairs) as well as to indirect non-selective read-out (via phosphates and deoxyribose 
interactions). Therefore, if mutations occur at the protein-DNA interface, these 
interactions, and their interaction networks become affected and altered. Dominant 
negative mutations in the STAT3, mostly  in the DNA-binding and SH2 domains, are 
associated with the Hyper-IgE Syndrome (HIES)191 and these mutations have been 
mapped in STAT3 obtained from cells of clinical material.175,176,191,192 
 The present study examines the dynamic features of (1) the Tyr705-
phosphorylated STAT3βtc homodimer:DNA complex, (2) unphosphorylated STAT3βtc 
monomer and (3) the 17 base-pair DNA with 5' overhanging ends, comprising the 
STAT3 binding site. The Tyr705 unphosphorylated STAT3βtc homodimer:DNA 
complex (4) is also examined, since evidence of unphosphorylated STAT3 binding to 
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DNA has been recently described by atomic force microscopy and by X-ray 
crystallography  (Parkinson et al 2012, manuscript in preparation). A major focus is on 
the conformational changes at the protein-DNA interface with respect to STAT3-DNA 
complex formation, and the X-ray structure of the STAT3-DNA complex181 (PDB id 
1BG1).
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4.2 AIMS:
Molecular dynamics (MD) simulations are used here to study the activated STAT3βtc 
homodimer:DNA complex, the latent unphosphorylated STAT3βtc monomer, and 
unphosphorylated STAT3βtc homodimer:DNA complex in an explicit water environ-
ment. The main questions set out to be answered by an analysis of the data obtained 
from MD simulations, each over a 50-ns time-frame are:
• How the transcription factor interacts with DNA,  what is the nature of the conforma-
tional changes, and how does it compare to the dynamics of the unbound STAT3 
monomer, and to the experimental (quasi-static) X-ray data?
• What are the key  residues contributing to the recognition events involved in STAT3 
protein-DNA interactions, and what role does the solvent play  in the protein-DNA 
recognition?
• What are the specific protein-DNA contacts that are affected by  the mutations in the 
DNA-binding domain, and what is their structural stability?
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4.3 METHODS:
The three main stages of this study were:
(1) construction and preparation of the macromolecular systems 
(2) calculation of explicit solvent classical MD trajectories 
(3) data analysis 
The MD trajectories were simultaneously used for generating multiple target conforma-
tions for a molecular docking study, described in CHAPTER 5.
4.3.1 Model building2
The STAT3 crystal structure181 (PDB id 1BG1 at  2.25Å resolution) is deposited in the 
PDB as a monomer. The missing residues in the structure (185–193, 689–701, and 717-
722) were identified as loops by the secondary structure prediction software JPRED193 
These were modeled by the ModLoop194 program. The loops were joined to the main 
structure and subjected to energy minimization procedures using GROMACS154 v 3.3.3 
while keeping the position of the atoms of the core crystal structure fixed. The complete 
monomeric subunit  was then used to construct the STAT3-DNA dimeric complex. The 
bases in the complementary DNA chain in the structure were modified using the Bio-
polymer software in the Insight II suite of programs (www.accelrys.com). The full 
model of the STAT3β homodimer:DNA complex was then subjected to a short  cycle 
(1,000 steps) of molecular mechanics energy  minimization to relieve any steric clashes 
from the structure.
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2 a model of the  STAT3!tc homodimer:DNA complex was built by Dr. Shozeb Haider, before commencing 
my PhD studies in 2009.
4.3.2 System setup and molecular dynamics simulation       
Each monomer of the generated STAT3 dimer comprised residues 136 to 7163, while 
the DNA duplex, in a B-form conformation, comprised a 17-mer duplex with a nine 
base pair (9-bp) high-affinity binding site (M67) and overhanging 5' ends (Figure 4.1). 
This high-affinity M67 site d(TTCCCGTAA) differs at the 7th base from the consensus 
9-bp target site d(TTCCCGGAA) previously described.37 A model of the unphosphory-
lated STAT3-DNA complex was generated by removing the phosphate group of the 
phospho-Tyr705 (pY705) in the STAT3 dimer, and saving the complex as a new pdb 
file. A model of the unphosphorylated STAT3 monomer was generated by a correspond-
ing manner, and saving the monomer as a new pdb file.  The quality  of the model was 
visually assessed by comparison and structural alignment with the crystal structure of 
the STAT3-DNA complex (PDB id 1BG1), and also with the crystal structure of the un-
phosphorylated STAT3 core fragment182 (PDB id 3CWG). The calculated root mean-
square deviation (RMSD) value of the corresponding protein residues of the unphospho-
rylated and phosphorylated STAT3 monomers was ~0.87 Å upon structural alignment 
using the PyMol195 program (www.pymol.org) with the structures visually well match-
ing (Figure 4.2). 
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3 the truncated STAT3 protein  STAT3!tc (residues 136-716) was used in the entire STAT3 in silico study.
Figure 4.1: Model of the STAT3βtc-DNA complex.
Displayed in cartoon representation, individual domains are colour coded; Coiled-coil domains (blue), 
DNA-binding domains (red), linker domains (green), SH2-domains (yellow), and a stretch of ordered 
residues at the C-terminus (magenta), with the pY705 highlighted in stick representation (cyan). The 17-
bp DNA with 5' overhanging ends is located between the two monomers (grey).
Figure 4.2: Structural alignment of the STAT3βtc monomers.
Unphosphorylated STAT3 core-fragment (PDB id 3CWG) (green); phosphorylated STAT3 monomer, 
used for model building (PDB id 1BG1) (red); and phosphorylated STAT3 monomer of the model (blue), 
all in cartoon representation.
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All of the MD simulations were full-atom simulations and were performed with the 
GROMACS v 4.5.3155 program, employing the improved protein side-chain torsion po-
tentials from the AMBER parm99sb-ILDN166 force field, together with the parmbsc0161 
force field, a refinement of the AMBER parm99164 force field for nucleic acids. The 
parmbsc0 force field was manually ported into GROMACS (as described in detail in 
CHAPTER 3). Further AMBER parameters for the phosphorylated-Tyr residues were 
also manually  ported to GROMACS, by introducing a new phosphorylated-Tyr residue 
parameters165 within the parm99sb-ILDN166 force field. Details are given in the 
‘INTERMEZZO‘ section, CHAPTER 3. The modified parm99sb-ILDN force field port 
was then renamed and saved as a new entity in the working directory. 
The simulation protocols were consistent for all four systems:
(1) phosphorylated STAT3βtc homodimer:DNA complex (pSTAT3-DNA complex)
(2) unphosphorylated STAT3βtc monomer (U-STAT3 monomer)
(3) 17-bp dsDNA STAT3 binding site (17-bp DNA)
(4) unphosphorylated STAT3βtc homodimer:DNA complex (uSTAT3-DNA complex) 
 The simulation systems were constructed by immersing the macromolecules in a 
dodecahedron of explicit TIP3P196 water molecules, with a minimal clearance of 20 Å 
between periodic images for the starting configurations (i.e a diameter of the simulated 
system, plus twice the distance of 10 Å were applied to set the dimension of the do-
decahedron box). Initially, hydrogen atoms were added to the simulated systems (except 
for dsDNA MD simulation) according to the protonation states of individual amino ac-
ids with protonable side chains at physiological pH. All Glu and Asp  residues were un-
protonated, hence assigned a negative partial charge (-1), while Lys and Arg residues 
were kept protonated (assigned with positive charge, +1). Cys residues were assigned as 
neutral, since STAT3 is a metal-free protein. Histidine side chains usually have pKa 
values close to physiological pH, and their protonation state determination can be a 
challenge. It has been reported197 that His side-chains are protonated only if their side-
chain nitrogen atoms are within 3.5 Å of a hydrogen bond acceptor in the structure, 
hence H437 was protonated in the model, while all other histidine residues were deter-
mined as neutral; in particular H147, H301, H332, H410 and H694 (Hδ) H447 and 
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H457 (Hε). Predicted pKa values were calculated by  means of the PROPKA198 web 
server. The negative net charge of the STAT3-DNA complexes, and the DNA duplex 
was neutralized by addition of excess positively-charged Na+ counter-ions, with nega-
tively charged Cl- ions, providing a final NaCl concentration of ≈ 150 mM, which 
approximates physiological conditions. The counter-ions were automatically placed 
throughout the box by the genion utility of GROMACS 4.5.3 (www.gromacs.org) re-
placing solvent molecules, using the option to first position those atoms with the most 
favourable electrostatic potential. 
 The total number of atoms in the resulting solvated systems were 559,839 
(pSTAT3-DNA complex), 371,422 (U-STAT3 monomer), 42,088 (17-bp DNA) and 
559,814 (uSTAT3-DNA complex) respectively. Each of the systems was then allowed to 
adapt to the aqueous ionic environment (to remove any  solvent-solvent and solvent-
solute clashes created during the construction process) by applying 5,000 cycles of po-
tential energy minimization, combining both steepest descent and conjugate gradient 
methods. This involved gradual relaxation of the initially-used harmonic restraints on 
the macromolecular atoms. With the greatest strain dissipated from the systems, the sol-
vent was allowed to adapt to the macromolecules by being able to move freely, while 
keeping all atoms of the macromolecule harmonically  restrained to their reference posi-
tions over the 150 ps period of molecular dynamics at 200K. Subsequently the uncon-
strained systems were slowly heated to 300K and equilibrated over 50 ps. 
 To compute MD trajectories, unrestrained production-level MD simulations 
were performed for 50 ns in the isothermal-isobaric ensemble (conserved NPT). 
Pressure and temperature were sustained at 1.0 bar and 300K, with temperature modu-
lated by a velocity  rescaling thermostat  with a stochastic term,199 and isotropic constant-
pressure conditions controlled via the Parrinello-Rahman200,201 algorithm. Non-bonded 
van der Waals interactions were calculated using Lennard-Jones 12-6 potentials with a 9 
Å cut-off. Long-range electrostatics effects were calculated using the Particle-Mesh-
Ewald algorithm (PME),122 with a cut-off for the real-space term of 9.0 Å. The corre-
sponding cut-off values of 9.0 Å for both non-bonded and long-range electrostatic inter-
actions were chosen to fulfill the force field and PME122 algorithm requirements of a 
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minimum cut-off value (< 8 Å), and to obtain superior performance with a minimum 
sacrifice in integration accuracy. The LINCS126 algorithm was employed to constrain all 
bonds.4 The integration time step  applied was 2.0 fs with the coordinates saved every 
5.0 ps. All MD simulations were computed on in-house Linux 64-bit Intel Core-i7 
workstations, with efficient  parallel scaling and double-precision calculations to prevent 
any energy conservation and stability issues. Trajectories were analyzed with the pro-
grams in the GROMACS 4.5.3 suite package, and visualized by means of the VMD202 
and PyMol195 programs. All graphs were plotted using the Xmgrace program 
(plasma-gate.weizmann.ac.il/Grace ). 
4.3.3 Principal Component Analysis (PCA)
Principal component analysis (PCA, i.e. Essential Dynamics) enables large-scale corre-
lated motions of atoms in the molecule to be identified and extracted from MD trajecto-
ries. Hence recurrent modes of structural changes can be eliminated from sets of struc-
tures, revealing the dominant modes and structures in the motion.203 The backbone atom 
coordinates of the protein part and backbone atoms of the DNA helix of (1) the 
complete pSTAT3-DNA and uSTAT3-DNA complexes, (2) monomers-A, (3) 
monomers-B and (4) the U-STAT3 monomer were analyzed by PCA throughout the last 
40 ns of the simulation time. PCA was then repeated considering only residues 321 to 
688 in the protein part of the complex and the DNA helix, since the protein-DNA region 
is of primary interest  in this study, and is stable throughout the MD simulation. 
The GROMACS program g_covar was used to calculate and diagonalize the mass-
weighted covariance matrix. All structures from the MD trajectory were fitted to a ref-
erence structure representing the biomolecular system at the start of the production run. 
The generated eigenvectors, which provide a vectorial description of each component of 
the motion with their corresponding eigenvalues representing the energetic contribution 
of each component to the overall motion, were analyzed using the program g_anaeig in 
the GROMACS program suite. Protein and DNA backbone atoms only were used to 
construct the covariance matrix, since the size of the matrix varies with the square of the 
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4 all-bonds constraints were applied, as a recommended setting at two different GROMACS workshops 
attended between 2009-2010.
number of atoms for which the covariance is calculated and Cα atoms alone may 
adequately sample large-scale correlated motions in proteins.204 The conformational 
changes of the STAT3 biomolecular systems were subsequently visualized by means of 
the porcupine plots,205 which were used to demonstrate the direction and magnitude of 
the extremes of fluctuations which were accounted for in the first and second eigenvec-
tor. The length and direction of the porcupine “needles” clearly  indicates the scope of 
that motion. The porcupine plots were generated using a porcupine script88 and visual-
ized using the VMD202 program.
4.3.4 Cluster Analysis
By definition, cluster analysis is designed to detect hidden clusters in a set of objects 
which are described by numerical or structural data so that the members of each cluster 
behave similarly  to each other and groups are well separated.206 To identify  clusters of 
structures in a trajectory, the RMSD can be used to assign distances between cluster sets 
with respect to the distances between structures, reflecting the range of conformations 
and their relative populations. The gromos agglomerative clustering algorithm207 was 
implemented via the GROMACS clustering utility (g_cluster). This was employed to 
extract the clusters of conformers in the STAT3β-DNA complexes generated over the 
simulation time-frame, with solely the duplex DNA, DNA binding domains, linker and 
SH2 domains (i.e residues 321 - 688) being considered, for the same rationale as de-
scribed above. The RMSD cut-off distance was 2.0 Å for two structures to be consid-
ered as neighbors. The initial 2 ns of the MD trajectories were rejected, and the last 48 
ns were used for the analysis.
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4.3.5 Protein-DNA and water contact-residues analysis
Structures representing the conformations of the pSTAT3-DNA and uSTAT3-DNA 
complex generated over the course of the simulations obtained from the cluster analysis 
were subjected to contact  analysis, focussing on the protein-DNA interface and water 
contacts. Interfacial interactions were defined on the basis of physicochemical and dis-
tance criteria between atoms. A 3.2 Å donor-acceptor distance for hydrogen bonds, and 
5.0 Å for electrostatic interactions between the charged side-chains of residues, and hy-
drophobic interactions was used. From the MD simulation generated trajectories, the 
interatomic distances between the hydrogen bond-forming residues were calculated us-
ing the GROMACS program g_mindist, and the overall time spent within the specified 
distance for each hydrogen bond was determined in terms of percentage of existence of 
the individual hydrogen bonds over the course of the simulation (i.e 48 ns that were 
analyzed). Also all the solvent molecules were analyzed to determine their interactions 
with the protein-DNA complex in terms of time spent within the hydrogen bonds 
formed with the protein, DNA or both (bridging waters). Water molecules were only 
accepted if they formed hydrogen bonds for longer than 1 ns. Dedicated tools in the 
Chimera208 and VMD202 programs were used for hydrogen-bond detection and analysis.
4.3.6 Water density maps5
Water density  maps were generated from snapshots (100 frames, 500 ps time-frame) of 
the protein-DNA complex in explicit water that were generated throughout the simula-
tion. For each area of interest, three consecutive residues on the same chain were chosen 
and used as a reference set to align all of the snapshots, using the program LSQMAN.209 
The water coordinates were extracted from each of the aligned files and placed in a sin-
gle file. These water files were then converted into density maps (.mtz file extension) 
using the CCP4 programs SFALL and FFT.210  Maps were then visualized with the Py-
Mol195 program, by means of the density map wizard  suite.  
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5 The structural alignment  followed by data extraction for water density maps was performed by Dr. Alan 
K. Todd 
4.4 RESULTS AND DISCUSSION
This study has focussed on four main areas: 
(1) nanosecond-scale trajectory analysis in terms of structural stability and conforma-
tional variability
(2) principal component analysis revealing the nature of the major concerted motions
(3) cluster analysis providing structures for mapping both the protein-DNA, and 
protein-protein interface (the latter being a focus of the following CHAPTER 5) to-
gether with an analysis of the hydration at the protein:DNA interface
(4) detailed mapping of the mutations in the DNA-binding region and their location to   
      specific contacts
The unphosphorylated unbound (U-STAT3) vs. the phosphorylated complex-bound 
STAT3 monomers are also compared (Figure 4.2; shown in the methods section), 
together with the effects of STAT3 dimerization followed by STAT3β-DNA complex 
formation with the DNA duplex target sequence. The unphosphorylated STAT3β-DNA 
complex is also brought into perspective to complement the study. These findings are 
then related to the X-ray crystal structure181 (PDB id 1BG1) that was used for the model 
building. In general the simulation results confirm earlier observations from the crystal 
structure, but are able to extend them to provide a dynamic picture of this protein:DNA 
system. 
 A view of the pSTAT3β-DNA complex is shown in Figure 4.1 (methods section). 
Each of the two monomers forming the anti-parallel dimer, is composed of four 
domains: (1) a coiled-coil domain formed by a N-terminal four-helix bundle (residues 
136 to 320), (2) a DNA-binding domain comprising an eight-stranded β-barrel (residues 
321 to 465), (3) an α-helical linker domain (residues 466 to 585), (4) a SH2 (Src 
Homology 2 domain (residues 586 to 688) with a stretch of ordered residues at the 
C-terminus, (residues 689 to 716) containing the important pY705.181
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4.4.1 Structural stability and conformational variability
The overall 200 ns simulation for the four STAT3 models resulted in energetically con-
served and stable simulations for the ~ 560,000-atom STAT3-DNA complexes, 
~ 372,000-atom U-STAT3 monomer,  and ~ 42,000-atom 17-bp DNA target sequence 
systems (Figure 4.3). 
Figure 4.3: Potential energy of the simulated systems as a function of time.
Plot is shown for the pSTAT3-DNA complex (black), uSTAT3-DNA complex (red), U-STAT3 monomer 
(green), and 17-bp DNA (comprising the STAT3 binding-site) (cyan). 
RMSD values for the backbone atoms as a function of the simulation time were used as 
a measure of stabilization of the four models during the simulation, comparing both ini-
tial reference, and time-averaged structures of the models, with the latter providing 
superior insight into the structures reaching the plateau (Table 4.1 and Figure 4.4). 
Table 4.1: Summary of the simulations together with the numbers of residues and RMSD values.
Environment
Simulation system
pSTAT3-DNA complex (1
pSTAT3 monomer-A
pSTAT3 monomer-B
17-bp DNA 
U-STAT3 monomer (2
free 17-bp DNA (3
uSTAT3-DNA complex (4
uSTAT3 monomer-A
uSTAT3 monomer-B
17-bp DNA 
Timescale Residues Water TIP3P RMSD bb vs. start RMSD bb vs. avg
50 ns 1,198 179,628 3.92 Å  2.05 Å
581 2.97 Å 1.93 Å
581 3.37 Å 1.64 Å
36 2.46 Å 1.35 Å
50 ns 581 120,459 5.19 Å 2.25 Å
50 ns 36 13,695 4.05 Å 2.32 Å
50 ns 1,198 179,623 3.80 Å 2.22 Å
581 3.45 Å 1.69 Å
581 3.27 Å 1.70 Å
36 2.46 Å 1.51 Å
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The conformational stability of the higher-order structures was also examined over the 
course of the simulation. The trajectory of the pSTAT3 complex was stabilized at 
around ~ 3.9 Å (and at  around ~ 2.0 Å with respect to the time-averaged structure ob-
tained from the MD), with the individual corresponding monomers-A and -B being sta-
bilized with ~ 0.5 Å difference in their respective RMSDs. Similarly, the uSTAT3 com-
plex was stabilized at around ~ 3.8 Å (and at around ~ 2.2 Å for the time-averaged 
structure), with the individual uSTAT3 complex-bound monomers-A and -B being stabi-
lized with ~ 0.2 Å difference in their respective RMSDs. Whereas there is a modest dif-
ference in the stability of the pSTAT3 complex-forming monomers, the uSTAT3 
complex-bound monomers show very  little difference in their RMSDs with respect to 
both their initial, and time-averaged structures. However, in both cases, the complex-
bound monomers show improved stability comparing to the unphosphorylated STAT3 
monomer. The slightly larger fluctuations in the U-STAT3 model suggest a stabilizing 
effect of the STAT3β-DNA complex formation towards both the STAT3 monomers and 
the DNA duplex (Table 4.1, Figure 4.4).
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Figure 4.4: RMSD plots following the stability of the STAT3 models. 
RMSD plots of the backbone atoms for the STAT3β-DNA complexes versus the starting (black/maroon) 
and time-averaged (grey/brown) structure (a), for the individual STAT3β-DNA complex-forming 
monomers-A (blue/turquoise), and monomers-B (red/orange), unbound unphosphorylated monomer 
(green) versus the initial (b, c) and time-averaged (d, e) structures; and for the complex-bound 17-bp 
dsDNA (magenta/indigo), and 17-bp M67 dsDNA (cyan) versus the initial (d) and time-averaged struc-
tures (e).
The flexible regions in the protein part of the STAT3 complexes, and the U-STAT3 
monomer were also analyzed by examining their structural fluctuations in terms of root 
mean square fluctuations (RMSF) as a function of residue number (Figure 4.5). Large 
fluctuations indicated by  sharp  peaks correspond to the loops. The magnitude of fluctua-
tions is most significant at both terminal regions of the models and in the DNA-binding 
domain, indicating significant interaction with the duplex DNA, in accord with the crys-
tal structure. Differences in the fluctuations within individual domains were observed 
for monomers A and B in both pSTAT3 and uSTAT3 complexes (Figure 4.5 a,c) so that 
despite the identity of their primary sequence, there is a real difference in their dynamic 
behavior.
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Figure 4.5: RMSF plots of the STAT3 models in comparison with experimental B-factors. 
RMS fluctuations averaged over each amino-acid residue for (a) pSTAT3β-DNA and (c) uSTAT3-DNA 
complex forming monomer-A (blue/turquoise) and monomer-B (red/orange), and for (b) unphosphory-
lated U-STAT3β monomer (green) during the dynamics runs. (d) The RMS fluctuations of the STAT3β 
models may be compared with the experimental B-factors for the STAT3β crystal structure (PDB id 
1BG1), which was used to build the initial model.
The complimentary pattern of fluctuations can be observed for the U-STAT3 monomer 
with the largest difference at  the SH2 domain and in particular in the elongated stretch 
of C-terminus residues (Figure 4.5 b). Whereas in the pSTAT3/uSTAT3 complex-bound 
form the “elongated arm-like” loop-forming residues 689-716 interact with the other 
STAT3 monomer (therefore the magnitude of fluctuations is partially limited), in the 
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case of the U-STAT3 monomer the terminal loop was observed to be free to move and 
fold onto the SH2 domain which may explain the very  large RMSF values for the 
U-STAT3 monomer C-terminal region. In terms of the pSTAT3 and uSTAT3 complexes, 
larger fluctuations of the DNA-binding domains and linker domains within the uSTAT3 
complex can be observed with respect to pSTAT3 (Figure 4.5 a,c), whereas the protein-
protein interacting domains (i.e SH2 domains with the stretch of C-terminal residues) of 
the pSTAT3 complex display larger fluctuations comparing to the uSTAT3 model. The 
pattern of experimental B-factor values in the crystal structure 1BG1, plotted as a func-
tion of residue number (Figure 4.5 d) show certain similarities to the fluctuations ob-
served in the STAT3 MD simulations. However, due to the extremely large values of the 
B-factors for atoms in the SH2 domain and the uncertainties surrounding the stretch of 
C-terminal residues in particular (with a number of residues missing), the STAT3 con-
formations generated here during the MD run can provide greater insight into the 
arrangement of the protein-protein interaction than the crystal structure. A comparison 
has also not been made between the crystallographic water molecules and those in the 
MD simulations in view of the uncertainties surrounding the former, which also mostly 
have high B-factors.  For any further analysis, the first  2 ns of the simulations were re-
jected, as a consequence of relaxation of the system, after which the trajectory  of the 
STAT3 systems was stable (Figure 4.4). 
 Since the major focus of this study is on the conformational changes at  the 
protein-DNA interface, with respect to the pSTAT3-DNA complex formation and to the 
X-ray structural data of the STAT3-DNA complex, RMSD plots on a per residue basis 
were generated for the DNA-binding domain, linker and SH2 domain (residues 321 to 
688) of both pSTAT3 complex-bound monomers-A and -B, as well as for the U-STAT3 
monomer, in order to obtain more insight into the stability of this key region (Figure 
4.6). These domains of monomer A and B were observed in the simulations to have 
comparable stabilities. Thus the mean RMSD per residue values are: DNAbin domain 
of monoA: ~ 2.8 Å, monoB: ~ 3.3 Å, Umono: ~ 3.0 Å; linker of  monoA: ~ 2.1 Å, 
monoB: ~ 2.6 Å, Umono: ~ 2.4 Å; SH2 domain of monoA: ~ 3.5 Å, monoB: ~ 4.3 Å, 
Umono: ~ 4.1 Å for the U-STAT3 monomer domains. The residues determined at the 
protein-DNA interface are highlighted (in light-grey) and the residues carrying the 
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mutations are marked in Figure 4.6, which will be discussed in more detail in the 
following sections.
Figure 4.6: RMSD per residue basis for the STAT3 core region.
(a) DNA-binding domain (residues 321-465), (b) linker (residues 466-585) and the (c) SH2 domain (resi-
dues 586-688) of the individual pSTAT3-DNA complex-forming monomer-A (blue), and monomer-B 
(red) unbound unphosphorylated monomer (green). Residues determined at the protein-DNA interface are 
highlighted in light-grey and the residues reported to be carrying the mutations are marked in by grey 
line.
Backbone-atom RMSD plots of the 17-bp duplex DNA (Figure 4.4 f,g) unsurprisingly 
show that STAT3-DNA complex formation has an overall stabilizing effect on the DNA, 
in agreement with the RMSF plots of the complex-bound and free 17-bp dsDNA (Fig-
ure 4.7), with the pSTAT3-DNA complex showing even stronger effect on the DNA sta-
bilization, resulting in overall smaller fluctuation of the DNA basis throughout the MD 
run. The terminal regions display larger fluctuations comparing to  the rest of the DNA 
helix since both the 5’ ends are overhanging. Furthermore, the amplified fluctuation at 
the T5’ region in the STAT3-DNA complex-bound forms can be explained by a strong 
interaction of the residues in monomer-A with the C(8) and G(7) nucleotides of the 
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opposite DNA chain, hence unwinding the duplex DNA at that terminal. The protein-
DNA interactions will be discussed in more detail in the following section.  
   
Figure 4.7: RMSF plots for the 17-bp dsDNA consensus sequence.
RMS fluctuation plots for the model of  the ‘free’ 17-bp dsDNA duplex (cyan),  pSTAT3 complex-bound 
DNA duplex (magenta), and uSTAT3 complex bound dsDNA (purple), all containing the M67 consensus 
sequence;  the corresponding DNA chains are plotted together: (a) chain 1 and (b) chain 2.
4.4.2 PCA: Defining the concerted motions in STAT3
The overall patterns of motions in both phosphorylated and unphosphorylated STAT3β 
homodimer:DNA complexes (and their individual monomers), and the U-STAT3 
monomer, were identified via principal component analysis (PCA), a method that ex-
tracts the dominant modes in the motion of the molecule from the trajectory obtained 
from the MD simulation, and provides a quantitative assessment of the correspondence 
between the MD data sets. PCA was performed on the backbone atoms of the STAT3 
models, employing the trajectory  from the last 40 ns of each of the simulations (with a 
25 ps time-step). The total variance was accounted for by the calculate eigenvectors and 
the corresponding eigenvalues from the covariance matrix of simulation. Two types of 
PCA were carried out: (1) including all backbone atoms of the protein-DNA complexes 
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(i.e residues 136 to 716 and dsDNA if relevant), outcome of which was further 
subjected to graphical visualization by  means of the porcupine plot  as described below; 
and (2) considering only  residues 321 to 688 of the protein with the DNA duplex 
(i.e DNA binding domains, linkers and SH2 domains). The first 10 eigenvectors were 
considered for further analysis, which showed that the first three eigenvectors account 
for ~50% of all the motion in the simulated systems (Figure 4.8).
Figure 4.8: PCA graphs capturing the concerted motions of the STAT3 models.
(a, c) Eigenvalue versus eigenvector index, and (b, d) cumulative eigenvalue (%) derived from PCA of 
backbone-atom MD trajectories for the first ten eigenvectors of the (a, b) pSTAT3-DNA complex (black), 
for the individual complex bound monomer-A (blue), and monomer-B (red), and U-STAT3 monomer 
(green); and for the (c, d) uSTAT3-DNA complex (maroon) and its individual complex bound monomer-
A (turquoise) and monomer-B (orange). Only protein residues 321- 688 and DNA helix are considered.
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The first two eigenvectors were represented by means of porcupine plots that show the 
scope and magnitude of the motion (given by the first and second eigenvector respec-
tively) for each of the backbone atoms, for residues 136-716 and DNA helix (Figure 
4.9), for both pSTAT3-DNA complex and uSTAT3-DNA complex. The orientation is 
such, that complex-bound monomer-A is always on the right within the Figure 4.9. The 
complex-bound motion of STAT3 monomer-A is compared with the U-STAT3 monomer 
(Figure 4.9 g, h). The first principal component for the STAT3-DNA complex confirms 
the observation made from the RMS plots that the most prominent motions are observed 
at the loops within the coiled-coil domain (the loop connecting helices α1 and α2), 
resulting in a characteristic scissor-like motion, with the duplex DNA in the middle act-
ing as a “hinge”. 
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Figure 4.9: Porcupine plots for the STAT3-DNA complexes and STAT3 monomer.
Porcupine plots for the (a) first and (c) second eigenvector for the pSTAT3 complex simulation with de-
tailed focus on the characteristic movement of the monomer-A DNA-binding domain at the protein-DNA 
interface, which differs significantly from that of the monomer-B DNA-binding domain movement (e). 
Complementary porcupine plots of the (b) first and (d) second eigenvector for the uSTAT3 complex and 
the close-up look at the DNA binding domains motion (f). DNA-binding domain of the monomer-A is in 
both cases marked in red-dotted circle; (g) porcupine plots of the first eigenvector for the pSTAT3 
complex-bound monomer-A (blue), and (h) unphosphorylated unbound U-STAT3 monomer (green). The 
models are shown as bond trace with the arrows attached to the individual backbone atoms representing 
the scope and the magnitude of the motion.
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Several observations can be made from the porcupine plots (corresponding to data from 
the RMS plots): 
(1) monomer-A undergoes overall greater motion than monomer-B; however the differ-
ence is  smaller  in the case of the uSTAT3-DNA complex.
(2) the dynamics/motion of the DNA-binding domain of monomer-A suggests that the 
DNA-interacting loops of monomer-A are inserted deeper into the DNA groove. 
This results in a greater span of interaction with the DNA duplex (further discussed 
below), and also indicates DNA unwinding at the T5' end. The larger magnitude of 
movement at the T5' of the DNA is also in accord with this observation, as shown in 
Figure 4.9. Similar patterns of movement, with monomer-A inserting further into the 
groove of the DNA helix, was observed within alternative MD simulations employ-
ing the ff03 force field, cubic solvation box and GROMACS v 3.3 (data not dis-
cussed). This then suggest that the described difference in STAT3 monomers move-
ments was not an artifact of the simulation.
(3) when comparing the DNA-binding domains of the pSTAT3 and uSTAT3 complexes, 
DNA-binding domain of monomer-A of the pSTAT3-DNA complex undergoes sig-
nificantly larger  motion, as shown in Figure 4.9 (e, f)
(4) the major flexibility at the SH2 domains region arises from the loop-like stretch of 
C-terminal residues (residues 689-716) that  forms an arm which reciprocally binds 
onto the other monomer.       
With respect to the predominant motion within the U-STAT3 monomer, the overall 
magnitude of fluctuations at  the incremented regions (protein-DNA interface) is smaller 
comparing to those for monomer-A (Figure 4.9 g, h), since there are no interaction part-
ners. The most significant difference in the movement lies within the SH2 domain with 
the folded C-terminal stretch of residues, and the direction of the movement is opposite 
compared to that in complex-bound monomer-A.
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4.4.3 Cluster analysis: Statistical description of the interface
Cluster analysis was applied to the large amount of data generated in order to provide a 
statistical description of the dynamics of the STAT3-DNA complexes. Here, only  resi-
dues 321 to 688 of both monomers (i.e DNA-binding domains, linker domains and SH2 
domains) together with the DNA helix were used for clustering. This analysis used the 
1920 frames extracted from the MD trajectory at a time interval of 25 ps (i.e 48 ns) for 
the matrix construction, with a 2.0 Å RMSD cut-off applied for the neighbor search. 
The first five of the 12 resulting clusters of the pSTAT3 protein-DNA complex are rep-
resented by  middle structures (Figure 4.10) – these are the conformations sampled dur-
ing the simulation at 300K. These were used for the analysis of the protein-DNA inter-
face detailed below. The first five clusters covered approximately  98% of the total en-
semble of sampled conformational space. Cluster 1 was the predominant conformer, 
being populated approximately 57% of the simulation time, whereas cluster 2 spanned 
over 10 ns of the simulation (~ 22% of the simulation time). In terms of the uSTAT3 
protein-DNA complex, 16 clusters were obtained from the corresponding trajectory (48 
ns, 1920 frames with 25 ps time steps). The first five of the 16 resulting clusters, repre-
sented by middle structures, spanned through approximately 90% of the total ensemble 
of sampled conformational space at 300K.  Cluster 1 was populated approximately  46% 
of the simulation time, being the predominant conformer, while cluster 2 represented 
nearly 10 ns of the simulation (~ 17 % of the simulation time). These five middle struc-
tures from the first five clusters were also subjected to the protein-DNA interface analy-
sis, hence provide a useful comparison with the phosphorylated STAT3 protein-DNA 
interface. Larger number of clusters of the uSTAT3 complex indicates, that despite 
good overall stability, there are indeed increased fluctuations in this modeled system 
resulting in more representative structures than for the pSTAT3 complex. Since the only 
difference between the two complexes is the phosphorylation of the specific amino acid 
residue, Y705, this may further indicate the increased association strength of the 
pSTAT3-DNA complex, which is in accord with the experimental observations. The 
characteristic features of the phosphorylated Y705 interaction with the partner SH2 
domain are fully  described in CHAPTER 5, employing the exact five clusters of the 
pSTAT3 protein-DNA complex.
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Figure 4.10: Cluster analysis of the DNA-binding region of the pSTAT3 model.
Structures representing the pSTAT3-DNA complex (residues 321-688 of both monomers and the DNA 
duplex),  obtained from the trajectory over the dynamics and gathered into 12 clusters of decreasing sizes 
(a), plotted against the simulation time (b). Only the middle structures of the first 5 clusters were used for 
the protein-DNA interfacial analysis (c).
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Representative structures of the true conformational space at 300K obtained from the 
cluster analysis of the 25-ns MD trajectories (2.5 Å cutoff, 1000 frames) subsequently 
provided multiple target conformations for a small molecule docking study, which is 
reported in CHAPTER 5. This approach is supported by recent studies demonstrating 
that state-of-the-art docking algorithms predict an incorrect binding pose for about 50-
70% of ligands when only a single fixed receptor conformation is considered.141
4.4.4 Mapping the protein-DNA-solvent interaction
The middle structures of the first five clusters obtained from the cluster analysis were 
used to describe the protein-DNA interactions, as they  represent over 98% (90% for the 
uSTAT3 complex respectively) of the conformational space covered throughout the 
50-ns MD run. Within a 5.0 Å distance cut-off, and a condition of at least one non-
hydrogen atom present in that distance range, 25 corresponding residues were identified 
at the protein-DNA interface of the pSTAT3β-DNA complex, within each of the 
subunits (monomer-A and -B). A further seven non-corresponding residues of 
monomer-A (G419, N420, G421, G422, A424, N425 and C426) and seven 
non-corresponding residues of monomer-B (M329, P330, H410, N553, K573, E616 and 
K642) were observed at  the interface (Table 4.26). Although the monomers are identical 
in terms of the reciprocal pY705 interaction at the SH2 domains and the high-affinity 
binding predominantly in the DNA major groove, the partial asymmetry of the 
monomeric protein-DNA interface and the specific dynamics of each monomer may be 
explicable by the asymmetric spiral (or “screw-like”) shape of the DNA duplex. A range 
of electrostatic, hydrophobic, and hydrogen bonds-forming contacts between the STAT3 
protein and the DNA duplex occur predominantly in the DNA-binding domains, 
although they  also occur in the linker domains of both phosphorylated STAT3β mono-
mers, and at the SH2 domain of monomer-B (E616, K642 and Q643). 
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6 * There are 39 residues in the interface, 25 of which are common to the two monomers. Residues forming 
hydrogen bonds with the DNA are highlighted in grey, and unless stated otherwise, the hydrogen bonds 
involve the DNA backbone atoms. Hydrogen bonds comprising the atoms of the DNA bases are listed. 
Point mutations at the protein-DNA interface are shown in dark grey, and residues forming hydrogen 
bonds with the solvent molecules are marked (WAT), with water molecules bridging the protein-DNA 
interaction indicated as (WAT-bridge).
Table 4.2: Contact residues within the pSTAT3 protein-DNA interface. 
Amino acid residues of the pSTAT3 complex-bound monomers-A and -B determined to be within the 5 Å 
cut-off protein-DNA interface of the first 5 middle structures obtained from the cluster analysis*.
monomer-A monomer-B
HB -solvent Occup. HB-DNA 5Å int-
Face
5Å int-
Face
HB-DNA Occup. HB-solvent
-- M 329 ✓
-- P 330 ✓
WAT ✓ M 331 ✓ dC(0) 95%
WAT ✓ H 332 ✓ dC(0) 98%
60% dG(0) ✓ K 340 ✓ dG(-1)_O6 24% 3x WAT-bridge
WAT-bridge ✓ T 341 ✓ 2x WAT-bridge
✓ G 342 ✓
✓ V 343 ✓ WAT-bridge
2x WAT-bridge 22% dA(-2) ✓ Q 344 ✓ dC(+2) 53%
73% dC(-1) dC(+1) 33%
WAT-bridge, WAT 98% dT(+4) ✓ R 382 ✓ dT(-4) 97%
-- H 410 ✓
2% dT(+3) ✓ R 414 ✓
4x WAT-bridge, 5x WAT ✓ E 415 ✓ 5x WAT-bridge, 3x WAT
69% dT(+4) ✓ R 417 ✓ dT(-4) 57%
83% dT(+3) dT(-3) 91%
✓ G 419 --
4%  dG(+7) ✓ N 420 --
7% dC3’(+8)
8% dC3’(+8) ✓ G 421 --
11% dC3’(+8) ✓ G 422 --
WAT 8% dA(+6) ✓ R 423 ✓  dT3’(-8) 5%
10% dT(+5) dT(-5) 42%
27% dC3’(+8)
10% dG(+7)_N3
35% dT(+6)_O2
6% dC3’(+8) ✓ A 424 --
3%  dC3’(+8) ✓ N 425 --
4% dC(+7) 
7% dG(+7)_N2
✓ C 426 --
✓ L 430 ✓
✓ I 431 ✓
90% dT(+5) ✓ V 432 ✓ dT(-5) 77%
WAT ✓ T 433 ✓ 3x WAT
✓ I 464 ✓
100% dT(+4) ✓ S 465 ✓ dT(-4) 100%
93% dT(+3)_O4 ✓ N 466 ✓ dT(-2)_O4 95%
65% dG(+2)_N7
dG(+2)_O6
dT(-3)_O4 90%
44%
✓ I 467 ✓ WAT-bridge
✓ C 468 ✓
WAT-bridge 92% dT(+4) ✓ Q 469 ✓ dT(-4) 95%
-- N 553 ✓
✓ D 570 ✓ 2x WAT
-- K 573 ✓ dG(-1) 2%
✓ K 574 ✓ dG(-1) 84%
-- E 616 ✓ 3x WAT
-- K 642 ✓ dT(-2) 78%
✓ Q 643 ✓
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In terms of the uSTAT3β-DNA complex, 23 corresponding residues were identified at 
the protein-DNA interface, with a further ten non-corresponding residues of monomer-
A (G342, N420, G421, G422, A428, I464, D570, E616, Q643 and N646) and three non-
corresponding residues of monomer-B (M329, R414 and N425). The observed asymme-
try within the unphosphorylated monomer-DNA interaction is even more amplified 
here, indicating that monomer-A inserts deeper into the groove, which is in accord with 
the structural stability behavior described above (RMSF plots Figure 4.5 and 4.9) Over-
all, there is agreement for 34 protein-DNA interfacial residues between  the two STAT3 
complexes, with five extra residues being present at  the phosphorylated complex inter-
face, namely  G419, A424, C426, N553 and K573; and two additional residues within 
the interface of at the uSTAT3-DNA complex, A428 and N646. 
 When analyzing the interfacial contacts, particular attention was paid to map-
ping the hydrogen bonds formed between the sugar-phosphate backbone of the DNA 
and protein residues, and in particular to those hydrogen bonds that involve DNA bases 
and/or have been reported to be affected by  point mutations.175,192 (Figure 4.11). Since 
the hydration of the protein surface may  well be crucial for the stability  and flexibility 
of the protein itself, the folding process, and molecular recognition, both water-protein 
and water-DNA interactions were analyzed, as well as features of protein-DNA recogni-
tion. The analysis of the hydrogen bonds formed between the solvent and STAT3-DNA 
interface throughout the MD simulation (1920 frames with 25-ps time-steps) used the 
VMD program. The water molecules were analyzed in terms of overall time spent 
within a distance required for a hydrogen bond formation, and only those water mole-
cules with residence time exceeding 1 ns, were considered. The hydration at the protein-
DNA interface was also analyzed in terms of water density maps  (Figure 4.12 a-f).
4.4.4.1 Hydrogen bonds at the pSTAT3 protein-DNA interface
 
Following these criteria, the STAT3-DNA-solvent hydrogen bonds were analyzed in 
both phosphorylated and unphosphorylated STAT3 complexes. The main focus here is 
on the pSTAT3-DNA complex interface (Figures 4.11 a, 4.12 and Tables 4.2 and 4.3), so 
            PART 1
87
the results on it will be discussed primarily, while the complimentary  uSTAT3-DNA 
interfacial residues will be outlined subsequently. Nine protein residues were identified 
as forming hydrogen bonds involving the sugar-phosphate atoms of the DNA backbone, 
or the atoms from the bases, at both monomer interfaces, namely  K340 (G(0) and G(-
1)), Q344 (bp±1, ±2), R382 (bp±4), R417 (bp±3, ±4), R423 (bp±5, ±8), V432 (bp±5), 
S465 (bp±4), N466 ( bp±2, ±3) and Q469 (bp±4). Monomer-A further formed stable 
hydrogen bonds between residues R414 – T(+3), N420 – C3’(+8) and G(+7), G421-
C3'(+8), G422 – C3'(+8), R423 – A(+6), T(+6) and G(+7), A424 -C3’(+8), N425 – 
G(+8), G(+7) and C(+7). Protein residues are always hydrogen bond-donors and the 
DNA bases are hydrogen bond-acceptors, with the exception of G(+7) and C(+8) that 
behaved both as hydrogen bond-donors and acceptors (Figure 4.13 a). Monomer-B ex-
clusively formed hydrogen bonds with the DNA sugar-phosphate backbone or the atoms 
from the bases; M331 – C(0), H332 – C(0), K573 – G(-1), K574 – G(-1), and K642 – 
T(-2).  Despite fewer hydrogen bonds being formed between monomer-B and the DNA, 
the occupancy period of these interactions was in general longer comparing to the nu-
merous interactions formed by monomer-A. This is due to the greater mobility  of the 
DNA-binding domain of monomer A, allowing the hydrogen bond-interacting residues 
in loops ab, cx, ef and gα5 to reach into the major groove while the interface with the 
monomer-B is less variable as the simulation time progresses (Figure 4.11). R382, 
V432, S465, Q469 and N466 in both monomers formed hydrogen bonds with the DNA 
that lasted practically throughout the entire simulation time, with N466 specifically  in-
teracting with both DNA chains. These five hydrogen bonds are in accord with the ex-
perimental data, since they are observed at the x-ray  structure of the STAT3-DNA com-
plex (PDB id 1BG1), however another newly  described interactions arise from two ar-
ginine residues R417 and R423; R417 of both monomers-A and -B forming long-lasting 
hydrogen bonds with T(±)3 and T(±)4, while R423 of monomer-A, specifically recog-
nizing bases T(+6) and G(+7) at the complementary DNA strand, and further forming 
hydrogen bond with the terminal base at the C3’ end of the opposite DNA chain, and 
A(+6) and T(+5), acting both as a hydrogen bond donor and acceptor; Also R423 of 
monomer-B formed hydrogen bonds with both chains of the DNA, namely  T(-5) and 
T(-8); N425 of monomer-A specifically recognized base G(+7) with the DNA base be-
having like hydrogen bond donor. 
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The most frequently  occurring residues in the protein-DNA interface are Arg, Asn, Lys 
and Gln residues, with Arg residues located in the AT-rich minor groove, which is in 
accord with findings of arginine-enriched DNA minor grooves reported by Rhos211 et al. 
There is also a large number of Gly residues at the monomer-A-DNA interface, in par-
ticular forming hydrogen bonds with the terminal base at the C3' end of the DNA strand.
 There are a total of 25 contacts formed between 21 different water molecules 
and 12 individual nucleotides (+5, +4, +3, +1, 0, -1, and -2 in the 5'-T strand 1; -4, -3, 
-1, 0, and +8 in the 5'-A strand 2). 16 of these 21 water molecules (water molecules are 
numbered 1-16 for simplicity - summarized in Table 4.3) bridge to the interfacial 
protein residues, forming indirect hydrogen bonds, for instance with E415 and T341 in 
both monomers, and additionally with Q344 and Q469 of monomer-A, and K340, 
V343, and I467 in monomer B. There is a pronounced pattern in the frequency of inter-
actions of base pairs T±4, T±3 with both protein residues and water molecules, and 
there are also numerous hydrogen bonds involved with bp0 and bp±1, despite the high 
sequence variability at these positions in natural DNA target sites.
Table 4.3: Bridging water molecules at the protein-DNA interface of the pSTAT3-DNA complex. 
These bridging water molecules mediate the indirect hydrogen bonds formed between the residues of 
monomer-A (white) and monomer-B (grey) and the DNA
pSTAT3-DNA complex-bound       
monomer
Bridging waters pSTAT3-DNA complex-bound       
dsDNA
E415 WAT 1 dT(+4)
E415, R282, T341 WAT 2 dT(+4), dT(+3)
E415 WAT 3 dT(+4)
Q344 WAT 4 dC(-1)
E415 WAT 5 dT(+4)
Q469 WAT 6 dT(+5)
Q344 WAT 7 dC(-1)
K340, I467 WAT 8 dC(0), dG(-1), dT(-2)
E415, T341 WAT 9 dT(-3), dT(-4)
T341 WAT 10 dT(-3)
K340, V338, E415 WAT 11 dC(0)
E415 WAT 12 dT(-4)
E415 WAT 13 dT(-4)
E415 WAT 14 dT(-4)
E415 WAT 15 dT(-4)
K340, V343, L413 WAT 16 dC(0)
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4.4.4.2  Hydrogen bonds at the uSTAT3 protein-DNA interface
Among the 36 protein residues identified at the protein-DNA interface, 34 of which are 
corresponding to the interfacial residues of the phosphorylated complex, the same nine 
protein residues, as in the case of the pSTAT3 complex, were identified forming hydro-
gen bonds involving the sugar-phosphate atoms of the DNA backbone, or the atoms 
from the bases, at both monomer interfaces  (i.e K340, Q344, R382, R417, R423, V432, 
S465, N466 and Q469). In monomer-B, an additional hydrogen bond between residues 
N466 and T(-4) was also identified. (Figure 4.11 b). Monomer-A further formed hydro-
gen bonds between residues N420 - T(+6) and G(+7), G422 - C3’(+8), K574 - G(+1) 
and Q643 - G(+2), where protein residues are always hydrogen bond-donors and the 
DNA bases are hydrogen bond-acceptors. In comparison to the phosphorylated 
monomer-A interactions, hydrogen bonds involving residues R414, G421, A424 and 
N425 are not present here. Monomer-B exclusively formed hydrogen bonds with the 
DNA sugar-phosphate backbone or the atoms from these bases: M331 - (0), H332 - 
C(0), H410 - C(+1) and R414 - A(-2); the first two of which are corresponding to those 
observed in phosphorylated monomer-B, while the latter two are unique. Hydrogen 
bonds comprising residues K573, K574 and K642 were not present here in the frame of 
selected criteria. In this case, an equal number of hydrogen bonds formed between  the 
unphosphorylated complex-forming monomers and the DNA, in particular 18 hydrogen 
bonds arising from 13 residues of each of the monomers (Figure 4.11 a and b for com-
parison). This is in accord with the structural stability  data and the PCA analysis (Figure 
4.9 d-f), which revealed overall very similar scope of movement among the DNA-
binding domains, monomer-A being dominant in terms of insertion into the groove of 
the DNA at  its C3’ terminal, hence forming contacts that are not observed at  the T3’ 
end of the complimentary DNA chain. By comparison with the pSTAT3 complex, there 
are a total of 25 contacts formed between 19 different water molecules and 14 individ-
ual nucleotides (+4, +3, +1, 0, -1, -2 and -3 in the 5'-T strand 1; -5, -4, -3, -2, -1, 0, and 
+1 in the 5'-A strand 2). 15 of these 19 water molecules bridge to the interfacial protein 
residues, forming indirect hydrogen bonds, for instance with K340, T341, Q344, R382, 
E415, I467 and Q469 in both monomers, and additionally with M331 and H332 of 
monomer-A.
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This study shows that the solvent molecules are indeed crucial for specific STAT3β-
DNA recognition, expanding the contact area formed between the protein and duplex 
DNA. For comparison, the same water-DNA contact analysis performed with the 17-bp 
DNA alone suggest that only  two water molecules interact with A(+5) and T(+4) of the 
opposite DNA strand, and do not exceed 2% of the overall occupancy time spent within 
that hydrogen bond. In terms of the U-STAT3 monomer, only one (E616) out of many 
residues previously determined to be at the interface of the STAT3-DNA complex in 
interaction with a solvent molecule, was found to actually  form a corresponding hydro-
gen bond with a water molecule, again with a shorter occupancy time. Three more inter-
facial residues determined from the STAT3-DNA complex were found to form hydrogen 
bonds with water molecules in U-STAT3, namely  A424, C426, F384 (with occupancy 
times not exceeding 3% of the analyzed 48 ns). Hydration maps representing the water 
density  at  bp±4 are shown in Figure 4.12 (c, d) (pSTAT3 complex only), where numer-
ous solvent molecules forming hydrogen bonds with the nucleotide were identified. (as 
also shown in Table 4.3). Three hydrogen bonds were also found to be formed between 
C(0) and the solvent molecules (Table 4.3 and Figure 4.12 e), or between K340 of 
monomer B with the solvent molecules (Figure 4.12 b). 
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Figure 4.12: Water density maps showing the hydration at the pSTAT3 protein-DNA interface. 
Protein residues of monomer-A are displayed in green,  monomer-B in magenta, and the dsDNA bases in 
orange. Regions with high water density, as observed throughout the MD run, are shown in blue “blobs” 
in mesh representation, where the size of the blobs corresponds to sizes of densely hydrated regions. 
Densely hydrated regions were defined as regions commonly occupied by water molecules throughout the 
simulation time, but they were not determining the exact number of water molecules present at the region 
(blob).
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4.4.5 Locating the mutations in the protein-DNA interface
31 different dominant-negative STAT3 mutations have been identified to date,175,192,191 
affecting predominantly  the DNA-binding and SH2 domains of STAT3. The clinical 
importance of these mutations, accounting for the vast majority of Hyper-IgE Syndrome 
(HIES) cases, has been reported and summarized.176 Since the focus of this study  is on 
the protein-DNA recognition aspects of STAT3, those point mutations affecting the 
DNA-binding region (17 mutations) were examined for possible structural explanations 
of these mutations, which are summarized in Table 4.4. There is a level of symmetry 
between the monomers in terms of the residues affected by the point mutations. Thus 
R382 has the largest frequency  of mutations observed in HIES patients, and it  affects 
hydrogen-bonded DNA recognition with V463 and E435. Four different mutations of 
N466 have been reported, with low frequency of occurrence but with crucial effects on 
the direct readout involving bases at both strands of the DNA, and further interactions 
with C468 and Q469 (~ 65% and ~ 35% HB occupancy respectively), causing a cascade 
of the subsequent alterations in STAT3-DNA recognition. RMS fluctuations on a per 
residue basis, for the DNA-binding region, have been examined as a comparison be-
tween the phosphorylated complex-bound monomers-A and -B and unphosphorylated 
U-STAT3 monomer, to explore the dynamics of the interfacial residues, and in particu-
lar the residues for which mutations were observed. However there is not a significant 
correlation between the residues with larger values of RMS and the occupancy  time 
they  spent forming hydrogen bonds with the DNA (Figure 4.6), and so these are not dis-
cussed further. In order to better map out the positions of the interfacial residues that 
may be mutated in terms of the phosphorylated complex-bound STAT3 and U-STAT3 
monomer, the first eigenvectors for the backbone atoms were structurally aligned (du-
plex DNA was kept in place as a reference). The locations of the affected residues are in 
good agreement in the two structures, with the exception of R423 which is further away 
from the groove in the case of the U-STAT3 monomer (Figure 4.13). This may be 
explained by  the high affinity  of the residues within the ef-loop of the complex-bound 
STAT3 for DNA, hence having a large effect on the mobility of that particular region. 
Overall, the most significant  structural difference between the two monomers is at the 
protein-protein interaction region, in agreement with the results discussed above.
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Table 4.4: Point mutations within the DNA-binding region and their interactions*. 
Point muta-
tion
Patients 
reported
HB affected in monomer-A HB affected in monomer-B
H332Y
R335W
K340N
G342D
V343L
R382L
R382W
R382Q
F384L
F384S
T389I
T412S
R423Q
V432M
H437P
H437Y
S465A
N466D
N466S
N466T
N466K
N466H
Q469H
N472D
K642E
3 M329, D334, R335, WAT dC(0), M329, R335, K573
2 H332, D334, D566, 2x WAT M329, H332, D334, D566, S574, 3x WAT 
1 dG(0), M329, V343 T341, V343, WAT8, WAT11, WAT16
1 L413 L413
1 K340, T412 K340, T412, WAT16
2 dT(+4), E435, V463, WAT2, WAT dT(-4), E435, V463
35
14
2 2x WAT D369, K383
1
1 K409, H410 ---
1 L387, V343 V343, L387, L411
6 dA(+6), dT(+6), dT(+5)
dG(+7), dC3’(+8), G380, WAT
dT(-5), dA(-6), dT3’(-8)
G380, A428, L430, E435
1 dT(+5), E435 dT(-5) , E435
1 D369, E435, V461 D369, E435, V461
1
2 dT(+4), Q469 dT(-4), Q469
1 dG(+2), dT(+3), C468, Q469 dT(-2), dT(-3), C468, Q469
1
1
1
1
1 dT(+4), S465, N466, A473, WAT6 dT(-4), S465, N466, A473
1 S476, 2x WAT S476, 2x WAT
1 N567, D570, E616, L645, N646 dT(-2), D570, E616, L645, N646
*All hydrogen bonds formed between the mutated residue and any other protein residue, DNA base, or 
solvent molecule throughout the course of the simulation, are listed. Bridging water molecules involved 
in the interactions are specifically labeled (corresponding to those in Table 4.3).
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Figure 4.13: Structural alignment of the first eigenvectors with locations of point mutations.
For the backbone atoms of the pSTAT3 monomer-A (blue) and unphosphorylated STAT3 monomer 
(green) with the single point mutations at the DNA-binding region highlighted in sphere representation 
(yellow for monomer-A, red for U-monomer). The DNA duplex (orange) corresponding to the conforma-
tion of the first eigenvector (for the STAT3 complex) is displayed in order to better define the orientation 
of this view.
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4.5 CONCLUSIONS
(I)  Despite their sequence and secondary structure identity, distinct  dynamic properties/
behavior was observed for monomers A and B within both phosphorylated and unphos-
phorylated STAT3β-DNA complexes, and their characteristic dynamic properties con-
trast with that of the unphosphorylated STAT3 monomer. There are differences in their 
magnitude of motion, among both complexes and with respect to the unbound latent 
STAT3 monomer, in particular in the SH2 domain with the stretch of C-terminal resi-
dues, that clearly folds in the case of U-STAT3.
(II) Examination of protein-DNA-solvent interactions focussed on those water mole-
cules that remained at the interface with an occupancy greater than 1 ns of the simula-
tion time. Water  molecules were shown to be important mediators of protein-DNA rec-
ognition; there were a number directly involved in recognition, forming stable multiple 
hydrogen bonds with the protein and DNA residues. Bridging water molecules were 
identified not  only  in the protein-DNA interfacial interactions (residues within 5.0 Å of 
the DNA), but also for instance between V338(B)- C(0), and L413(B) – C(0). While the 
water-DNA interactions in both phosphorylated and unphosphorylated STAT3 com-
plexes were stable over the simulation time, only  two water molecules forming hydro-
gen bonds with the duplex DNA alone were identified which did exceed the overall 1-ns 
occupancy (hydrogen bonds with A(+5) and T(+4)). The simulation of the duplex DNA 
alone did not show unwinding at the terminal regions on the time scale of the simula-
tions, despite the 5' overhanging ends. The protein dimer does then have a stabilizing 
effect on the DNA, although a small amount of  DNA unwinding was observed at the 
complex-bound DNA, at the T5’ region as a consequence of the multiple interactions of 
monomer A with the opposite chain of the DNA in the region C3'(+8), G(+7). In case of 
the unphosphorylated STAT3 complex, the protein-DNA interaction described by means 
of hydrogen bond formation is not so strong at the C3’ region, spanning less residues 
and DNA bases than in the phosphorylated complex.
(III) Experimentally determined point mutations191,192 in the DNA-binding domain were 
located at the protein-DNA interface.
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(IV) Molecular dynamics provides more detailed insight into the structural description 
of the protein-DNA recognition compared to the only currently available crystal struc-
ture of the STAT3β-DNA complex,181 which has been used to date for docking studies 
of STAT3 SH2 small-molecule ligands. These new data should therefore provide a 
more-robust platform for in silico approaches to the design of STAT3-STAT3 inhibitors.
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==============================================================
CHAPTER 5:
Characterization of molecular recognition of STAT3 SH2 domain, and 
its small-molecule inhibitors by means of combined in silico           
approaches
==============================================================
5.1 BACKGROUND
There has been considerable progress in recent years in terms of the disruption of di-
meric transcription factors (such as STAT3) with small molecules that directly  target the 
protein-protein interface of the protein complex. However, the modulation of protein-
protein interactions (PPIs) for therapeutic intervention poses significant  challenges, with 
respect to the structural features of proteins and the chemistry  of their interactions.212 
Among the identified general PPI targeting hurdles are: extensive contact surfaces 
(1,500-3,000 Å2); lack of suitable pockets for small-molecule ligands despite the inter-
faces being studded with clefts and indentations; and the nature of their predominantly 
hydrophobic interactions. Thus the physico-chemical properties of the potential small-
molecule inhibitors that would maximize binding complementarity appear to be de-
manding and non-drug-like (high molecular weight, large hydrpohobic surfaces). Fur-
thermore, PPIs involving Src Homology  2 (SH2) domains, such as STAT3, can be par-
ticularly challenging for pharmacological intervention as they are characterized by 
highly-polar phosphotyrosine (pY) residues.181
5.1.1 Targeting STAT3 SH2 domains for therapeutic intervention
SH2 domains are ubiquitously  present within signal transduction proteins (such as 
STATs) and they  mediate protein-protein interactions (PPI) by recognizing specific 
phosphotyrosine (pY) sequences on a target protein.213 SH2 domains represent the larg-
est class of pY-selective recognition domains in the human proteome, and they are 
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highly  conserved among all family  members of tyrosine kinases.214 It is known that 
compounds targeting the STAT3 SH2 domain may inhibit  STAT3 function by (1) pre-
venting docking to cell surface receptors, thus impeding phosphorylation of Y705, sub-
sequent dimerization, nuclear translocation, and gene expression; and by (2) disrupting 
STAT3 dimers thus preventing translocation to the nucleus and DNA binding, leading to 
inhibition of downstream gene expression involved in survival, cell cycling, or 
angiogenesis.215 
 Whereas most  groups have developed inhibitors that block the SH2 domain, the 
DNA-binding domain and N-terminal domain have also been targeted to inhibit DNA 
binding and nuclear translocation respectively. Because of this, a very diverse range of 
molecular inhibitors have been patented for STAT3 protein function inhibition.216 
An overview of these inhibitors, ranging from peptidomimetics and oligonucleotides to 
small molecules and platinum-based compounds is given in CHAPTER 1. Here I will 
only provide an outline of computational studies, where molecular docking has been 
employed to rationalize and rank known biologically active STAT3 ligands (in the 
absence of structural data), and has provided further insight into their complexes with 
STAT3 SH2 domain by means of MD simulations and subsequent binding energies 
calculations.
5.1.2 Dynamic aspects of  STAT3 studies: experimental and in silico view
A dynamic view of a macromolecular target for drug discovery  is essential in order to 
obtain valuable insight into its behavior. The dynamic aspects of STAT3 behavior have 
been studied experimentally, at the STAT3 signaling pathway level, as well as computa-
tionally, via molecular dynamics simulations, at the level of a single STAT3 macro-
molecule or its complex. For instance, Watanabe et al217 investigated the mobility and 
dynamics of STAT3 in IL-6 signaling in living cells by means of fluorescence correla-
tion spectroscopy, employing a STAT3-GFP hybrid. Mohr et al218 revised all the aspects 
of dynamics and non-canonical JAK/STAT signaling, supporting the observations of 
unphosphorylated STAT3 not only forming a homodimer, but  also translocating to the 
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nucleus and binding specific DNA sequences.179  Now that the original STAT3 signaling 
dogma has been challenged by these observations, it follows that both phosphorylated 
and unphosphorylated STAT3 dimers should be taken in account for small-molecule in-
hibitors design. Molecular docking studies of phosphorylated and unphosphorylated 
STAT3 SH2 domain forms will be presented and discussed in the following sections.
 In terms of in silico dynamics studies, comparative explicit  solvent molecular 
dynamics study of STAT3 and STAT1 homodimers has been carried out by Lin et al183 
with the focus on conformational changes of the two studied complexes over a 50-ns 
frame at  310 K, employing NAMD219 with CHARM27159 force field. In contrast, a 
comparative explicit  solvent MD study of STAT3-DNA complex, with respect to its la-
tent unphosphorylated monomer, has been reported by  Husby et al220 using the 
GROMACS program and employing the AMBER force field. Comprehensive molecu-
lar docking studies, employing AUTODOCK221 v 4.2 and VINA v 1.1, were carried out 
by Dhanik et al222 to identify the most potent STAT3 SH2 domain ligand out of the 142 
currently known peptidomimetic inhibitors. The authors reported ~65% correlation be-
tween predicted binding energies and experimental IC50 values, using a single confor-
mation of the STAT3 SH2 domain obtained from the STAT3 X-ray structure.181 
5.1.3 Origin of the “ESP” library of small molecules for molecular docking study
  
A medium throughput screening of ~ 25.000 biologically  active and chemically  diverse 
small molecules (i.e Diversity  Set library), provided by the Evotec drug discovery 
company, was performed at the European Screening Port (ESP) in Hamburg, Germany. 
Initially, a biochemical cell-free Fluorescent-Polarization (FP)-based primary PPI bind-
ing assay  was carried out at a fixed 40 µM compound concentration, which formed 223 
hits that showed > 50% inhibition. Out of the 223 hits, only 54 were commercially 
available  compounds and purchased by the CRUK PPI Drug Discovery research group 
at the UCL School of Pharmacy. A dose response FP analysis was carried out on those 
54 compounds, leading to a selection of six compounds (Figure 5.1), based on their op-
timal dose response curve shapes (MTS assay-based). The next step, currently still in 
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process, is the assessment of STAT3 transcriptional activity  inhibition in cells via a 
STAT3 luciferase reporter assay, with the SV40 luciferase assay being employed as a 
control (Supplementary Figure S5.1). 
Figure 5.1: Six compounds selected from the ESP HTS with optimal MTS dose-response curve shapes.
Chemical structures together with the MTS-assay graphs are shown for each of the experimentally 
selected molecules.
The 54 compounds were also used within a comparative STAT3 molecular docking 
study, in order to gain insight into their possible modes of interaction with the STAT3 
SH2 domain. Recent studies revealed that state of the art docking algorithms predict an 
incorrect binding pose for about 50-70 % of ligands when only a single fixed receptor 
conformation is considered.141 However in the present study, multiple conformations of 
the receptor, SH2 domain of both phosphorylated and unphosphorylated STAT3, were 
used to partially  overcome the numerous computational docking challenges, and to ob-
tain more accurate docking predictions. 
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5.2  AIMS
Work was carried out simultaneously with the ongoing MD simulations of the 
STAT3βtc systems as described in CHAPTER 4, so the MD simulations setup and ex-
plicit solvent trajectory calculations will not be described here. However, their exact 
trajectories (of the pSTAT3 and uSTAT3 complexes), previously  analyzed in terms of 
protein-DNA interactions, were employed here with the focus on the PPIs mediated by 
the SH2 domains. The ultimate goal is to study  and understand the shape and difference 
in their respective pY705/Y705 binding pockets. This in turn provides a platform for a 
comparative molecular docking study from various perspectives; i.e. two molecular 
targets whose only difference is phosphorylation of the incriminated tyrosine residue 
(Y705); use of multiple representative structures (i.e multiple receptor conformations, 
MRC); and a comparison of two well-known and widely-used molecular docking soft-
ware packages. Insight into the chemical features that are specific for the pY recognition 
by opposite SH2 domain, as well as into thermodynamic stability  of the STAT3:STAT3 
complexes, respective to their phosphorylated- and unphosphorylated-form, then 
completes the “picture”. The main questions set out  to be answered within this 
combined-in silico approach are:
• What are the structural differences in the shape of the pY705 and Y705 binding pock-
ets at the protein-protein interface of the pSTAT3 and uSTAT3 complexes respectively?
• What are the specific chemical features of the pY705-containing tetrapeptide interac-
tions with the reciprocally-bound SH2 domain, and how stable they are?
• How can simultaneous use of two well established molecular docking software 
packages, combined with a set of multiple receptor conformations enhance a successful 
prediction for a potential PPI inhibitor?
• What is the binding affinity of the pSTAT3 protein-protein association with respect to 
uSTAT3, and what is the difference in their respective free binding energy at the 
protein-DNA level?
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5.3  METHODS
Two parts of the explicit solvent MD trajectories of the pSTAT3 and uSTAT3 complex 
were employed to collect multiple representative structures (multiple receptor confor-
mations, MRC), that were then employed within the subsequent studies:
• 25-ns MD-trajectories of the pSTAT3 complex and uSTAT3 complex were used for 
collection of representative MRC (SH2 domains)  for a subsequent comparative mo-
lecular docking study with over ~50 biologically active compounds, employing two es-
tablished, constantly  improving, and popular molecular docking suite of programs: 
GOLD223 and DOCK6224(section 5.3.1 - 5.3.3)
• full-length 50-ns MD-trajectories (48-ns respectively) were utilized for the ensuing 
energetic analysis of the protein-protein, and protein-DNA interaction in both pSTAT3 
and uSTAT3 complex (section 5.3.4); and for the 3D-pharmacophore modeling of 
phospho-Tyr705 (pY705) interactions in the pSTAT3-DNA complex (section 5.3.5); 
5.3.1 Preparation of the multiple-target conformation via cluster analysis
Trajectories of the pSTAT3 and uSTAT3 complex, sampled over 25-ns and 50-ns time-
frames respectively, were examined by  a clustering agglomerative algorithm, in order to 
collect multiple target conformations for molecular docking and 3D-pharmacophore 
modeling study, on the basis of the following scenario:
(1) 25-ns trajectories of the pSTAT3 complex, and uSTAT3 complex, were clustered 
with a RMSD cutoff distance of 2.5 Å. The entire STAT3-DNA complex (e.i resi-
dues 136-716 and dsDNA) was considered for clustering, and the three most popu-
lated clusters of the pSTAT3 and uSTAT3 complexes, represented by a middle struc-
ture sampled at 300K, were chosen for  comparative molecular docking study.
(2) the 50-ns (48-ns respectively) trajectory of the pSTAT3-DNA complex was clustered 
applying the RMSD cut-off distance of 2.0 Å for two structures to be regarded as 
neighbors. Only  the SH2 domains with the stretch of C-terminal residues (i.e resi-
dues 586 - 716) were considered for clustering here, to follow up on the protocol 
described in previous chapter (section 4.3.3).
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5.3.2 Ligand preparation
Minimized structures of 54 biologically active compounds, - an ‘ESP-library’ selected 
by a medium throughput screening completed at the European ScreeningPort laborato-
ries in Hamburg (and purchased for further biological evaluation carried in our laborato-
ries) were constructed with ChemBioOffice (www.cambridgesoft.com), exported in pdb 
format, and subsequently converted into the Sybyl molecule mol2 file format, to be used 
as input for the GOLD223 and DOCK6224 molecular docking simulations. The ligand 
structures were protonated, assigned atomic partial charges employing the AM1-BCC225 
charge (i.e atomic charges with simple additive bond charge corrections) calculation 
method within Chimera’s Dock Prep module, and their atom types (AMBER GAFF226) 
were assigned using the ANTECHAMBER170 program as implemented in UCSF 
Chimera.208 
5.3.3 DOCK6 docking protocol
The DOCK algorithm,227 implemented into the DOCK6 suite of programs, addresses 
rigid body  docking using a geometric matching algorithm to superimpose the ligand 
onto a negative image of the binding pocket of the macromolecular receptor. An algo-
rithm for flexible-ligand docking, on-the-fly optimization and improved algorithm’s 
ability  in finding the lowest-energy binding mode of the small-molecule ligand,  to-
gether with free academic licensing makes DOCK6 a popular choice for molecular 
docking (and virtual screening) studies. DOCK6 was the  primary choice for the dock-
ing study with multiple target conformations of the SH2 domain, sampled through MD 
simulations of the pSTAT3 and uSTAT3 complexes. The simulation protocols were kept 
identical for the consistency of the results and their subsequent comparison.
 Several steps of receptor preparation were necessary prior to docking of the 54 
small molecules with the three conformations of the pSTAT3βtc-SH2 domain and three 
conformations of the uSTAT3βtc-SH2 domain (residues 586-688) in  DOCK v 6.4;224 
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• Receptor structures were processed with the Dock Prep module of Chimera, through 
which hydrogens at the terminal residues were added, and protein residues were as-
signed AMBER ff99SB partial charges. The receptors were then output in mol2 and pdb 
file format.
• A molecular surface for the receptor was generated by the dms program (based on the 
algorithm developed by Richards and adapted by  Connolly228 by rolling a ball the size 
of a water molecule over the van der Waal’s surface of the receptor. Simultaneously, the 
surface normal vector at each surface point was computed for the subsequent  sphere 
calculations.
• The binding site was represented by a set of spheres (with the minimum and maximum 
sphere radius of 1.4 Å and 4.0 Å respectively), selected within 10.0 Å from the  struc-
ture of the ‘natural ligand’, represented by  a pentapeptide P704-(p)Y705-L706-K707-
T708 of the opposite STAT3 monomer (Figure 5.2). The pentapeptide was prepared fol-
lowing the procedure described above, - hydrogens were added and standard amino ac-
ids were assigned AMBER ff99SB167 partial charges, while AM1-BCC225 charges were 
computed for the non-standard pY residue. A binding site of each of the six receptor 
conformations was in an average defined by 68 ± 8 spheres. Small-molecule ligands 
were then automatically orientated into those spheres, cycling through a maximum of 
500 orientations (default value is 100), to allow a generous conformational search. 
Figure 5.2: Defining the binding site of the PPI, via the SH2 domains of the STAT3βtc complexes.           
(a) pY705-containing loop of an SH2 domain (pSTAT3), shown in ribbon representation (cyan), binds to 
the opposite SH2 domain, shown in molecular surface representation (white); (b) Y705-containing loop of 
an SH2 domain (uSTAT3), shown in ribbon representation (dark blue), binds to the opposite SH2 domain, 
shown in molecular surface representation (light green). 
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• To account for the receptor contribution to the score (i.e force field based score) 
throughout docking, grids that store the van der Waals (VdW) and electrostatic compo-
nents for the receptor were computed, allowing for a rapid energy score evaluation.  The 
scoring grids were computed with  0.3 Å spacing between grid points along each axis, 
resulting on average to ~ 130 x ~130 x ~150 grid points per side (x, y, z).
• An anchor-and-Grow224 algorithm for incremental ligand construction was employed 
to sample the internal degrees of freedom of each small molecule ligand (i.e. flexible 
ligand treatment). Upon the ligand’s largest rigid substructure identification (defined by 
a minimum of five heavy atoms), and its rigid orientation in the binding site, the result-
ing orientations were ranked according to their score, spatially clustered and pruned 
(based on RMS-distance between each candidate and a top-ranked reference configura-
tion). Subsequently the remaining flexible portions of the ligand were built onto the best 
anchor orientations and re-optimized.
• To discriminate among orientations of the molecules DOCK6 implemented scoring 
functions were employed. Prior to scoring, the orientations of the ligand which signifi-
cantly overlapped receptor atoms were discarded (via the bump filter). Subsequently, 
grid-based primary energy scoring function was used during rigid orienting, anchor-
and-grow steps, and minimization. For the final minimization, scoring, and ranking of 
the molecules, the Hawkins GB/SA131,229 (GB model supplemented with the solvent ac-
cessible surface area SA term) secondary scoring function with a 150mM  salt  concen-
tration was used (as an implementation of the MM-GBSA method) using the pairwise 
GB solvation model by  Hawkins.230,231 The total interaction between the ligand and re-
ceptor were then represented by unscaled Coulombic and Lennard-Jones 12-6 potentials 
(MM) with the change in solvation (GBSA). A total of three secondary scored ligand 
conformations were saved for each of the small molecule ligands, with the best-ranked 
conformation being considered for further analysis by means of Chimera v1.5 software.
 To test and validate the choice of the docking protocol parameters, a phosphoty-
rosine residue was docked with the three target conformations of the pSTAT3 SH2 do-
main, and subsequently a tyrosine residue was docked with the uSTAT3 SH2 domain 
representations, into their respective binding sites defined by the PpY/YLKT pentapep-
tide. The top-ranked ligand poses were then visually assessed and compared.
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5.3.4 GOLD docking protocol
GOLD, an automated ligand docking program that employs  a genetic algorithm to ex-
amine the complete range of small-molecule ligand conformational flexibility in 
partially-flexible protein binding site. GOLD223 (Genetic Optimisation for Ligand 
Docking), was the second program of choice for the comparative molecular docking 
study employing the  multiple target conformation approach. The GOLD docking pro-
gram has been in continuos development since it  was first introduced more than 15 
years ago, making GOLD one of the most widely used and cited docking programs cur-
rently available.232,233 
 Automated docking was carried out using GOLD v 5.0.1, with the binding site 
of each of the receptors’ six total conformations (three pSTAT3βtc-SH2 domain, and 
three uSTAT3βtc-SH2 domain) defined as the residues with at least one heavy atom 
within 10 Å from a protein atom, NH1 of residue R609. The region of interest was 
restricted to concave, solvent-accessible surfaces, by applying the cavity  detection algo-
rithm, as implemented in GOLD. There was no water present at the binding site, and all 
missing hydrogen atoms (i.e at  the terminal residues) were added. The default docking 
protocol was applied, employing the GoldScore fitness function, which has a van der 
Waals treatment of clash and dispersion terms and uses a crystal structure-derived 
treatment of hydrogen bonds (and also metal terms).223 GoldScore comprises three main 
components: (1) a hydrogen bonding term (based on empirical values for the strength of 
hydrogen bonds between different atom types); (2) a van der Waals term (which 
accounts for for protein-ligand hydrophobic interactions) and (3) a ligand internal 
energy term (which comprises ligand internal vdw and  torsional strain energy).223 A 
genetic algorithm (GA), implemented within GOLD, was utilized to optimize the fitness 
score of the docked ligands. An evolutionary  strategy was employed during exploration 
of the conformational variability of the ligand within the binding site. The most accurate 
(slow speed) parameter settings was chosen through the interactive GOLD interface, 
with the number of operations (i.e the number of operators that  are applied over the 
course of the GA run) set to 100,000. Each docking was then performed ten-times on 
each ligand. The best pose, a predicted best ligand binding position assessed by a 
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dimensionless fitness score, was saved for a subsequent analysis. Only the torsions 
around the ligand’s flexible bonds were optimized during docking (i.e flexible ligand 
treatment). In terms of the receptor, GOLD allows for partial protein flexibility, hence 
the torsion angles of residues Ser, Thr and Tyr hydroxyl groups (-OH) were allowed to 
rotate during docking, providing a better level of optimization of the hydrogen-bonding 
interactions of these residues with the ligand. A corresponding principle of optimization 
applied to NH3+ groups of Lys residues, otherwise all other parts of the receptor were 
kept rigid. 
5.3.5 Intermolecular interaction energy calculations for the STAT3:STAT3 and   
 STAT3dimer:DNA association
To obtain a quantitative estimate of the binding free energy of the pSTAT3βtc complex 
and uSTAT3βtc complex formation at both the protein-protein and protein-DNA level of 
molecular association, the interaction energy together with the solvation free energy 
were calculated employing the Molecular Mechanics/Poisson-Boltzmann (Generalized-
Born) Surface Area (MM/PB(GB)SA) method implemented in AMBER 11. 
 MM/PB(GB)SA methods have been commonly used to investigate PPIs and 
other protein-ligand and/or protein-DNA interactions since they combine the speed of a 
continuum approach to modeling solvent interactions with the MM-based level of theo-
retical (and accurate) approach toward full-atomic modeling of the biomolecular inter-
actions. The principle of this method can be well outlined by its abbreviation: MM 
stands for the molecular mechanics force fields employed to calculate both intermolecu-
lar and direct intramolecular contributions to binding free energies; PB and GB refer to 
the implicit solvent methods used to calculate the electrostatics contributions, and SA 
stands for solvent accessible surface area (SASA) methods used to calculate the non-
polar contributions to binding free energies.123 The entropic contributions are calculated 
separately, and may added in further refinement. 
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The interaction energies of the STAT3:STAT3 association (ΔGbind(PPI)), and the 
STAT3dimer:DNA complex formation (ΔGbind(PDI)), for both pSTAT3 complex and 
uSTAT3 complex, are described by calculating the Gibbs free energies for the complex, 
receptor and ligand individually, across the configurational ensemble obtained from the 
MD trajectory,  according to the following equation:
ΔGbind(PPI)&=&&GSTAT3:STAT3&&C&&(GSTAT3CmonoA&&+&&GSTAT3CmonoB)   (5.1)ΔGbind(PDI)&=&GSTAT3:DNA&complex&&C&&(GSTAT3:STAT3&&+&&GDNA)    (5.2)
where GSTAT3:STAT3, GSTAT3-monoA, GSTAT3-monoB, GSTAT3:DNA complex and GDNA are the calcu-
lated average free energies of the STAT3βtc homodimer, STAT3βtc homodimer-forming 
monomers A andB, STAT3βtc homodimer:DNA complex and the 17bp DNA helix re-
spectively. The calculated average free energy of each term can be broken down accord-
ing to the following equation: 
ΔGbind&=&∆EMM&+&∆GSOL&&C&T∆S       (5.3)ΔGbind&=&(∆Eint&+&∆Eele&&+&∆Evdw)&+&(∆GPB/GB&+&∆GSA)&C&T∆S   (5.4)
where the average molecular mechanics energy  (∆EMM) term is a sum of the internal 
energy (bonds, angles and dihedrals), electrostatic energy and van der Waals term, while 
the  ΔGSOL term accounts for the solvation energy, that comprises both polar and non-
polar component. The polar part of the solvation term then accounts for the electrostatic 
contribution to solvation, and was calculated using a theoretically more rigorous 
Poisson-Boltzmann (PB) model, and an alternative, computationally-efficient 
Generalized-Born (GB) model developed by Onufriev et al234 (igb=2; model GBOBC1) 
with rescaled effective Born radii, accounting for interstitional spaces between atom 
spheres. For both GB and PB calculations the value of the exterior dielectric constant 
was set to 80 at 300K, while the solute dielectric constant was set to 1; salt concentra-
tion was set to physiological conditions (and corresponding to the MD simulations pro-
tocol) ~150 mM. The entropy contributions (T∆S) were neglected in these calculations, 
since a comparison of two very similar systems, phosphorylated and unphosphorylated 
STAT3 complexes, was carried out. 
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The MM/PB(GB)SA calculations were performed employing the last 40 ns (1600 
frames, 25-ps/step) of a single trajectory obtained from the explicit solvent MD simula-
tion of pSTAT3βtc-DNA and uSTAT3βtc-DNA complexes, from which the unbound 
receptor and ligand structures were extracted. Since the two MD simulations were car-
ried out with GROMACS MD package, employing the AMBER force field, the com-
pressed trajectory files (containing the coordinate, time and box vector information; 
‘xtc’ file) needed to be converted into AMBER trajectory  file format (‘mdcrd’ file) for 
the MM/PB(GB)SA calculations. This was achieved with the VMD visualization pro-
gram, by  uploading the trajectory and saving it in NAMD trajectory  file format (‘dcd’ 
file), which was subsequently processed by  the AMBER coordinate/trajectory process-
ing program ptraj, to produce a trajectory in the desired ‘mdcrd’ file format.  
 Topologies and input files necessary for the AMBER molecular mechanics pro-
grams were generated by means of the LEaP program, via xleap, a window-based inter-
face to LEAP. Firstly, a reference pdb file of the pSTAT3 complex and uSTAT3 com-
plex, which represented the conformation at the start of the MD simulation was gener-
ated, and subsequently coordinates corresponding to the STAT3:STAT3 homodimer 
(residues 136 to 716), monomer-A, monomer-B and dsDNA helix were saved as sepa-
rate entities, for both phosphorylated and unphosphorylated systems; those were then 
processed by xleap, providing molecular topology files with the necessary force field 
parameters stored in them. Corresponding force fields that were used for the MD simu-
lation in GROMACS were employed also here, namely the AMBER parm99sb-ILDN166 
force field, together with the parmbsc0161 force field, and the parameters for the phos-
phorylated tyrosine residue (in case of the pSTAT3 simulation), were loaded manually.
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5.3.6 3D-pharmacophore modeling
The pharmacophore concept, and its simplicity, enable the complexity of intermolecular 
interactions between ligand and its protein receptor to be reduced to a small set of at-
tributes,235 such as hydrogen bond donor, acceptor, hydrophobic interaction, or excluded 
volumes. The LigandScout v 3.0 application framework236,237 was used to detect  crucial 
interaction patterns within the PPI contact area of pY-containing tetrapeptide PpYLK 
(residues 704-707) with the SH2 domain of the opposite pSTAT3βtc homodimer-
forming monomer.
 Here, the ‘rigid’ 3D structure-based pharmacophore modeling approach was 
combined with ‘dynamic’ information with respect to the conformational flexibility  of 
the  protein (SH2 domain) and its binding partner (pY-containing tetrapeptide), as ob-
tained from the MD simulations by cluster analysis over the 50-ns time frame. Five rep-
resentative structures, i.e the middle structures of the five largest clusters sampled at 
300 K over the 50-ns MD simulation, were used for the detection of protein contacts via 
structure-based pharmacophore modeling. The SH2 domain of monomer-A (residues 
586 - 688) was always extracted from the representative structures and used as a recep-
tor, while the terapeptide PpYLK (residues 704-707) of the opposite binding partner 
was extracted, saved as a new pdb entity, and used as a ligand.  
 
Default settings of LigandScout236,237 were used for ligand interpretation followed by 
pharmacophore generation. The pharmacophore features and cutoff thresholds were 
specifically defined within LigandScout as follows:
• The protein-ligand interaction cutoff thresholds were defined in terms of spheres sur-
rounding each non-hydrogen atom of the ligand, and all non-hydrogen atoms of the 
protein that are within that sphere “environment”, whose cutoff distance is 7 Å, were 
considered to be potential interaction partners. 
• In terms of the steric constraints and circumstances of the macromolecule, the mini-
mum and maximum distances were set to 2 Å and 4 Å respectively, such that an 
excluded volume feature on an alpha carbon was generated if the alpha carbon had in-
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teractions with the ligand atoms closer than the maximum distance, and no other feature 
was closer than the minimum distance.237
• Flexible hydrogen bonds were discriminated against rigid hydrogen bonds interac-
tions, relative to the hybridization of their heavy  atoms (Figure 5.3); While rigid hydro-
gen bond interactions, as typically occurring at the sp2 hybridized heavy atoms, must 
fulfill the 50° angle range for sp2 hybridized heavy atoms, the flexible hydrogen bonds, 
as occurring at sp3 hybridized heavy atoms, have a 34° default angle range. 
Figure 5.3: Rigid and flexible hydrogen bond constraints on sp2 and sp3 hybridized heavy atoms7.              
Rigid hydrogen bond donor represents for instance an sp2 hybridized amide nitrogen, and flexible hydro-
gen bond can be found at an sp3 hybridized hydroxy group.
• Charge interaction features, as well as hydrophobicity features were regarded as dis-
tance constraints (the pharmacophore feature definitions and distance constraints pa-
rameters outlined in Table 5.2, within the Results section). Similarly, aromatic features 
which represent π-π (orthogonal and parallel) and cation-π interactions were defined by 
distance constraints, and also angle constraint between the interacting planes.  
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7 Figure adapted, and modified, from Inte:ligand LiganScout v.3 online manual  www.inteligand.com/ligandscout3/
5.4 RESULTS AND DISCUSSION
The core of this chapter is focussed on the PPI of STAT3, specifically  at phosphotyro-
sine (pY705) binding in particular, and compared with the unphosphorylated form 
(Y705). The finding of a significant difference in the shape of pY705/Y705 binding 
pockets has been incorporated into the molecular docking study of STAT3 SH2 domains 
with a library of structurally different small molecules (ESP library). Then 
3D-pharmacophore modeling of the chemical features characterizing the pY705 binding 
site over a 50-ns time frame was used to confirm the pY705 binding site stability. Fur-
thermore, thermodynamic stability of the STAT3-STAT3 interaction was evaluated by 
means of binding energy calculations of both pSTAT3 and uSTAT3 complexes, at  the 
level of PPIs but  also reflecting the protein-DNA interactions. Representative structures 
of the molecular targets were obtained from trajectories of two (25-ns and 50-ns) 
explicit  solvent MD simulations of two forms of STAT3βtc homodimer:DNA 
complexes, described above.
The results are presented in a comparative manner, in terms of : (1) structural differ-
ences of pY705/Y705 binding sites, (2) the molecular docking study of small-molecule 
ligands with multiple receptor (target) conformations, (3) thermodynamic stability of 
the STAT3-STAT3 association, and (4) protein-protein contact analysis based on 
3D-pharmacophore modeling.
5.4.1 Looking into “the” pocket: structural differences of the pY705 and Y705 binding 
 site 
Studies by other research groups have shown that STATs SH2 domains possess strik-
ingly similar backbone conformations that  are different from non-STAT SH2 
domains215,238 (which might reflect the high level of structural conservation of the STAT 
SH2 domains); and that the STAT3 SH2 domain-binding peptide sequence PpYLKTK 
selectively blocks STAT3 DNA-binding activity, by mechanistically  disrupting 
STAT3:STAT3 dimers (in vitro).53  It has also been shown that the inhibition can be sig-
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nificantly improved by choosing phosphopeptide sequences of other STAT3-interacting 
proteins (such as gp130) and their constrained hybrids.54,241 Furthermore, it has been 
shown that modulations of the pY+1 (L706) residue reduced the phosphopeptides bind-
ing affinity to the STAT3 SH2 domain, supporting the  importance of that particular 
residue for STAT3 binding.215 The phosphopeptide binding surface residues (forming 
three distinct clefts) are known. However, targeting STAT3 domain in order to inhibit 
protein functions for drug discovery has remained a daunting task.239 
 With the mounting body of evidence that unphosphorylated STAT3 form homo-
dimers (via reciprocal interaction of their SH2 domains) which are able to bind their 
target DNA sequence, it is appropriate to examine the structural properties of the un-
phosphorylated STA3 SH2 domain binding site with respect to the phosphorylated one. 
This information can be then used in molecular docking studies with therapeutic  small-
molecules. Dynamic point of view into the phospho- and unphosphorylated-binding 
pockets, defined by a pentapeptide sequence P-pY/Y-L-K-T, has been employed here. 
Three representative structures from the respective 25-ns MD simulations were used, 
corresponding to ~70% of the conformational space sampled at  300K. All six represen-
tative structures of the SH2 domains with the pentapeptide of the opposite STAT3 
monomer (three phospho- and three unphospho-STAT3 complex bound monomers) 
were visually  explored. A distinct feature of the pY705/Y705 -accommodating pocket 
has been observed (Figure 5.4); in the case of the pY705, residues K591, R609, S611, 
E612 and S613 form a tight clamp-like binding pocket around the polar (negatively 
charged) phosphate group (Figure 5.4 a), however in the case of the unphosphorylated 
Y705 residue, the shape of the binding pocket is significantly changed due to a re-
arrangement of residues K591 and E594 (Figure 5.4 b). Residue K591, which would 
normally interact  with pY705, and contribute to the specific shape of the pY-binding 
site, is now completely  flipped out of the site, with its position being partially  replaced 
by E594. It can be speculated that  this is a consequence of the relatively bulky  and 
negative charge-carrying phosphate group being replaced by a hydroxyl group from the 
regular tyrosine residue, which does not attract the lysine residue (with protonated side 
chain at simulated neutral condition) so strongly.
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Figure 5.4: SH2 domain binding pocket of the Y705/pY705-containing pentapeptide (res 704-708). 
(a) phosphorylated PpYLKT pentapeptide bound to the opposite dimer-forming SH2 domain; (b) unphos-
phorylated PYLKT pentapeptide bound at the SH2 binding site of the opposite unphosphorylated STAT3 
monomer. Residues within 7Å of the pentapeptide binding site are used in molecular surface representa-
tion (white/light green), while the pentapeptide is shown in licorice representation (cyan/dark blue).  Resi-
dues R609, S611, E612 and S613 are shown in gray while the fifth, pY705 binding pocket-forming resi-
due K591 is displayed in lilla, and E594 in purple. 
The altered, wider, shape of the Y705 pocket with respect to the more enclosed pocket 
formed around pY705 was observed for all three unphosphorylated target representa-
tions that were explored and used for subsequent comparative molecular docking stud-
ies, described in the next section. With regard to the very  different shape of the Y705/
pY705 binding pocket, resulting from a phosphate group presence/absence, it might  be 
expected that structurally different ligands will preferentially  bind there. The chemical 
environment of the pocket, where either the positively charged lysine, or un-protonated 
glutamate comes into direct interaction with a pocket-occupying ligand may affect the 
preference for a suitable ligand. This knowledge has to be kept in mind with respect to 
the subsequent molecular docking study of potential STAT3 inhibitors, since both phos-
phorylated and unphosphorylated STAT3 dimers, and subsequently STAT3-DNA com-
plexes  can occur.
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5.4.2 Molecular docking with multiple target conformation of the STAT3 SH2 domain
54 chemically  and structurally  diverse small molecules, that were selected by  medium 
throughput screening  of  ~25.000 compounds (ESP Laboratories  Hamburg) against the 
unphosphorylated STAT3 SH2 domain with phosphorylated hexapeptide probe, were 
used for a multiple-target conformation molecular docking study, using the two well-
established programs for protein docking, GOLD and DOCK6. The molecular target 
representations were obtained by cluster analysis of 25-ns trajectories of the pSTAT3-
DNA and uSTAT3-DNA complexes respectively. In both cases, the three middle struc-
tures of the three largest clusters spanned over ~70% of the conformational space (sam-
pled at 300K), and were used as molecular targets in the docking study. The consistency 
and comparability  of the results was then secured by using a total of six corresponding 
conformations of the STAT3β SH2 domain in both GOLD and DOCK6 small-molecules 
docking studies. The general overview of the comparative molecular docking study  that 
was applied here is shown in Figure 5.5.
Figure 5.5: The overall outline of the molecular docking study.
A total of six rigid conformations of the molecular target of STAT3β-SH2 domain (phosphorylated/
unphosphorylated) and two molecular docking programs, GOLD and DOCK were employed; The struc-
tural alignment is shown for the target representations - SH2 domains from phosphorylated (grey shades) 
and un-phosphorylated  (green shades) STAT3:DNA complex,  as obtained by cluster analysis of the 25-ns 
MD trajectories.
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Whereas the default optimized setting was used while employing GOLD, DOCK6 re-
quired careful selection of the input parameters in order to obtain sensible binding poses 
of the small molecules within the target binding site. Parameter selection was tested and 
optimized based on the “trial-and-error” method, with the final settings validated by 
docking pY705 and Y705 residues in their respective binding sites within the three 
STAT3 SH2 domain conformations (Figure 5.6; Table S5.1 in the Supplementary sec-
tion). Docked pY705 with pSTAT3 SH2 domain conformations 1 and 2 displayed excel-
lent agreement in terms of the binding pose and orientation with the phosphopeptide-
bound pY705 (Figure 5.6 a and b). In the third case, the phosphate and aromatic parts of 
pY705 were overlapping between the docked and phosphopeptide-bound residues, but 
the amido-portion of the residue was observed to have partially  flipped (Figure 5.6 c). A 
well-defined pY705-binding pocket, as well as the characteristic L706 binding pocket, 
were observed for all three conformations of the pSTAT3 SH2 domain.
Figure 5.6: pY705 and Y705 docked into their respective binding sites 
pY705 and Y705 were docked with three receptor conformations (i.e six in total) as obtained from the 
MD runs of pSTAT3 and uSTAT3 complexes; (a-c) pY705 docked with three conformations of the oppo-
site STAT3 SH2 domain; (d-f) Y705 docked with three conformations of the SH2 domain, its binding 
partner from the uSTAT3 complex.  SH2 domains are shown in surface mesh representation (white/ pale 
green), while the binding site-defining pentapeptides of the opposite SH2 domain are shown in stick rep-
resentation (cyan/ navy blue). Docked pY705 and Y705 are colored in magenta and pink respectively. 
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On the other hand, Y705 docked with the pentapeptide binding site of the uSTAT3 SH2 
domains did not display a strong correlation with the pentapeptide-bound Y705 poses 
and orientations, when the corresponding docking parameters were used (Figure 5.5 d-
f). The first and the third target  binding site conformations had slightly more ordered 
structural features than the second conformation. This may  explain the greater overlap 
of the tyrosine aromatic-ring portions that was observed for the otherwise weakly over-
lapping Y705 residues. However, the shallower and more open binding site of uSTAT3 
SH2 domain provides a less-restricted conformational space for the ligand to explore 
and adapt to, as is visible even from the different orientations of pentapeptide-bound 
Y705.
 During the docking of the 54 small molecules with total of six different repre-
sentations of STAT3 SH2 domain (using GOLD and DOCK6), the ligands predicted 
binding poses within previously defined binding sites were scored by means of (1) the 
dimensionless fitness function, GoldScore223(GOLD), which is optimized for the 
prediction of ligand binding positions rather than predictions of binding affinities; and 
(2) the Hawkins GB/SA230,231 scoring function which was employed in the final mini-
mization and ligand scoring/ranking routine in DOCK6, which provides ligands binding 
affinities for the molecular target in kcal/mol. The results obtained were filtered for sub-
sequent analysis according to the following criteria:
• First, ligands that did not successfully dock with all six target conformations (i.e three 
phospho- and three unphosphorylated STAT3 SH2 domain representations) in both 
GOLD and DOCK6-employing docking studies were removed (a total of 12 com-
pounds).
• Second, mean values (and their standard deviations) of ligand fitness scores 
(GoldScore) and binding affinities (secondary GB/SA score, primary GRID-based 
score) were calculated over the three conformations of the phosphorylated, and unphos-
phorylated molecular target, for both GOLD and DOCK6 predictions. Ligands whose 
calculated mean fitness score/binding affinity  for the phosphorylated molecular target 
(p-SH2 domain) had high values (stdev ≥ 10) their respective standard deviations were 
removed (a total of three compounds).
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• Third, ligands whose mean fitness score/binding affinity  values were smaller than half 
of the top ranked compound by means of GoldScore and GB/SA scores within both 
phosphorylated and unphosphorylated STAT3 SH2 domains (p-SH2 and u-SH2) were 
removed. For example, if the top  mean value of a compounds fitness score with the p-
SH2 target was estimated as 44 by means of GoldScore, those ligands with mean fitness 
score smaller than 22 were removed (a total of six compounds).
 34 compounds remained for further analysis upon processing the docking results 
through the “criteria selection funnel”. Based on fitness scores/binding affinities of the 
ligands, the top six ligands were selected for the phosphorylated and unphosphorylated 
molecular targets (p-SH2 and u-SH2) (Table 5.1). These compounds, presented in four 
categories (i.e GoldScore p-SH2, GoldScore u-SH2, GB/SA secondary score p-SH2 and 
GB/SA secondary  score u-SH2) were combined, leading to a total of 10 ligands from 
the original ESP-library of chemically-divers (CD) small molecules. 
Table 5.1: Top six compounds predicted by MRC docking with GOLD and DOCK6.
GoldScore (GOLD) and GB/SA binding affinity secondary scoring function (DOCK6) for phosphorylated 
and unphosphorylated receptor (STAT3 SH2domain). Ligands with experimentally-determined optimal 
dose response curve are marked in blue.
Rank GOLD DOCK6
GoldScore; p-SH2 GoldScore; u-SH2 GB/SA score; p-SH2 GB/SA score; u-SH2
1 26810_CD 25113_CD 29768_CD 28373_CD
2 25113_CD 24601_CD 28373_CD 24601_CD
3 28373_CD 26810_CD 26810_CD 26745_CD
4 25117_CD 25117_CD 24601_CD 26810_CD
5 29768_CD 24846_CD 26745_CD 25113_CD
6 29292_CD 28373_CD 25117_CD 28018_CD
Among the combined top  10 (Table 5.1 and 5.2) potential small-molecule inhibitors, 
ligands 26810_CD and 24601_CD were shown to have optimal dose response curve 
shapes (determined experimentally, prior to the start  of the computational study, Figure 
5.1). Furthermore, ligand 26810_CD and 28373_CD were selected among the top six 
compounds in each of the four categories; ligands 24601_CD, 25113_CD and 
25117_CD occurred among the top  six compounds three times; ligands 29768_CD and 
26745_CD twice; and ligands 29292_CD, 280180_CD and 24846_CD once. When 
comparing only  predictions for the  phosphorylated target, there is a match in four out 
of the top six compound between GOLD and DOCK6, which is 75% agreement.
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Table 5.2: The 10+2 top compounds selected via MRC docking (p-SH2 and u-SH2).
The top 10 compounds in the table are the combined best scored compounds as listed in Table 5.1; the 
two compounds at the bottom (highlighted in grey) were additionally analyzed due to their optimal shape 
of dose-response curves that were previously experimentally determined. The compounds are listed in a 
numeric order. GoldScore 
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Compound 
id #
26810_CD
24601_CD
25113_CD
25117_CD
26745_CD
28373_CD
29768_CD
24846_CD
28018_CD
29292_CD
24712_CD
28580_CD
Structure GOLD DOCK6
p-SH2 u-SH2 p-SH2 u-SH2
GoldScore GoldScore GB/SA score   
[kcal/mol]
GB/SA score    
[kcal/mol]
58.89 ± 3.73 53.34 ± 5.27 -27.37 ± 2.83 -23.68 ± 7.46
39.46 ± 7.44 54.44 ± 10.62 -27.14 ± 4.52 -25.74 ± 2.53
55.90 ± 5.53 55.34 ± 0.35 -26.21 ± 2.11 -22.73 ± 2.71
49.77 ± 2.94 53.13 ± 2.27 -26.39 ± 1.76 -18.82 ± 10.36
46.24 ± 6.46 47.32 ± 3.82 -27.12 ± 0.52 -24.11 ± 6.15
51.54 ± 1.43 52.05 ± 6.02 -30.17 ± 2.75 -27.05 ± 4.36
49.26 ± 6.58 48.26 ± 3.44 -30.47 ± 1.03 -21.19 ± 14.24
43.03 ± 3.09 52.38 ± 4.75 -24.28 ± 1.94 -18.05 ± 12.53
38.05 ± 4.75 41.91 ± 2.98 -23.52 ± 1.85 -22.62 ± 2.22
47.06 ± 3.22 46.26 ± 8.20 -23.44 ± 0.25 -20.02 ± 3.50
46.49 ± 8.34 47.12 ± 3.45  -19.21 ± 4.14 -13.36 ± 4.79
40.20 ± 2.74 45.60 ± 5.12 -19.41 ± 4.47 -14.75 ± 0.55
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Considering the experimental data for all 54 ligands, and in particular those with opti-
mal shape of their dose-response curves, ligands 24712_CD and 28580_CD were fur-
ther analyzed together with the top 10 selected ligands, as they  passed the initial “crite-
ria selection funnel”, but failed to be among the top six compounds in four categories. 
Hydrogen bonds formed between the each of the 12 (10+2) ligands docked with a total 
of six target conformations were calculated by means of UCSF Chimera program (Table 
5.3) and compared. 
Table 5.3: Hydrogen bond-forming residues of the MRC docked with selected ligands.
Hydrogen bonds formed between the top 10+2 ligands previously selected (Table 5.2) and p-SH2/u-SH2 
receptor representations (six conformations in total; 3+3) were determined by means of UCSF Chimera 
program. In the table, three lines per ligand correspond to three conformations examined.  Protein residues 
involved in hydrogen bond interactions are listed for each of the three receptor conformations.
Ligand 
id #
p-SH2 hydrogen bond-forming residues u-SH2 hydrogen bond-forming residues
GOLD p-SH2 DOCK p-SH2 GOLD u-SH2 DOCK u-SH2
24601
24712
24846
25113
25117
26745
26810
28018
28373
28580
29292
29768
K591 E625 I589, E594, E612, S636 E594
Q635, S636, T620 K591, E638 E594, R595, S636 E625
E594, I634, S636 E625 E594, I634, S636 S636, E638
R609, S611, E612, S613 R609, S611, E612, S613 S611, E612, S636 S611, E612, S636
R609, S611, E612, S613 Q633 R595 R595
E592, R609, E612 R609, E612 I589, R609, F610 K591
E612 --- E594, R609 S636
K591, R595, E638 K591, E594, R609, S636 R595 S611, S636
S611. E612 --- R609, T620 S636
R609, E612 Q635 S611, E612, S636 ---
R609 K591, S636 R609, E612, S613, S636 S611
R609, E612, S613 R609, S611, E612, S613 K591 ---
Q635 S611 E612, V637 ---
R609, S636 E594, S636 E594, R609, E612, S613 E594, S611, S613, S636
R595, R609 M660 E594, R609, S611 ---
K591, R609, Q635 Q644 S611, E612, S636 S611
K591, E592, R609, E612 Y657 S611, S613 S611
K591, R609, E612 --- R609 S611
R609, S611, E612, S613 S636, E638 E594, S611, E612, S613 R609, E612, S613
R595, R609, S611, E612, S613 S636 R595, I634 S611, E612
R591, R595, R609, S611, E612, S613 S636 I589, I634 K591
--- K591, R609, S613 S636 S611, E612
R609 K591, S613 K591, R595 S636
K591, R609, E612 R609, E612 R595 R595
Q635 Q635, S636, E638, Y657 K591, S611, S636 S636
R595 K591 K591, E612, S613 E594, R595
K591, R609, E612 K591, E612, S613 E594, R609, S611, E612, I634 ---
S611, S613, E638 --- T620, S636, V637 E594, V637, E638
K591, S636, V637 R595, Q633 E612, S613, I634, S636 E594, S613, S636
R609, S611 I659, M660 E592, E594, R595, I634 ---
K591, R609, S611, E612, S613 K591, R609, S611, S613 E594, S611, E612 S611
R609, S611, E612, S613, E638 R595, S636 R595 ---
R609, S611, E612, S613 I659, K658 S613 K591, S611, S613
K591, R609, E612 K591, R609 R593 ---
K591, R609, S611, E612 K591, R609 --- R595
E592, R609, E612 K591, R609 R595, I634 ---
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The analysis of hydrogen bonds formed between the ligands docked with MRC of the 
pSTAT3 and/or uSTAT3 SH2 domain can be summarized as follows:
• more hydrogen bonds were predicted to be formed between ligands docked with the p-
SH2 domain than with u-SH2 domain conformations by ~ 25%, which may reflect the 
tighter, more enclosed shapes of the p-SH2 receptor pockets, comparing to the wider 
and shallower pockets formed by u-SH2.
• in terms of the ligands docked with the p-SH2 MRC, the total number of hydrogen 
bonds determined within GOLD-predicted interactions (101 hydrogen bonds) is ~ 55% 
higher than for DOCK6-predicted solutions (65 hydrogen bonds), suggesting that 
GOLD-predicted binding poses my be more accurate predictions.
• the difference in the total number of predicted hydrogen bonds by  GOLD and DOCK6 
is even higher for the ligands docked with the u-SH2 MRC; as the GOLD-predicted 
binding poses (87 hydrogen bonds) of the ligands formed ~ 93% more hydrogen bonds 
than the DOCK6-predicted (45 hydrogen bonds) binding poses. 
• those protein residues forming hydrogen bonds with the ligands upon docking, were 
generally  in better agreement across the three receptor conformations of p-SH2 domain 
than for the u-SH2 domain. A better correspondence was also found among the GOLD-
suggested solutions when compared to the DOCK6 solutions (i.e ligand 24712_CD, 
26745_CD, 26810_CD, 29292_CD, and 29768_CD); 
The ligands binding poses and orientations within the MRC pocket were further exam-
ined, with the following findings:
• in a number of cases, the GOLD-predicted binding poses of a flexible ligand were tar-
geting a corresponding pocket, with at least  two of the three ligand orientations in 
agreement, but  the DOCK6-predicted binding poses were spread all over the initially 
defined binding site (i.e 26810_CD; Figure 5.7 a-d).
• for ligand 29768_CD, both GOLD and DOCK6 ligand binding poses and orientations 
were in good correspondence among the p-SH2 domain receptor conformations, but 
quite diverse for the u-SH2 (Figure 5.7 e-h).
• also the opposite situation, where ligand binding poses predictions were barely corre-
lated for the p-SH2 receptor conformations in both GOLD and DOCK6, but well-
matched for the u-SH2 receptor was found for ligand 25117_CD (Figure 5.7 i-l).
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Figure 5.7: Structurally-overlaid selected ligands docked with MRC of p-SH2 and u-SH2 domain.
Each line in the panel shows predicted binding poses of the ligands with p-SH2 and u-SH2 receptor con-
formations (a total of six) as obtained by means of GOLD (gold, yellow and pale yellow) and DOCK6 
(black, gray and pale blue). The defined binding sites are shown in molecular surface mesh representa-
tion,  beige for three p-SH2 domain conformations (on the left side of the panel) and pale pink for three u-
SH2 domain representations (on the right side of the panel).  All ligands are shown in licorice representa-
tion; (a-d) ligand 26810_CD, (e-h) ligand 29768_CD and (i-l) ligand 25117_CD.
 The first target representations (i.e the most populated conformation found in the 
25-ns MD simulation) for both p-STAT3 and u-STAT3 SH2 domains were further con-
sidered for the comparison of ligand poses and orientations predicted by  GOLD and 
DOCK6. Excellent agreement was observed for two relatively  rigid ligands 24712_CD 
and 29292_CD docked with the p-SH2, and they also displayed a good correlation 
within the u-SH2 binding pocket (Figure 5.8 a-b, c-d). In contrast, a flexible ligand 
26745_CD, that has seven rotatable bonds, showed excellent correlation between 
DOCK6 and GOLD binding pose prediction in the u-SH2 target, but not in p-SH2 (Fig-
ure 5.8 e-f). This suggests that the choice of a docking software may  have a significant 
impact on the selection of a promising inhibitor candidate. Combining the DOCK6 and 
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GOLD predictions together with the MRC that were examined, a potent STAT3 inhibi-
tor would be expected to preferentially  occupy the same binding pocket of both phos-
phorylated and unphosphorylated receptor, with a decent agreement of both software 
tools employed. Accordingly, rigid ligands such as 24712_CD and 29292_CD, or quite 
contrary, flexible ligands such as 29768_CD or 26810_CD were found to fulfill these 
criteria.
 
Figure 5.8: Comparison of the GOLD and DOCK6 predicted ligand’s binding poses.
Selected ligands are docked with the most populated conformation of p-SH2/u-SH2 domain. The p-SH2 
domain (white) and the u-SH2 domain (grey) are shown in solid molecular surface representation. The 
space occupied by the PpY/YLKT pentapeptide (res 704-708) is shown in mesh molecular surface repre-
sentation in beige and pale pink color respectively. The position of R609 within the molecular target is 
highlighted in blue (as a reference point). Binding poses of the individual ligands are always shown in 
licorice representations; carbon atoms are shown in gold (GOLD) and black (DOCK6), and further color-
coded by atom name (oxygens in red,  nitrogens in blue, hydrogens in white). (a-b) ligand 24712_CD, 
(c-d)  ligand 29292_CD, and (e-f) ligand 26745_CD.
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5.4.3 Binding free energies of the STAT3:STAT3 and STAT3 dimer:DNA                  
 intermolecular association calculated by means of the MM/PB(GB)SA method
 
The interaction energy  and the solvation free energy for the phosphorylated (1) and 
unphosphorylated (2) STAT3:STAT3 (protein-protein) intermolecular association, as 
well as for the phosphorylated (3) and unphosphorylated (4) STAT3 homodimer:DNA 
complex formation was calculated from the explicit solvent MD trajectories of the 
respective STAT3 complexes (Figure 5.9), by means of the post-processing MM/
PB(GB)SA method as implemented in MMPBSA.py in AMBER 11. The single trajec-
tory approach was employed, hence configurational ensembles for the complex 
(STAT3-DNA complex or STAT3:STAT3 homodimer), receptor (STAT3:STAT3 homo-
dimer or STAT3 monomer-A) and the ligand (dsDNA helix or STAT3 monomer-B) were 
extracted from a single MD trajectory of the phosphorylated and unphosphorylated 
STAT3βtc-DNA complex respectively. The choice of this method was convenient 
because of its faster calculation time, comparing to the multiple trajectory approach. 
Also the generation of separate trajectories via explicit solvent MD simulations of all 
complex-forming components would not be feasible due to the computational time 
required for this size of the simulated systems (~1235 residues). However, one needs to 
be aware of this method’s assumption that  there is no significant structural or dynamic 
changes between the bound and unbound macromolecules, potentially  leading to incor-
rectly estimated ∆G values.135,241
Figure 5.9: Representation of the intermolecular association of the STAT3 complex formation.
(a) shows the STAT3:STAT3 association,  where the STAT3 monomer-A (black) was regarded as a recep-
tor for the calculation, while monomer-B (silver) was assigned as a ligand; (b) represents the STAT3-
DNA complex (protein-DNA) intermolecular association, with STAT3 homodimer (black) being the re-
ceptor,  and the dsDNA (silver) is the ligand. The corresponding principle was applied both to the pSTAT3 
complex and uSTAT3 complex.
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The importance of entropic contributions to the otherwise “enthalpic view” of free bind-
ing energy of macromolecular association has been emphasized by numerous studies, 
and reviewed for instance by  Harris and Laughton.133,151 The conformational entropy 
calculations have proven to be very challenging, and the inclusion of an entropy term 
has been shown to not always improve prediction accuracy.136 Moreover, since the free 
energy calculations of very  closely  related systems were carried out here, the only  dif-
ference between the pSTAT3 and uSTAT3 complexes being the phosphorylation of in-
cremented residue Y705, it  can be assumed that the entropic contributions to the abso-
lute binding free energies would cancel each other out when we are interested in the 
relative free energy of binding between a phosphorylated and unphosphorylated com-
plex, either at  the protein-protein or protein-DNA level of biomolecular 
association.135,229 
 The calculated binding free energy  (ΔGbind) for the STAT3-STAT3 interaction 
(PPI) in the pSTAT3βtc complex was -201.36 kcal/mol using the MM/PBSA method, 
and -186.72 kcal/mol using the MM/GBSA method, while -102.14 kcal/mol (MM/
PBSA) and -99.56 kcal/mol (MM/GBSA) respectively, for the uSTAT3 protein-protein 
interaction. In terms of protein-DNA association (PDI), the corresponding calculated 
binding energies for the pSTAT3βtc and uSTAT3βtc complexes are: ΔGbind values of 
-140.10 kcal/mol (MM/PBSA) and -96.17 (MM/GBSA) for the pSTAT3:DNA complex, 
and -140.73 kcal/mol (MM/PBSA) and -97.53 kcal/mol (MM/GBSA) for the 
uSTAT3:DNA complex. Both PB and GB methods predicted that the binding free en-
ergy of the protein-protein association is two-fold more favourable for pSTAT3βtc than 
for the uSTAT3βtc complex. These energies (summarized in Table 5.4) are in good 
qualitative agreement with the experimental data described by Nkansah et al. (manu-
script submitted for publication, 2012). By  employing combined experimental tech-
niques (PEMSA and x-ray crystallography), uSTAT3 protein binding to dsDNA was 
demonstrated, and its strong similarity to pSTAT3-DNA interaction was shown. These 
observations have been further supported by  CD spectroscopy, that  suggested well-
folded and stable pSTAT3-DNA and uSTAT3-DNA complex conformations, and by MD 
simulations described above.  
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Table 5.4: Overview of the MM/PB(GB)SA binding energies for pSTAT3 and uSTAT3 protein-protein 
and protein-DNA interactions. 
ΔGbind [kcal/mol] pSTAT3 : uSTAT3
ratioMM/PBSA MM/GBSA
pSTAT3 - pSTAT3
uSTAT3 - uSTAT3
uSTAT3 - DNA
pSTAT3 - DNA
-201.36 -186.72 2:1
-102.14 -99.56
-140.10 -96.17 1:1
-140.73 -97.53
While there is a good agreement between the PB and GB methods at the PPI level for 
the uSTAT3 complex (~3 kcal/mol difference), the presence/absence of pY705 in the 
calculated system caused a difference of  additional ~10 kcal/mol between the PB and 
GB method binding energy predictions. The difference between predicted biding ener-
gies by means of PB and GB methods is, however, significantly larger for the PDIs, as 
the calculated difference between the two methods is ~45 kcal/mol for both pSTAT3-
DNA and uSTAT3-DNA complexes. This is not too surprising though, as the accuracy 
of PDIs binding energies by means of MM/GBSA methods is known to be lower than 
for PPI complexes. Furthermore, the ratio of the predicted binding energies (ΔGbind) 
remained constant (2:1 and 1:1 respectively) for both MM/PBSA and MM/GBSA calcu-
lations, providing the aimed-for estimate of free energy difference of the STAT3 binding 
with respect to the phosphorylated vs unphosphorylated,  protein-protein and protein-
DNA association.
5.4.4 Protein-protein contact analysis based on 3D-pharmacophore modeling
Experimental studies of highly conserved SH2 domains have revealed that ~50 % of the 
binding affinity is attributed to the phosphate moiety of the pY705 residue itself, while 
residues in positions from -2 to +4, relative to pY705, modulate binding specificity.214 
In particular pY705 and L706 have been shown (by means of SAR, and alanine 
scanning mutagenesis studies) to be critical for STAT3 binding. Therefore multiple 
representative structures of the pY705-containing tetrapeptide PpYLK (residues 704-
707) binding to the SH2 domain of the opposite pSTAT3 homodimer-forming 
monomer-A were employed in this 3D structure-based pharmacophore modeling 
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approach. This allowed mapping out (and confirmation) of the characteristic features of 
the interaction to be undertaken, while utilizing the information of the protein confor-
mational flexibility as suggested by MD simulation. With respect to the principal focus 
being at the protein-protein interface, only the SH2 domains with the stretch of 
C-terminal residues were considered for the RMSd-based cluster analysis in this case. 
Five representative structures obtained from the cluster analysis of the 50-ns trajectory 
(48 ns respectively) of the pSTAT3-DNA complex, spanned over ~ 86% conformational 
space sampled, with the first two clusters representing 58% (32% + 26%). 
The hypothesis obtained 30 features, summarized in Table 5.5 and graphically  shown in 
Figure 5.10. 
Table 5.5: Specific features of the PpYLK-SH2 domain interaction represented by  3D-pharmacophores.
Specific features observed at the five representative structures  are all summarized here.
Pharmacophore feature distance constraints tetrapeptide PpYLK receptor residues
Hydrogen bond donor
Hydrogen bond acceptor
Hydrophobic interactions
Negative ionizable area
Positive ionizable area
Excluded volume
2.2 - 3.8 Å L706(NH) S636
K707(Nz; ε-amino side chain) E638
2.2 - 3.8 Å pY705(OP) K591, R609, S611, E612, S613
pY705(OS) R609, K591
L706(O) E638
P704(O) Q635
1.0 - 5.9 Å pY705(aromatic side chain) T620, P639
L706(aliphatic side chain) W623, V637
1.5 - 5.5 Å pY705(OP) K591, R609
1.5 - 5.5 Å K707(Nz; ε-amino side chain) E638
sterical circumstances tetrapeptide PpYLK K591, R609, S611, E612, S613
T620, F621, W623, Q635, S636
V637, E638, P639, Y657 
With respect to the PpYLK ‘ligand’, there are two hydrogen bond donors and six accep-
tors, two hydrophobic groups/interactions with four different residues, one negative and 
one positive ionizable area, and 14 excluded volumes, which are derived from the steri-
cal circumstances of the macromolecule. The two hydrogen bond donor features of the 
PpYLK tetrapeptide (residues 704-707) reflect the (i) NH group of L706, which hydro-
gen bonds with the side chain (OH group) of S636, and (ii) the protonated amino group 
of the K707 side chain, forming hydrogen bond with the un-protonated side chain of 
E638. The four hydrogen bond acceptor features of the PpYLK ‘ligand’ then reflect 
hydrogen bond formation between (i) the negatively charged phosphate group of pY705 
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with five residues forming a tight pocket where the phosphate group of pY705 binds, 
namely R609 and K591, S611, E612 and S613 (which is in agreement with other theo-
retical and experimental studies216); (ii) the backbone atoms involved in hydrogen bond 
formation between L706 (tetrapeptide) and E638, which makes L706 and E638 both 
hydrogen bond donors and acceptors respectively; and (iii) a hydrogen bond between 
the carbonyl oxygen of P704 with Q635.  
Figure 5.10: Structure-based 3D-pharmacophore model of the PpYLK tetrapeptide.
The model is based on second representative structure obtained from the cluster analysis of the 48 ns MD 
trajectory. (a) 3D-pharmacophore is shown in licorice representation, with its binding pocket shown as 
molecular surface. (b) 2D representation of the PpYLK pharmacophore shows the specific features de-
scribing the interaction with the SH2 domain.
 The charge interaction features, i.e negative and positive ionizable areas, are 
defined by distance constrains only. The interactions evolve around the charged portions 
of the tetrapeptide (PpYLK) ligand; specifically  at the negatively-charged phosphate 
group of pY705 interacting with the positively charged side chains of K591 and R609. 
Also the positive charge-carrying side chain of K707 which forms further electrostatic 
interaction with the hydrogen-bond forming un-protonated side chain of E638. Hydro-
phobic spheres were occupied, for all five conformations that were examined, by  the 
aromatic ring of pY705. This pharmacophore feature is reflected in the hydrophobic 
pocket formed by  T620 and P639. Distinct hydrophobic interactions are also formed 
between the branched side chain of L706 with the receptor residues W623 and V637, 
which form a relatively shallow hydrophobic pocket. The 14 excluded volume features 
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of the receptor, as determined by LigandScout over the five representative structures, 
reflected potential steric restrictions, and correspond to the positions sterically claimed 
by the macromolecular environment surrounding the pY705-containing tetrapeptide 
(residues K591, R609, S611, E612, S613, T620, F621, W623, Q635, S636, V637, E638, 
P639 and Y657). A combined structure-based 3D-pharmacophore model (representing 
~60% of the sampled conformational space at 300K) with the hypothesized  key chemi-
cal featured for the  PpYLK tetrapeptide recognition is shown in Figure  5.11. 
Figure 5.11: Shared 3D-pharmacophore for the PpYLK tetrapeptide. 
The shared structure-based pharmacophore model representing the features of the PpYLK-SH2 domain 
interaction as found for the first two - first (grey) and second (black) - representative structures. Hydrogen 
bond interactions are shown as arrows, donors in green,  acceptors in red. Hydrophobic interaction 
features yellow sphere,  while the charge interactions are shown as blue (positive) and red (negative) 
cones. 
 The pharmacophore-based analysis of the residues forming the protein-protein 
contacts in positions from -1 to +3  with respect to pY705 by LigandScout, confirms the 
importance of the known pY705 pocket forming residues (K591, R609, S611, E612 and 
S613) and other tetrapeptide-accommodating residues. For instance McMurray215,241 et 
al reported a detailed description of STAT3 SH2 domain residues involved in direct 
interaction with high affinity phosphopeptides. Their data were derived from static 
molecular docking simulations, and two 3-ns MD simulations of the SH2 domain-ligand 
(constrained phosphopeptides) complexes respectively. Here, the STAT3-own tetrapep-
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tide sequence PpYLK was studied utilizing the knowledge of conformational flexibility 
obtained from the 50-ns MD simulation, thus providing reassuring information about 
the importance of certain previously reported contact residues, but also demonstrating 
the features of the network over time. L706 has indeed been shown to be key residue in 
terms of modulating STAT3:STAT3 specificity, since it  acts as both a hydrogen bond 
donor (with S636) and a hydrogen bond acceptor (with E638) through interactions em-
ploying its backbone amid-nitrogen and carbonyl-oxygen respectively. Its branched ali-
phatic side chain is accommodated in a hydrophobic pocket  defined by W623 and 
V637. Also E638 was shown to be important hydrogen bond donor and acceptor simul-
taneously, whereas Q635 seems to be in direct, hydrogen-bonding, interaction with 
P704, at position pY -1, which is only at  one of the five studied conformations obtained 
from MD. This suggests that P704 is perhaps not so important in terms of structural 
recognition and the binding pocket definition for a potential high-affinity ligand. On the 
other hand, persistent hydrophobic interaction of the pY705 aromatic ring with T620 
and P639, help  to define the tight clamp-like pocket around the phosphate portion of 
pY705, which in turn is wide open toward the following residue L706, thus providing 
much more space for structural variety of the ligands functional groups (Figure 5.10 a). 
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5.5  CONCLUSIONS 
Conformations of pSTAT3-DNA complex and uSTAT3-DNA complex sampled through 
two parts of explicit solvent MD simulations were utilized in a multiple-approach in 
silico study of the STAT3 PPI interaction, with the primary focus at  the pY705/Y705 
binding region. To date, no comparable computational study  of this scope or approach, 
where phosphorylated and unphosphorylated STAT3 forms were compared, and their 
structural differences further applied in MRC docking study  has been reported. It  is 
proposed, that this comparison approach is relevant to potential small-molecule STAT3-
STAT3 inhibitor intervention, since a mounting body of evidence has suggested a non-
canonical STAT3 signaling pathway, leading to the unphosphorylated STAT3 dimer 
forming a complex with its target DNA sequence in the nucleus.
(I) Distinct features of the unphosphorylated Y705-binding pocket were found with re-
spect to the widely studied and structurally described pY705-binding site. In multiple 
target representations K591 was found to be flipped out of the tight pY binding pocket 
(formed of residues K591, R609, S611, E612 and S613) in the case of the unphosphory-
lated tyrosine residue, and replaced by E594. This partial pocket re-arrangement leads 
to a wider, less structurally-defined binding site for the uSTAT3 SH2 domain. The 
chemical features of the binding pocket are also influenced and/or altered  when the 
K591 was observed to have flipped.
(II) A MRC docking study of 54 experimentally-determined small molecules docked 
with both phosphorylated and unphosphorylated STAT3 SH2 domain (in a total of six 
conformations), using two docking softwares, provided a more thorough insight into the 
ligand-receptor (STAT3 SH2 domain) interactions at numerous levels. SH2 domains, 
including the pY-binding pocket, are principally known to be structurally conserved. 
However subtle conformational changes have shown to have a strong effect on pre-
dicted binding poses and orientations of small molecule ligands that were examined, 
and has demonstrated that this combined docking approached provides an advantage 
over the conventional single receptor conformation concept. Ligands 24712_CD, 
29292_CD, 29768_CD or 26810_CD have consistently  shown good results in terms of 
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binding energies, targeting the pY705 binding site at numerous receptor conformations, 
as well as decent agreement between the two softwares employed in ligand binding-
poses predictions.
(III) Binding free energies of the STAT3:STAT3 and STAT3 dimer:DNA intermolecular 
association calculated by means of the MM/PB(GB)SA methods have shown to be cor-
responding for both pSTAT3-DNA and uSTAT3-DNA complex in terms of the protein-
DNA interaction. However, the binding free energy  of the protein-protein association is 
two-fold more favourable for the pSTAT3 complex than for the uSTAT3 complex. These 
predicted free energies of binding are in good qualitative agreement with experimental 
data, which demonstrated uSTAT3 protein binding to dsDNA, forming a stable confor-
mation (Nkansah et al, manuscript submitted for publication, 2012).
(IV) A shared 3D-pharmacophore model of the pY705 containing tetrapeptide (P704-
pY705-L706-K707) based on five representations of the pY-binding pocket (obtained 
from a 50-ns MD trajectory), confirmed the significance of residues pY705 and L706 in 
STAT3 binding, and their respective binding pockets. Collected specific features of the 
tetrapeptide - SH2 domain interaction/recognition may then provide a useful “guidance” 
in rational design of potential small molecule inhibitors of the STAT3-STAT3 interac-
tion. Sterical restrictions of the pY-binding pocket (i.e the explicit  protein residues) 
were also taken in account.
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Supplementary information for CHAPTER 5:
Figure S5.1: Overview of the full screening cascade for the potential STAT3 small-molecule inhibitor8 
The initial HTS with ~25.000 molecules was carried out at the European Screening Port (ESP) in Ham-
burg, employing a FP-biochemical cell-free assay as a primary PPI binding assay. Out of the 223 com-
pounds selected by HTS (based on PPI % inhibition > 50% at 40 µM concentration), 54 compounds were 
purchasable, and brought into further biological experiments and in silico studies.
            PART 1
135
8 The screening cascade overview was kindly provided by Dr. Giovanna Zinzalla
Table S5.1: Overview of the selected parameters employed in the DOCK6 docking protocol.
Molecule Library Input Parameters
ligand_atom_file                                  
calculate_rmsd                                               
Orient Ligand Parameters
orient_ligand                                               
automated_matching                                          
receptor_site_file                                   
max_orientations                                            
Internal Energy Parameters
use_internal_energy                                         
internal_energy_rep_exp                                 
Flexible Ligand Parameters
flexible_ligand                                              
min_anchor_size                                            
pruning_use_clustering                                       
pruning_max_orients                                       
pruning_clustering_cutoff                                  
pruning_conformer_score_cutoff                              
use_clash_overlap                                           
Bump Filter Parameters
bump_filter                                               
bump_grid_prefix                                           
max_bumps_anchor                                          
max_bumps_growth                                       
Master Score Parameters
score_molecules
Grid Score Parameters
grid_score_primary                                          
grid_score_grid_prefix                                      
Hawkins GB/SA Score Parameters
gbsa_hawkins_score_secondary                               
gbsa_hawkins_score_rec_filename                            
gbsa_hawkins_score_solvent_dielectric                       
gbsa_hawkins_use_salt_screen                                
gbsa_hawkins_score_salt_conc(M)
gbsa_hawkins_score_gb_offset                                
gbsa_hawkins_score_cont_vdw_and_es                        
gbsa_hawkins_score_vdw_att_exp                             
gbsa_hawkins_score_vdw_rep_exp                            
Simplex Minimization Parameters
minimize_ligand                                              
minimize_anchor                                             
minimize_flexible_growth                                  
simplex_anchor_max_iterations                               
simplex_grow_max_iterations                                  
simplex_secondary_minimize_pose                             
simplex_secondary_max_iterations                            
Molecule Library Output Parameters
ligand_outfile_prefix                                        
num_primary_scored_conformers_rescored                  
num_secondary_scored_conformers                            
write_secondary_conformations                               
rank_secondary_ligands                                      
/path/docking/ligand*.mol2
no
yes
yes
/path/docking/selected_spheres.sph
500
yes
12
yes
5
yes
100
50
25
no
yes
/path/docking/grid
6
6
yes
yes
/path/docking/grid
yes
/path/docking/receptor-charged*.mol2
78.5
yes
0.15
0.09
yes
6
12
yes
yes
yes
500
500
yes
100
ligand*
5
3
yes
no
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PART 2
MOLECULAR MODELING STUDIES OF G-QUADRUPLEX     
DNA  COMPLEXES WITH SMALL-MOLECULE  LIGANDS
 
“ T h e  p u r p o s e  o f  a  m o d e l  i s  n o t  t o  f i t  t h e  d a t a  b u t  t o  s h a r p e n  t h e  q u e s t i o n s . “
( S a m u e l  K a r l i n ,  1 9 8 3 )
137
‘Overture’
Nucleic acid sequences containing multiple short sequences of guanosine nucleotides 
(G-tracts) can form higher-order structures, termed G-quadruplexes. These structures 
typically have a core of 2-4 G-quartets, each of which comprises four in-plane guanine 
bases in a highly stable hydrogen-bonded arrangement.242,16 Successive G-quartets are 
held together by  π-π stacking interactions, together with an array of metal ions coordi-
nated to the O6 guanine substituents at the center of each quartet.243 Quadruplex se-
quences occur at the telomeric ends of eukaryotic chromosomes. Thus in human telo-
meres a well-studied intramolecular quadruplex can be formed from four tandem re-
peats of the sequence d(TTAGGG). 242,244,14 Quadruplex sequences are also prevalent in 
other genomic locations,73,245 notably in oncogenic promoters. In general the sequences 
connecting the short G-tracts may adopt structural linker roles, connecting the G-
quartets in a particular manner. They can form loops (for example TTA loops in human 
telomeric quadruplexes), with relationships to the stack of G-quartets that depend on the 
overall topology of the quadruplex.16 Structural information on G-quadruplex architec-
ture has become available from X-ray crystallography, and from NMR structure deter-
minations for human and a few other telomeric quadruplexes, and for a small number of 
promoter quadruplexes, for example for the c-MYC, c-KIT and b-RAF oncogenes.76,246 
These studies have revealed a high degree of structural diversity, with dependency on 
not only  primary  sequence but also on a number of environmental factors, notably the 
nature of the metal ion and quadruplex concentration. 
 The potential occurrence of quadruplex structures in cellular environments has 
suggested that they can be targets for therapeutic intervention, for example to down-
regulate the transcription of cancer-associated genes or to inhibit the maintenance of 
telomeres in cancer cells.74-76 A large number of small-molecule compounds have been 
devised and evaluated for quadruplex binding and as potential effectors of quadruplex 
cellular action. The majority of these compound classes have common structural fea-
tures – planarity  and cationic substituents, and attempts at developing more diverse 
structural types have in large part used library  screening approaches.99,247,248  
Structural-based methods the rational design of more potent and selective compounds 
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are still in their infancy  and have been hampered by the relatively small number of ex-
perimental structures available to date. In silico screening of libraries has been reported 
in several instances.  
 It is now widely recognized that many G-quadruplexes can adopt multiple con-
formations and topologies, and so a major challenge to the design of high-affinity 
ligands is the specificity of targeting G-quadruplexes with different folding patterns. It 
is known that  particular small molecules can stabilize one topological type over another. 
For example, the anti-parallel hybrid topologies found in dilute solution for some intra-
molecular telomeric quadruplexes are stabilized by ligands such as the natural product 
telomestatin,249 whereas the parallel topology can be stabilized by, for example, various 
tetra-substituted naphthalene diimides.79 The majority of small-molecule compounds 
reported to date bind to the more general features of quadruplexes – the planar surface 
of a terminal G-quartet and the anionic phosphate groups, and the overwhelming major-
ity  bind to the planar G-quartet termini rather than predominantly  in the grooves. Ex-
tended substituents are presumed to bind in the grooves and loop regions, although the 
available structural data on these features is limited to date. The discrimination between 
G-quadruplexes and other forms of DNA, in particular duplex DNA, is also of practical 
therapeutic importance, and is more straightforward to achieve. A fundamental goal 
remains the ability to design a small molecule that is highly selective for a particular 
quadruplex. Analysis of crystallographic data has shown that even for a given quadru-
plex type, the loops have conformationally flexible conformations, with bound small 
molecules inducing ligand-specific conformational change.250 Thus loop flexibility  adds 
another layer of complexity to the design challenge.
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==============================================================
CHAPTER 6:
A multiple molecular dynamics approach for systematically examining 
conformational space in small-molecule/G-quadruplex interactions
==============================================================
6.1 BACKGROUND:
For rational drug design and effective G-quadruplex ligand optimization, it is of key 
importance to understand the interactions between small-molecule ligands and their G-
quadruplex targets. X-ray diffraction and NMR experiments provide detailed insight 
into the structures of G-quadruplexs, and ligand-quadruplex complexes. However, they 
give little insight into the dynamic conformational rearrangements that small molecu-
le–quadruplex complexes undergo, and the ligand transitions leading to G-quadruplex 
stabilization. Obtaining the most favourable binding poses of the compounds in silico 
has been challenging due to specific features of quadruplex nucleic acid molecules (i.e 
highly  charged backbone, presence of stabilizing alkali metal cations, the basic quadru-
plex architecture) and in particular flexibility of the G-quadruplex structures is an 
important issue to be considered within the framework of G-quadruplex ligands dock-
ing. Quality of the G-quadruplex docking results, and subsequently  the binding affinity 
of potential G-quadruplex ligands, might be strongly affected by  the flexibility of the 
loop regions.98  
 The present study has approached the problem of probing and predicting the 
low-energy arrangements and conformational profile for small-molecule-quadruplex 
binding by developing a set of computational tools for examining large ensembles of 
potential binding sites and loop conformations. The intramolecular human telomeric 
quadruplex structure has been used as the quadruplex platform, since the native struc-
ture and complexes with a wide range of ligands have been determined by X-ray 
crystallography. The methodology though is applicable to all quadruplexes for which 
even a low-resolution topological description is available.  
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Two contrasting small molecule ligands have been used as probes. The compound 
pyridostatin,251 based on a N’,N’’-bis(quinolinyl)pyridine-2,6-dicarboxamide scaffold, 
has high selectivity  for quadruplex vs duplex DNA. Its ability  to target telomeric quad-
ruplexes has been demonstrated252 and it  has also been show that pyridostatin interacts 
selectively with a terminal G-quartet of a G-quadruplex through a stacking mode. 
Furthermore, Rodriguez252 et al have also provided evidence that pyridostatin targets 
the common structural feature shared by G-quadruplex motifs regardless the nature of 
the loop  sequences. This ligand has itself a high degree of conformational flexibility, 
with a total of 13 rotatable bonds. Although it has been suggested that the pyridostatin 
molecule would have a preferred near-planar conformation as a result of potential coor-
dination of four inner-facing nitrogen atoms to a water molecule, the present study has 
not assumed that this would occur. By contrast the pentacyclic acridine derivative 
RHPS4253 has no rotatable bonds and just methyl and fluorine substituents. RHPS4 and 
a number of its analogues bind to human telomeric quadruplex DNA with high affinity 
and some selectivity  for quadruplex compared to duplex DNA, although the measure of 
selectivity is dependent on the methodology used. An NMR study of RHPS4 bound to 
the tetramolecular quadruplex d(TTAGGGT)4 has shown that  all four strands are paral-
lel in this complex254 and has provided an experimental structure to which simulation 
studies can be compared.
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6.2 AIMS: 
The aim of this work is to develop a systematic and general approach to determining all 
plausible positions for binding a ligand to a G-quadruplex structure, taking fully  into 
account the flexibility of both the target and the ligand, as well as any  conformational 
change upon ligand binding, and then evaluating the energetically  most favourable 
binding regions of the resulting complexes using multiple free-energy  of binding calcu-
lation techniques.
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6.3 METHODS:  
The four principal stages in the approach involve (1) in silico construction and prepara-
tion of the two ligands, (2) sampling of the G-quadruplex/ligand conformational space 
via calculations of explicit  MD full-atomistic trajectories of the G-quadruplex/ligand 
complexes starting from numerous ligand positions, (3) clustering of the ligand confor-
mations determined by  the MD calculations, and (4) calculation of binding energies of 
the proposed binding poses of the complexes using two different methods.
6.3.1 System setup and molecular dynamics simulation
Molecular structures of pyridostatin251 and RHPS4254 were constructed using the 
ChemBioOffice (Cambridgesoft) package, and saved as a Sybyl 'mol2' file format. 
Since RHPS4 is a rigid molecule (Figure 6.1 a) there were no intramolecular conforma-
tions to explore. However pyridostatin has a number of flexible bonds (13 rotatable 
bonds in total) which allow the molecule to adopt a wide range of different conforma-
tions. For the starting positions it was assumed that the central part of the pyridostatin 
molecule was planar (Figure 6.1 b). There were several possible conformations where 
the aromatic systems and the peptide linkages could be co-planar. Each peptide linkage 
has three rotatable bonds, and since we are assuming that the molecule is flat, each of 
the central rotatable bonds has two possible conformations. Because there are six of 
them in total, there could be 26 (or 64) conformations. However for steric reasons, only 
16 conformations were possible (Table 6.1 in the results section). 
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Figure 6.1: Models of the ligands, and the human telomeric G-quadruplex structure (22-mer).
(a) rigid RHPS4 molecule and (b) flexible pyridostatin molecule. The central “flattened” atoms of pyrido-
statin in one of its possible conformations, highlighted in the yellow panel; (c, d) human telomeric G-
quadruplex in surface representation with the 2 Å grid aligned with the least squares plane of the guanine 
bases; The grid is placed 3.4 Å above the plane (2 Å above the surface),  5'site is shown here. These grid 
points on both 3'- and 5'site were used as starting points for multiple MD-runs.
The crystal structure of telomeric G-quadruplex15 (PDB id 1KF1 at 2.1Å resolution) 
was used as a starting-point for the molecular dynamics studies. Consecutive K+ ions 
vertically aligned within the central core of the G-quadruplex mid-way between each G-
quartet were retained at their respective crystallographic positions, while the K+ ion 
outside of the central core of the G-tetrad (at the 5'-site) was removed. The positions of 
each ligand were explored on both the 3'- and 5'-face of the quadruplex molecule. The 
G-quartet on the binding site of the quadruplex was aligned with the x,y axes by  firstly 
calculating the least-squares plane of the guanine base atoms. Eigenvalues for the least-
squares plane calculation were obtained using the linear algebra module from the 
NumPy255 package. The G-quartet was then oriented accordingly. The position of the 
center of mass of the atoms belonging to bases of the G-quartet on the binding site of 
the quadruplex was calculated, and the molecule translated so that this lay on the origin. 
Each of the 16 planar conformations of the (flattened) pyridostatin molecule was 
aligned to lie on the same plane as the x-y  axes by calculating the least-squares plane of 
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the central atoms and rotation accordingly. The molecules was then translated so that the 
center of mass of the planar central scaffold was on the origin and they were translated 
in the z-direction so that  they lay 3.4 Å above the least-squares plane of the chosen 
quadruplex binding site. These positions were uses as a reference for any  further trans-
lations and rotations (Figure 6.1 c,d). The single structure of the RHPS4 molecule was 
prepared in the same way. Each molecule was then rotated in 45° steps to produce eight 
orientations and each oriented molecule was translated to positions on the x-y plane in a 
grid-like manner to produce 36 different positions at 2 Å intervals in both the x and y 
directions (-5, -3, -1, 1, 3, and 5 Å  form the original position in both the x and y  direc-
tion). Each position was then tested for clashes with the quadruplex and all those with 
any ligand-quadruplex separations of less than 2.4 Å were rejected.
 All of the MD simulations were full-atom simulations and were performed with 
the GROMACS v 4.5.3 program,154,155 employing the parmbsc0161 force field, which 
was ported previously  into GROMACS (as described in CHAPTER 3). The topologies 
and other parameters for the two ligands were generated using the ACPYPE169 tool, 
which employs the ANTECHAMER170 module of the AMBER11 program with the 
Generalized Amber Force Field (GAFF).226 The simulation protocols were consistent 
for both 22-mer quadruplex ligand-bound systems. The models were solvated in a peri-
odic box of TIP3P196 water molecules, with a minimal clearance of 20.0 Å between pe-
riodic images for the starting configurations. Additionally, positively  charged K+ 
counter ions were included in the systems to neutralize the negative net charge on the 
DNA backbone. Subsequently the systems were subjected to 10,000 steps of robust po-
tential energy  minimization (steepest descent followed by conjugate gradient algo-
rithm), followed by 100 ps of molecular dynamics at 200K while keeping the solutes 
constrained. The systems were then slowly heated to 300K, with further unconstrained 
equilibration steps over 50 ps. Production-level MD trajectory calculations were carried 
out at 300K with a time constant  for coupling of 0.1 ps under the control of velocity 
rescaling thermostat,199 and isotropic constant-pressure boundary conditions controlled 
by the Parinello-Rahman200,201 algorithm with pressure coupling at 1.0 bar. Non-bonded 
van der Waals interactions used the Lennard-Jones 12-6 potential with a 10.0 Å cut-off, 
and the particle mesh Ewald (PME)122 method was employed for electrostatic interac-
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tions. All-atom bonds were constrained by  the LINCS126 algorithm. The time step ap-
plied was 2.0 fs, with coordinates saved every  5.0 ps. All the MD simulations were run 
in 100 ps blocks, up to 1 ns, which was considered to be an equilibrium position.
6.3.2 Cluster analysis
After each block of the 100-ps explicit solvent  MD simulations, an average structure 
over the final 10 ps was generated. This structure was then aligned against all of the 
preceding averaged structures for that starting conformation. Two opposite guanine 
bases on the G-quartet adjacent to the bound ligand molecule were used as a reference 
for the alignment (the guanine bases of the quadruplexes were found to be relatively 
stable during the simulations). The bases were aligned by calculating the principal mo-
ments of inertia and the molecules were then translated so that the center of mass of the 
chosen guanine bases was at the origin and the molecules were rotated so that  the prin-
cipal axes of inertial corresponded to the coordinate axes. The structures were then clus-
tered, based on the positions of the central part  of the ligand molecules. The root-mean-
square distance (RMSD) of the central atoms between each pair of averaged structures 
was calculated. Hierarchical agglomerative clustering was then carried out using the 
nearest linkage method to an RMSD cutoff of 1.2 Å. If a ligand was found to share a 
cluster with a previous average structure or had been run for a total of 1 ns, a simulation 
was begun with a new starting position. Eventually, all the truncated and completed MD 
runs were clustered based on the criteria described above.
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6.3.3 Binding energy calculations
Two different  methods were used to calculate the free-energy change on quadruplex-
ligand complex formation, for all final conformations sampled throughout the numerous 
MD simulations (dynamic docking): (1) using the semiempirical quantum chemistry 
program MOPAC2009 v.11.3 (http://openmopac.net) with the MOZYME256 linear-
scaling algorithm (2) using the force field-based molecular mechanics/Poisson-
Boltzmann (or generalized Born) surface area (MM/PB(GB)SA)131,132,229 methods as 
implemented in MMPBSA.py  python module within the AMBER11 package. Binding 
energies of a small subset of the structures were calculated employing the force field-
based Generalized Born/volume integral (MM/GBVI)257 method within the MOE pack-
age (http://www.chemcomp.com) were also used as an additional, third method, for a 
comparison purposes.9 All binding energy calculations were performed using the same 
set of structures, in each case five frames representing the last  10 ps of the final 100-ps 
block of the individual simulations. Free-energy changes of the energy-minimized 
systems were also calculated with MOPAC2009, to evaluate the initial G4/ligand inter-
actions prior to MD simulations. Binding energy calculations by means of MOPAC2009 
calculations were employed in order to evaluate the correlation/differences between 
semi-empirical and empirical methods (MM/PB(GB)SA), and to obtain statistically 
stronger set of calculations for the subsequent analysis. 
• the PM6-DH2 method258 (with correct dispersion and hydrogen bond terms), together 
with a single-point calculation (1SCF), was employed within MOPAC2009 to calculate 
the interaction energy  between the quadruplex and the ligands. The effect of a solvent 
model surrounding the molecules was approximated via the COSMO method259 with a 
dielectric constant for the implicit solvent set to 78. The intermolecular interaction en-
ergy EINTER was then given by  calculating the heats of formation of each of the three 
systems; G-quadruplex/ligand complex (G4-LIG), G-quadruplex (G4) and the ligand 
(LIG) (equation 6.1)
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9 I acknowledge Dr. J.A. Platts for the valuable advice and mentoring in free binding energy calculations 
by different approaches described in this chapter.
EINTER&=&&∆Hf(G4CLIG&complex)&C&∆Hf(G4)&&C&&∆Hf(LIG)&&&! ! ! !       ! (6.1)
where ∆Hf(G4CLIG& complex)& ,& ∆Hf(G4) and ∆Hf(LIG) are the heat of formation of the complex, 
G-quadruplex and ligand respectively. Five frames of the MD trajectory, representing 
the final 10 ps of the final 100-ps 'blocks' of each of the conformations, positions and 
orientations were saved as pdb files and subsequently used as input for the MOPAC 
binding-energy calculations. A single value of the calculated intermolecular interaction 
energy was obtained as an average over the five frames.
• the MM/PB(GB)SA131,132,229 method computes the relative free energies of binding, 
employing the thermodynamic cycle that combines the molecular mechanical (MM) 
energies with the implicit solvent methods. This method takes advantage of multiple 
snapshots from a trajectory, to provide an average of energies. The change of free-
energy of the molecules upon complex formation was calculated (for each of the snap-
shots) as a difference of free energy between their bound and unbound states is given in 
equation 6.2 (more details of the MM/PB(GB)SA method are provided in CHAPTER2); 
free energy of each term was then calculated according to equation 6.3:
        &∆Gbind&=&&&G(G4CLIG&complex)&&C&G(G4)&C&G(LIG)&&&     (6.2)
         ∆G&=&&&∆EMM&&&+&&∆GSOL&&C&T∆S       (6.3)
where the molecular mechanics energy (EMM) term is a sum of the internal energy 
(bonds, angles and dihedrals), electrostatic energy and van der Waals term; while the 
GSOL term accounts for the solvation energy, comprising both polar and nonpolar com-
ponent. The polar part of the solvation term accounts for the electrostatic contribution to 
solvation and was calculated using both Poisson-Boltzmann (PB) model, and the 
generalized-Born (GB) model developed by Onufriev et al234 (igb=2; model GBOBC1) 
with rescaled effective Born radii, accounting for interstitional spaces between atom 
spheres. Solvent probe radius, dielectric constants grid-spacing parameters were kept at 
program’s default  values. The entropy term (T∆S) was not included in our simulations 
as different conformations/ binding poses of one ligand were explored. All the calcula-
tions were performed employing the single-trajectory approach, and used the five 
frames of the final 10 ps (corresponding to the approach for the MOPAC calculations). 
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Prior to the binding free energy calculations, the individual trajectories (stripped from 
the explicit  solvent) were converted from GROMACS compressed trajectory ‘xtc’ file 
into AMBER trajectory  file format (‘mdcrd’ file) via VMD visualization program, and 
via AMBER trajectory processing program ptraj.
• the generalized Born/volume integral (GB/VI)257 method that estimates the free energy 
of hydration (together with cavitation energy), based on a VI London dispersion energy 
(unlike the GB/SA hydration model, that is based on atomic surface area, SA) employed 
with the MOE (an acronym for Molecular Orbital Environment) software package was 
used as the third method to estimate the free energy of binding of the G4/ligand com-
plexes. This method was applied only to a limited number of G4/ligand conformations, 
serving rather as a ‘test method’.
6.3.4 Statistical analysis
The mean binding energies for each cluster were calculated. In order to determine the 
statistical significant of the differences between these, one way analysis of variance 
(ANOVA) was carried out using the statistical package R,260 considering all clusters that 
had three or more members. RMSD calculations for the guanine bases proximal to the 
ligand were calculated using the program LSQMAN.209 The variations within clusters 
were examined for each cluster with three or more members, by  determining the RMSD 
between each pair of cluster members and calculating the mean RMSD value. The 
variations between clusters were also calculated and each cluster was compared with 
every  other cluster. Comparison of two clusters was performed by calculating the 
RMSDs of each member of the first cluster (cluster A) with each member of the cluster 
that it is being compared with (cluster B), and the cluster similarity was taken to be the 
mean RMSD. So for example if cluster A had 8 members and cluster B had 3 members, 
a total of 24 RMSD calculations were carried out and the mean value of these RMSDs 
was considered to be the similarity of the two clusters.
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6.4 RESULTS AND DISCUSSION:
The aim of this work is to develop a systematic and general approach to determining all 
plausible positions for binding a ligand to a G-quadruplex structure, taking fully into 
account the flexibility of both the target and the ligand, as well as any conformational 
change upon ligand binding, and then evaluating the energetically most favourable 
binding regions of the resulting complexes using multiple free-energy calculation tech-
niques. 
Several levels of analysis are presented here: 
(1) two structurally very  different ligands, the rigid RHPS4 molecule, and the confor-
mationally flexible pyridostatin molecule, were examined for all sterically-plausible 
conformations, as well as for orientational and positional flexibility with respect to the 
G-quartet faces of the quadruplex. 
(2) both 5' and 3' termini of the human telomeric quadruplex were explored in order to 
avoid any  false-positive binding on one of the sites, as well as to inspect whether there 
is an energetic preference for either of the binding sites.
(3) the changes in free energy resulting from intermolecular interaction of the quadru-
plex with ligand were calculated, using a semiempirical quantum chemistry level tech-
nique (MOPAC), and molecular mechanics (force field-based) methods (MM/
PB(GB)SA and MM-GB/VI). The semiempirical (MOPAC) calculations were per-
formed for a comparison purposes, complementary to the empirical MM/PB(GB)SA 
approach. Subsequently, the correlations between the methods were statistically and 
graphically examined.
(4) the structural-stability effects of the ligands on the G-quadruplex structure were 
inspected by means of RMSD calculations of the non-hydrogen atoms within the 3'/5' 
termini G-quartets. The structural differences within the clusters, as well as in between 
the clusters, were calculated.
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The overall workflow of the MD simulations ('dynamic docking'), structural alignment 
and clustering, subsequent free energy calculations on quadruplex-ligand complex for-
mation, and the statistical and structural analyses, is represented in Figure 6.2.
Figure 6.2:  Schematic overview of the workflow. 
Upon numerous MD simulations employing different ligand's conformations, orientations and positions 
on the G4 3' and 5'face,  time-averaged structures over the final 10 ps of the last 100-ps blocks used for 
clustering were further employed for the target's face stability calculation (heave atoms only), as well as 
for the charge-charge score calculation between the positively-charged side chains of the ligand and the 
negatively-charged G4-DNA backbone; five frames representing the final 10 ps of the 100-ps MD runs 
were then used for the MM/PB(GB)SA calculations, as well as for the MOPAC calculations.
! The individual components of the procedure were automated via in-house py-
thon scripts10, in order to cope with the very  large number of starting structures (2436 in 
total) and extensive output data. Explicit-solvent molecular dynamics simulations were 
performed, with 232 starting positions for the quadruplex-RHPS4 complexes, and 2204 
individual starting positions of pyridostatin in 16 different conformations (Table 6.1) 
over both 3' and 5' ends of the quadruplex (Figure 6.1). The disproportion in the amount 
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10 The automation of the simulation procedure via python scripts was performed by Dr. Alan K. Todd
of MD simulations started for the two ligands is due to the nature of their structures; 
since pyridostatin is highly  flexible and conformationally variable, the amount of possi-
ble binding modes exceeded the number of RHPS4's positions nearly  10-fold. Further-
more, the difference in the overall number of simulations performed on the 3' and 5'-site 
respectively is possibly  due to the difference in shape of the 3’- and 5’site; the latter be-
ing significantly flatter, thus providing larger surface to sample. Table 6.1 further sum-
marizes the trend of the individual pyridostatin conformational transitions throughout 
the MD runs. 
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Table 6.1: Overview of the 16 explored pyridostatin conformations.
These 16 conformations of pyridostatin were examined by an extensive MD study (i.e fully dynamic 
docking) for both 3’- and 5’face of human telomeric G-quadruplex. A number of the started MD runs, a 
number of 100-ps blocks performed for each of the conformations, and the percentage of gain/loss of that 
particular conformation throughout the multiple MD runs is given.
Pyridistatin conformations 
explored
5’site MD simulations 3’site MD simulations
# MD runs 
started
# 100-ps
blocks
Conform. 
gain/loss
# MD runs 
started
# 100-ps
blocks
Conform.
gain/loss
000000 105 536 + 32% 17 123 + 165%
000001 104 561 + 14% 26 200 − 15%
000010 116 570 − 3% 40 287 − 12%
000011 90 595 − 50% 38 256 − 50%
000100 121 565 + 21% 25 225 + 64%
000101 99 476 + 15% 18 145 + 39%
000110 101 594 − 8% 38 221 − 13%
000111 116 586 − 28% 34 237 − 53%
001000 117 474 + 11% 26 214 + 50%
001001 104 507 − 9% 43 283 − 14%
001010 111 512 + 2% 8 64 + 75%
001011 112 509 − 6% 30 229 − 43%
001100 119 433 + 16% 33 154 + 12%
001101 120 535 + 7% 18 129 + 28%
001110 110 414 0 28 189 − 4%
001111 124 543 − 22% 13 119 − 62%
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With 32% (5’site) and 165% (3’site) conformational “gain” throughout the MD runs, 
conformation '000000' was shown as favourable by both G-quadruplex faces, with the 
largest increase of this conformation by  a conversion of other, less favourable, pyrido-
statin conformations explored. Similarly, conformations '000100', ‘000101’, ‘001100’, 
‘001101’ and ‘001010’ have increased in their numbers throughout the simulation time. 
On the other hand, conformation ‘000011’ showed the largest loss of structures 
(~50% on both 3’ and 5’ sites) throughout the MD runs, converging to other preferable 
conformations. Table 6.2 provides an overview of the total number of simulations 
started, completed (i.e reached 1 ns), and truncated throughout the MD run for both 
ligands on each site of the G4. In terms of the rigid ligand, RHPS4, less than 10% of all 
the simulations that started, reached the maximum simulation time of 1 ns, and over 
90% were even truncated prior to/at  0.5 ns. This situation applies to both 5’ and 3’ face 
of the G-quadruplex, and may be understood as a consequence of the rigidity  of the 
RHPS4 compound, together with the presence of no rotatable bonds, resulting only in a 
little conformational requirements of the ligand. A different  trend is observed for the 
conformationally  flexible ligand, pyridostatin; on the 5'-face of the G-quadruplex, over 
60% of the MD runs were truncated, as a result of clustering, halfway through the 
maximum length of 1 ns, and only  ~ 30% completed the 1-ns run. The trend on the 3' 
site is reversed, with ~60% of the MD runs completing the full 1-ns trajectory, while 
only about 30% runs are truncated prior to/at 0.5 ns. This finding may  be a consequence 
of the 3’site shape (i.e more “bowl”-like shape), as well as the conformational demand 
of pyridostatin molecule.
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Table 6.2: Overview of the results and statistics for the two studied G4/ligand complexes.
The rigid RHPS4 was compared with the highly flexible pyridostatin. Both 3'- and 5' sites of the   
telomeric G-quadruplex structure (22-mer, PDB id 1KF1) were examined. 
(* p-value is a statistical value that details how much evidence there is to reject the most common expla-
nation for the data set)
RHPS4 PYRIDOSTATIN
5‘site 3‘site 5‘site 3‘site
No simulations started
No 100-ps blocks
Completed 1 ns 
Truncated prior 0.5 ns 
MOPAC mean [kcal/mol]
MM-GBSA mean [kcal/mol]
MM-PBSA mean [kcal/mol]
No clusters ≥3
Structures within clusters
MOPAC ANOVA grand mean [kcal/mol]
MOPAC ANOVA P-value
MM-GBSA ANOVA grand mean [kcal/mol]
MM-GBSA ANOVA P-value *
MM-PBSA ANOVA grand mean [kcal/mol]
MM-PBSA ANOVA P-value
Correlation MOPAC - MMGBSA
Correlation MOPAC - MMPBSA
Correlation MMGBSA - MMPBSA
141 91 1769 435
275 207 8184 3075
2% 10% 31% 59%
94% 90% 64% 35%
-24.76 -26.37 -39.50 -36.77
-27.04 -27.35 -43.25 -39.53
-25.75 -26.36 -39.49 -37.33
20 7 138 26
105 (75%) 73 (80%) 961 (54%) 119 (27%)
-24.87 -26.87 -40.74 -36.61
1.38x10-11 0.010 2.2x10-16 1.36x10-5
-27.08 -27.52 -44.28 -40.15
0.022 0.269 2.2x10-16 2.13x10-4
-25.75 -26.43 -40.49 -37.30
0.053 0.444 2.2x10-16 9.14x10-7
0.46 0.74 0.835 0.825
0.51 0.52 0.882 0.917
0.70 0.72 0.876 0.860
Graphical representation of the MD runs in their 100-ps “blocks” and their truncation 
along the simulation time, hence the clustering network, is shown in Figure 6.3 for one 
of the pyridostatin conformations (conformation termed as ‘000000’) explored.
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Figure 6.3: Diagram showing truncated completed MD-runs of one of pyridostatin’s 16 conformations.
Conformation termed as ‘000000’ on the 5‘site is shown; The initial grid positions and rotations of the 
individual ligand structures are indicated. The length of corresponding lines represents the length of each 
of the simulations, 100 – 1000 ps, with the red lines representing the clustering network.
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6.4.1 Clustering the multiple molecular dynamics simulations
The clustering of the MD runs was performed on the basis that  once ligand has adopted 
a certain conformation, which was already represented in a pool of structures within 
other clusters, the subsequent ligand's transition would be alike, hence the MD run 
would be truncated, allowing for a new simulation to begin from a different starting 
point on the grid and in different  orientation and/or conformation. Positioning the ligand 
along the grid with 2 Å spacing and 45 degrees rotations (orientations) allowed fine-
sampling of the G-quadruplex surface with sterical requirements of the macromolecule 
being taking into account. 
 To statistically determine the similarity  and difference between individual clus-
ters of structures, one way analysis of variance (ANOVA), was carried out.  In principle, 
ANOVA is a statistical method that allows simultaneous comparisons between two or 
more means, thus it determines whether or not the means of the studied variables are all 
equal. Here, only clusters that contained three and more members were considerd; there 
were 20 RHPS4-clusters on the 5'site and seven RHPS4-clusters formed of three or 
more members, which represented ~80% of all generated RHPS4-clusters. In the case of 
the pyridostatin-formed clusters, there were 138 clusters with three or more members on 
the 5'site, comprising ~55% of the structures generated, and 26 clusters ≥3, spanning 
only ~30% of the structures produced upon structural alignment and clustering. This 
observation suggests that both the shape of the sampled G4-site, as well as the confor-
mational richness of pyridostatin plays a major role in adopting a particular binding 
pose of the ligand. However, mean binding energies obtained for these clusters via 
ANOVA analysis correspond closely to the mean values as calculated for all structures, 
without the consideration of the cluster size (Table 6.2) This will be further discussed in 
the following section.
 The largest clusters of structures obtained from the MD runs are represented in 
Figure 6.4, including the transition paths from the ligand's starting positions on the grid, 
toward the newly-formed cluster of structures. The largest cluster of RHPS4 structures 
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placed on either site of the G-quadruplex (prior to MD simulations) comprised 10 struc-
tures on the 5' face, and 25 structures on the 3' face. Pyridostatin formed a 33-member 
comprising cluster on the 5' site, while the largest cluster on the 3' site was formed of 13 
structures. The 5‘face of the G-quadruplex is flatter, comparing to the 3‘face that  is 
more curved, thus it  provided more “open space” where the ligands in their initial con-
formation were placed, avoiding the steric hindrance of the receptor. The molecules 
within a cluster are likely to follow a corresponding transition. To bring the positions of 
clusters and the orientation of the ligand within individual clusters (with three or more 
members) into visual perspective, simplified representations of the two structurally dif-
ferent ligands were created. These simplified representations with a “boomerang-like” 
resemblance are shown in Figure 6.5, and their triangular shape is defined by simple 
lines, connecting C05, C17 and C22 atoms of RHPS4 (Figure 6.5 a); and atoms C30 and 
C18 with the middle-point of the distance between atoms C4 and N4 of pyridostatin 
(Figure 6.5 b). All clusters with three and more structures were then visualized alto-
gether on the grid, with each of the clusters represented by a single bead (the bead rep-
resented the centre of mass of the ligand). This provided an insight into the overall trend 
of clusters formation on the G-quadruplex 3' and 5' site, as shown in Figure 6.5. The 
bead representation however only  served as one-dimensional description, without a 
sense for the ligand's orientation with respect to other clusters as well as the 
G-quadruplex. Using the boomerang-like representation of the ligands, whose boldness 
(thickness) reflected the size of the clusters, while preserving the information about the 
size of the ligand relative to the G-quadruplex (pyridostatin is a larger ligand, hence 
larger boomerang) the preferred orientation of the ligands was shown.
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Figure 6.5: Clusters of structures of the of the G4/RHPS4 and pyridostatin/G4 complexes.
Simplified representation of the examined ligands, (a) the rigid RHPS4 and (b) the conformationally 
variable pyridostatin, are for the visualization purposes displayed as “boomerangs”, created by connecting 
atoms C05, C17 and C22 atoms of the RHPS4 molecule; and atoms C30 and C18 with the middle point 
connecting atoms C4 and N4 of pyridostatin molecule.  Clusters of structures (≥3) of the G4/RHPS4 and 
the pyridostatin/G4 complexes are shown for both 3’- and 5‘site of the quadruplex, upon structural align-
ment and clustering. To reduce the dimensionality of the complex systems, each of the clusters is repre-
sented by a single “bead” per cluster located on the grid (top), and by a boomerang (triangular) represen-
tation, where the orientation of the resulting clusters is preserved/shown. The boomerang’s size is propor-
tional to the actual size of the ligand with respect to the G-quadruplex, and thickness of the “boomerangs” 
represents the size of the cluster.
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6.4.2 Free energy calculations: semiempirical versus empirical methods
Intermolecular interaction energies of the G-quadruplex/ligand complexes were calcu-
lated for each of the final positions reached by the ligands in particular conformation, 
orientation and starting position on either site of the G-quadruplex. The means of the 
binding energies obtained by semiempirical approach (MOPAC) and molecular 
mechanics-based MM/PB(GB)SA methods as implemented in AMBER11, are summa-
rized in Table 6.2, and graphically represented in Figures 6.6 and 6.7. To ensure consis-
tency and comparability  of the results, all calculations were performed using corre-
sponding five frames representing the very last 10-ps of each completed simulation. The 
MM/PB(GB)SA calculations were performed over short trajectories (five frames, last 
10 ps of each final simulation) upon the trajectory  file format conversion, and MOPAC 
calculations were performed over five separate entries (for each final conformation), 
and their free energy values were averaged into one representative value. 
 Binding energies as calculated by  means of MOPAC, and MM/PB(GB)SA, were 
plotted for each cluster of structures (≥ 3). The clusters of the flexible pyridostatin 
ligand are somewhat energetically different, with the extreme difference of 
~25 kcal/mol between two clusters on the 5‘face (for instance a six-membered cluster 
#8 and a five-membered cluster #46) but no trend of more/less favourable energies with 
respect to a specific region on G-quadruplex were found. The calculated binding ener-
gies are in a good agreement among the methods for both of the ligands bound to either 
terminal site of G-quadruplex (Table 6.2), but there was a considerably higher level of 
correlation of the methods found for pyridostatin compared to RHPS4. This might be a 
consequence of (1) ligand’s flexibility and its conformational variability adopted by 
pyridostatin upon binding, and (2) charge-charge interactions (phosphates of the 
G-quadruplex with positive side chains of pyridostatin) that contribute to binding and 
stabilization of G-quadruplex. While pyridostatin might have a preference for the 5‘site 
of G-quadruplex, by ~4 kcal/mol when compared to the 3‘site, no significant difference 
in RHPS4 binding energies was found between the two sites of the G4, suggesting that 
there may not be a strong preference of the ligand for either of the sites. 
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Figure 6.6: Calculated binding energies of the RHPS4 clusters with G-quadruplex structure.
Binding energies calculated by MOPAC (blue), MM/PBSA (red) and MM/GBSA (green) for RHPS4 
clusters,  obtained by multiple MD-runs are plotted for individual clusters of structures (≥ 3) upon struc-
tural alignment and clustering on 5' (a) and 3' site (c) of G-quadruplex. The dynamic response of the 3' (b) 
and 5' (d) face of the G-quadruplex is shown as mean RMSd value for each cluster (≥ 3), obtained by av-
eraging all the RMSd's of structures within clusters (grey).
Since the side chains of pyridostatin carry a positive charge (the overall net charge +3), 
while the backbone of G-quadruplex has a negative charge, an independent method for 
evaluation of the charge-charge contribution to binding was performed by measuring 
the inverse square distances between each of the positively-charged side chains and the 
negatively-charged phosphates of the DNA backbone within 8 Å cutoff distance. The 
resulting score provided insight into the electrostatic contribution to the pyridostatin-G4 
interaction. (Figure 6.7 a, d). Mean RMSD values within each of the clusters were also 
brought into perspective with the binding-energy and charge-charge contribution to 
binding (pyridostatin only) graphs (Figure 6.7 (b, d) and 8 (c, f). The rational behind 
stability  calculation of the G-quartets on either 3' or 5' site was to quantify the response 
of G-quadruplex to the ligand binding with respect to the strength of the interaction. 
G4-stem is generally stable, while the loops are very flexible even in the native 
G-quadruplex structure, and so RMSD of the loops only would not realistically reflect 
the effect of ligand binding. Both ligands were found to have a stabilizing effect on 
G-quadruplex structure, when compared to G-quadruplex stability with no ligand 
bound.
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Figure 6.7: Calculated binding energies of the pyridostatin clusters with G-quadruplex structure.
Binding energies calculated by MOPAC (blue), MMPBSA (red) and MMGBSA (green) for pyridostatin 
clusters,  obtained by multiple MD-runs,  are shown for individual clusters of structures upon structural 
alignment and clustering on 5' (b) and 3' site (e) of G-quadruplex. Charge-charge contribution to interac-
tion between (+)-ve amino groups on the ligand's side-chains, and (-)-ve phosphate groups of the G-
quadruplex is evaluated by a 'charge-charge' score (yellow) for both 5' (a) and 3'site (d), and the mean 
RMSd values of the heavy atoms of the 5' (c) and 3' (f) site G-quartets of the individual clusters (≥ 3) are 
displayed in (grey).
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6.5 CONCLUSIONS
A systematic and general approach to determining all plausible positions for binding a 
ligand to a G-quadruplex structure was developed. The flexibility of both the target and 
the ligand, as well as any conformational changes upon ligand binding were fully taken 
into consideration. Two structurally different compounds, rigid RHPS4 (with no 
rotatable bonds), and conformationally  variable pyridostatin (with 13 rotatable bonds) 
were compared, both being biologically-active telomeric G-quadruplex binders, inter-
acting with terminal G-quartet of a G-quadruplex through a stacking mode. 
(I) Multiple starting positions for explicit solvent MD simulations were generated 
subsequent to placing the ligands in a grid-like manner and in multiple orientations, 
parallel to the ends of the quadruplex structure. This allowed for large areas of confor-
mational space for both the ligand and its target, together with ligands transitions, to be 
explored. A total of 2436 starting structures (2204 pyridostatin/G-quadruplex complexes 
and 232 RHPS4/ G-quadruplex complexes) were employed, converging into a number 
of stable binding conformations rather than just one. Thus rather than a static model for 
binding, a fully dynamic model was utilized, providing an advantage over a simple 
docking  approach. 
(II) There was a good agreement (consistent energies) between the three methods used 
for binding free energy calculations (i.e semi-empirical PM6-DH2, and force field-
based MM/PBSA and MM/GBSA). The averaged binding energies calculated for the 
rigid ligand RHPS4 were in better agreement than for the flexible pyridostatin molecule 
(with respect to the three methods employed). Notably higher correlations of the bind-
ing free energies predictions were found for the flexible pyridostatin molecule, when the 
individual methods were compared among each other. The highest correlation was 
found between the MOPAC and MM/PBSA predictions for pyridostatin on both 3’ and 
5’ site of G-quadruplex, with a correlation coefficient of 0.88 and 0.92 respectively. 
Close correlation with a semiempirical method (i.e a higher level of theory) suggests a 
good level of accuracy of the force field-based method MM/PBSA, for free energy 
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calculations of a flexible ligand with strong electrostatic contribution to the overall 
interaction.
(III) No significant difference of calculated binding energies was found between the 
3‘face and 5‘face of the G-quadruplex. In terms of the rigid RHPS4 molecule, the aver-
aged binding energies of RHPS4 clusters bound with the 3‘face of G-quadruplex dif-
fered only by ~1 kcal/mol (more favourable) comparing to the 5‘face. However pyrido-
statin has shown an overall preference for the 5‘site stacking interaction with the 
G-quadruplex by ~ 4 kcal/mol difference when compared to the 3‘site. 
(IV) The G-quadruplex grooves were not explored in this study, which could be seen as 
a limitation to the overall “picture”. Although based on experimental data, the end-
stacking mode of interaction is relevant for these two ligands. This study has shown that 
the end stacking G-quadruplex ligands interact in multiple stable binding conformations 
on both the 3’- and 5’ face of the G-quadruplex, without a strong preference for a 
particular “energetically favourable” region.
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==============================================================
CHAPTER 7:
Fragment-based design of G-quadruplex DNA ligands targeting        
c-MYC 
==============================================================
7.1 BACKGROUND:
G-quadruplexes have been found to occur in tandem repeat regions of telomeres242,244 
in eukaryotic organisms and are abundant throughout the GC rich regions of the 
genome, particularly  in gene promoters.73,245 G-quadruplexes have been identified in the 
promoters in of several clinically-relevant oncogenes, notably c-MYC, KRAS, and c-
KIT, amongst others.76 Furthermore, it has been shown that G-quadruplexes that can 
form within the P1 promoter of c-MYC can regulate its transcription. Small molecules 
that bind and stabilize the c-MYC G-quadruplex have since been shown to suppress 
transcriptional activity  in cancer cells.261,262 Ongoing research in the groups of Neidle 
and Balasubramanian have shown the potential of small molecules to attenuate or pro-
mote the transcriptional activity  of the c-KIT oncogene in human cells.263 G-quadruplex 
ligands are not only valuable as tools for elucidating the mechanistic role of these sec-
ondary structural motifs, but also as possible therapies for a range of diseases that 
depend on the expression (and over-expression) of a particular gene.264 The potential of 
G-quadruplex ligands in cancer therapy has been illustrated with CX-3543,265 the first 
G-quadruplex interactive agent to enter human clinical trials, which disrupts nucleolin/
rDNA (i.e recombinant DNA) G-quadruplex in the nucleus. 
 An important challenge arising from the discovery  of these biologically relevant 
G-quadruplexes is the necessity  to identify drug-like small molecules that can discrimi-
nate not only between G-quadruplex and duplex DNA, but also between different 
G-quadruplexes.99 This can be pursued through rational design, designing G-quadruplex 
binding small molecules based on what we know about the secondary structure of the 
G-quadruplex and using molecular modeling approaches. Knowledge of the crystal 
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structures of several complexes between human telomeric quadruplexes and substituted 
naphthalene diimide derivatives79 has led to rational design of improved analogues with 
superior pharmacological properties (Micco et al, to be published). Another approach is 
to use smaller fragments to self-assemble around a labelled or tagged target, whereby 
bound fragments can be identified. Fragment-based methods have successfully been 
used to discover high affinity ligands for protein active sites, as well as target protein-
protein interfaces. For example, Yang et al266 used a thiol-based tethering strategy to 
screen 15.000 fragments to discover an inhibitor for BACE-1 (β-site amyloid precursor 
protein cleaving enzyme), a prominent target in Alzheimers disease. For nucleic acids, 
only a few examples of a fragment-based approach are available in the literature: most 
notably the recent  efforts to target to target RNA riboswitches.267 To date, however, tar-
geting DNA by a fragment-based approach is still largely unexplored.
 This work presents a fragment-based small molecule screen of the c-MYC G-
quadruplex structure, which has been determined by the NMR methods (Nasiri et al, 
manuscript in preparation, 2012). Hit  molecules, which are shown to bind c-MYC 
G-quadruplex structure in vitro and down-regulate cellular c-MYC in human HT1080 
osteosarcoma cells, have been successfully discovered in Balasubramanian’s research 
group (University of Cambridge), with a screening platform against c-MYC DNA, with 
an intercalator-displacement binding assay, where thiazole orange (TO) was used as an 
intercalator. TO is highly  fluorescent when bound to target DNA and quenched after 
displacement (ΛEx= 501nm; Em= 539nm). In preliminary  experiments, the dissociation 
constant (Kd) of TO to c-Myc DNA was determined (Kd = 3.5 µM  ±0.69). Subse-
quently, the intercalator-displacement-assay (IDA) was applied in a high throughput 
fashion to screen an internal fragment library, which has been proven to be suitable for 
targeting RNA riboswiches against the G-quadruplex DNA target. The available frag-
ment library of 1377 fragments were structurally and chemically diverse entries, com-
piled from various commercial sources, kindly  provided by Professor Christopher Abell 
(University  of Cambridge). Library compounds obey the ‘rule of three’, where; MW≤ 
300 Da, clogP ≤ 3, no more than three hydrogen bond donors and acceptors. All frag-
ments were ≥ 95% pure and have ≥ 1mM  aqueous solubility. 15 hits were defined 
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through the statistically-robust assay, and the identified hit fragments were then subdi-
vided in groups based on their chemical structure (Figure 7.1).
Figure 7.1: Top 15 fragment hits selected from the TO-intercalator displacement binding assay HTP 
screening against c-MYC DNA. 
These 15 fragments were subsequently subjected to an in silico study using the NMR structure of 
biologically-relevant G-quadruplex element in human c-MYC promoter region (PDB id 1XAV).
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7.2 AIMS:
From the 15 small-molecule (fragment) hits identified by screening an in-house library 
of fragments by means of an IDA assay (with TO employed as an intercalator), the best 
ten hits were further tested in a dose response titration experiment, and the best five 
fragments were then subjected to Biacore experiments to determine binding affinities 
(used as an independent secondary  counter assay). All the experimental work outlined in 
this chapter was carried out by Balasubramanian’s research group (University  of Cam-
bridge), as described by Nasiri et al (manuscript in preparation, 2012).
 
In parallel with this experimental work, an in silico study was performed with the aim to 
assess whether this could provide a reliable, more rapid and economic approach to find-
ing hit fragments. For the in silico work, the NMR structure of the biologically relevant 
G-quadruplex element in the human c-MYC promoter268 was used (PDB id 1XAV). The 
G-quadruplex adopts an intramolecular parallel-stranded quadruplex conformation with 
three guanine tetrads and three stable side loops, including two single-nucleotide side 
loops and one double nucleotide side loop, connecting the  guanine strands.
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7.3 METHODS:
The NMR structure of the biologically relevant G-quadruplex element in the human c-
MYC promoter268 (PDB id 1XAV) was retrieved from the PDB Database. A full length 
22-mer d([TGA GGG TGG GTA GGG TGG GTA A]) and its 5' truncated version (the 
flanking dT5' removed; i.e 21-mer), were used for a molecular docking study with 15 
best-ranked fragment hits identified by HTP screening (Figure 7.1, page 166). Subse-
quently, explicit solvent MD simulations were carried out for the 15 21-mer/fragment 
complexes, followed by MM/PB(GB)SA131,132,229 calculations.
7.3.1 System setup and molecular docking
The 3D structures of the fragments were built by means of the ChemBio Office suite, 
and their conformations were optimized by a short cycle (500 steps) of MM2269 energy 
minimization procedure (as MM2 is commonly used for small organic molecule calcu-
lations). With the exception of fragment 2F2 (net charge +2) their overall net charges 
were kept neutral. Suggested conformations of those fragments, with functional groups 
attached to their substituted cyclohexane ring, such as 4H11 and 7A3, were inspected by 
means of the Discovery Studio Visualizer program (http://accelrys.com). The equatorial 
position for their functional groups was verified, as it is sterically more plausible than 
the axial position. The 15 fragments were then docked with the energy-minimized 
G4-cMYC 22-mer (1) and the 5' truncated 21-mer (2) using the DOCK v 6.4224 pro-
gram. The entire surface of the G-quadruplexes was defined as a “binding site” (all the 
spheres generated by the sphgen program of DOCK 6, representing the binding site 
were employed (i.e cluster 0) to allow all possible binding poses of the small molecule 
ligands to be examined. As previously  described in the DOCK 6 docking protocol 
(CHAPTER 5, section 5.3.3), the anchor-and-growth strategy for incremental ligand 
construction, allowing for the ligand's flexibility, was employed. Grid-based (primary) 
and the Hawkins GBSA230,231 (secondary) scoring functions were subsequently used to 
rank the three best ligand's orientations, with the highest-ranked binding pose of each 
fragment being further examined.
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7.3.2 Molecular dynamics simulation and MM/PB(GB)SA calculations
5-ns molecular dynamics simulations were performed for the 21-mer alone (as a refer-
ence), and for the 15 21-mer/fragment complexes with the best  binding poses of the 
ligands suggested by molecular docking. All full-atom simulations were performed with 
the GROMACS v 4.5.3 program, employing the parmbsc0161 force field previously 
ported into GROMACS. The topologies and other parameters for the small-molecule 
fragments were obtained via the ACPYPE169 tool, employing the ANTECHAMBER170 
module of the AMBER11 program with the GAFF226 force field. All MD protocols were 
kept identical for consistency of the results. Explicit solvent simulations were per-
formed at T=300K with a time constant for coupling of 0.1 ps under the control of a 
velocity  rescaling thermostat,199 and isotropic constant-pressure boundary conditions 
controlled by the Parinello-Rahman200,201 algorithm of pressure coupling. Long-range 
electrostatics were calculated using the PME122 algorithm with grid spacing of 1.17 Å, 
and the LINCS126 algorithm was employed to constrain all bonds. Non-bonded van der 
Waals interactions were treated in terms of Lennard-Jones 12-6 potential with a 10.0 Å 
cutoff. The solute was soaked in a triclinic box of TIP3P196 water with a minimal clear-
ance of 20.0 Å between periodic images for the starting configurations. Additionally, 
positively-charged K+ counter-ions were included in the systems to neutralize the nega-
tive net-charge on the DNA backbone. In each of the MD runs, there were two 
temperature-coupling groups; DNA with the structural K+ ions (and ligand, when pre-
sent), and water with counter-ions. Subsequently, the systems were subjected to 10,000 
steps of potential energy minimization, followed by 300 ps of molecular dynamics at 
200K while keeping the solutes constrained, and further 100 ps of MD during which the 
systems were slowly heated to 300K and further equilibrated prior to unconstrained 5-ns 
production-level MD trajectory calculations. The time-step applied was 2.0 fs with 
coordinates saved every 5.0 ps. The initial 500 ps were then rejected for the subsequent 
MM/PB(GB)SA calculations, that were carried out over 450 frames representing the last 
4.5 ns of the 5-ns production runs of the 21-mer/fragment complexes. A corresponding 
protocol previously described in  CHAPTER 6, methodology  section 6.3.3. was applied 
here.
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7.4 RESULTS AND DISCUSSION:
The bound fragment positions found by the docking for the truncated c-MYC 21-mer 
(T5’ removed) are shown in Figure 7.2, together with schematic drawing of the native 
c-MYC 22-mer (PDB id 1XAV). A corresponding numbering of quadruplex bases was 
used (Figure 7.2 a). The truncated 21-mer was of greater relevance comparing to the 22-
mer, as the former was also employed in the experimental part  of this study. Thus only 
the results concerning the 21-mer will be discusses further.  All fragments, with the 
exception of 7A3, were found to be docked within the T14-A15 loop region. Fragment 
7A3 docked within the  groove formed between the third G4-tetrad (G9-G13-G18-G22) 
and the 3’-terminal residues stacking over the top  of the 3rd G4-tetrad (Figure 7.2 b,c). 
This finding is in accord with the experimental cell-based studies, where different 
behavior of fragment 7A3 was observed compared to the rest of the 15 fragments.
Figure 7.2: Schematic views of the c-MYC 22-mer G-quadruplex, and binding poses of the 15 fragments 
with the truncated 21-mer, found by the DOCK6 procedure.
(a) the cMYC 22-mer schematic drawing; strand directionality is indicated by the arrows, and the loops-
forming nucleotides are highlighted by beige circles (Adapted from Ambrus et al.,  2004). The 21-mer was 
formed by deletion of the 5’-thymine as shown. (b,c) Two views of the 21-mer with binding poses of the 
fragments found by DOCK6, in ribbon representation (green) with guanines in grey, and loop-forming 
nucleotides highlighted in beige. The fragments in stick representation are colored orange.
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In terms of the structural stability observed throughout the 16 (15 complexes and the 
reference native 21-mer structure) 5-ns MD runs, the G-quadruplex structures remained 
entirely  intact (with the structural K+ ions present in the channel) for all complex-bound 
(21-mer/fragment complex) and the reference (21-mer alone) model. RMSD values for 
the all-atom 21-mer/fragment complexes, and the complex-bound 21-mers respectively, 
as a function of simulation time were used as a measure of stabilization of the 15 com-
plexes. Correspondingly, RMSD values for the all atom reference 21-mer (the uncom-
plexed 21-mer) were calculated. The simulation for this structure stabilized at ~2.4 Å, 
and ~1.4 Å respectively  for the time-averaged RMSD plot (Figure 7.3 a). However, 
whereas majority  of the ligands remained at  their initial binding site (the T14-A15 
loop), or at its vicinity, throughout the MD run, fragments 2G5, 11D6 and and eventu-
ally 9B4 left the binding site completely, and 'escaped'. Also fragment 2F2 was found to 
be moving away from binding site toward the end of the 5-ns simulation time, while 
fragment 1B2 only  flipped-out of the binding site in the last 1 ns of the 5-ns MD run. 
Two fragments, 1B5 and 6A8 were found to relocate from their initial binding site on 
top of the 3rd G4-tetrad formed by G9-G13-G18-G22, with the latter stacking with G18 
(Figure 7.3 b, c, Table 7.1). 
 The flexible regions of the 21-mer G-qudruplexes (16 in total, one reference 21-
mer and 15 complex-bound) were also analyzed by examining their structural fluctua-
tions in terms of the RMSF as a function of residue number (Figure 7.3 d). Overall, the 
G-tetrads have are very stable, with most of the overall structural flexibility (indicated 
by peaks) in the quadruplexes in large part arising from the loops. However, these fluc-
tuations are relatively marginal, reflecting the nature of the stable, single- (T10 and 
T19) and double-nucleotide (T14-A15) loops. All 15 fragments showed a stabilizing 
effect on the T14-A14 loop  region where they were initially docked, when compared to 
the reference 21-mer (Figure 7.3 d). The binding of fragments 6H8, 4H11 or 15B11 
significantly reduced loop flexibility. In contrast, the 5’-flanking G5-A6 sequence show 
increased flexibility in almost all of the 21-mer/fragment complexes (except with frag-
ment 14H8) compared to the native c-MYC 21-mer. The 3’-flanking T23-A24-A25 
sequence is stacked over the top of the 3rd G4-tetrad in all 16 models, showing some 
            PART 2
173
structural flexibility, suggesting that the 3’-end maintains a stable conformation over the 
course of the 5-ns simulation.
Figure 7.3: RMSD and RMSF plots showing the stability of the simulated systems during the MD simu-
lations of the c-MYC 21-mer/fragment complexes.
(a) all-atom RMSD of the truncated 21-mer with respect to the initial (black) and the time-averaged 
(grey) structure; (b) all-atom RMSD plots of the G4/fragment complexes with respect to their starting 
structures,  and (3) all-atom RMSD of the complex-bound 21-mer with respect to the time-averaged struc-
tures over the 5 ns MD run; Fragments 2G5, 11D6 and 9B4 ‘escape’ the binding site; (d) RMSF per resi-
due plots of the complex-bound 21-mer with respect to the initial structure. The truncated 21-mer (alone) 
is shown in black dotted line, to demonstrate the fragment’s stabilizing effect.
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Relative binding energies for each of the 21-mer/fragment complexes were calculated 
from the MD  trajectories by means of the MM/PB(GB)SA program (AMBER11 pack-
age). MM/PB(GB)SA computes the binding energies employing the thermodynamic 
cycle that combines molecular mechanics (MM) energies with implicit solvent  methods 
(Table 7.1). The initial 0.5 ns of each trajectory were rejected, and the last 4.5 ns repre-
sented by 450 frames were used for the calculations. Plausible hydrogen bonds formed 
between the individual fragments and the truncated c-MYC 21-mer were initially de-
termined by means of the UCSF Chimera program upon docking the fragments with the 
G-quadruplex target (this is the ‘static state’, using the best ranked fragment pose upon 
docking). Hydrogen bonds formation throughout the short MD runs was also mapped 
with the VMD molecular visualization program (with hydrogen bond distance cutoff 3.2 
Å). Only hydrogen bonds lasting at least 0.5 ns were considered (Table 7.1) 
 The overall score for each fragment was assessed, by ranking each according to 
its predicted binding energy  (MM/PBSA and MM/GBSA) and stability from 1 (best) to 
15 (worst), and combining their scores. Hydrogen bonds formed between the G4/
fragment complexes were also considered within the overall score (Table 7.2). Overall, 
fragments 6H8 and 16C10 performed the best with consistent predicted binding energy 
and complex stability throughout the MD trajectories. These gave improved 
G-quadruplex stabilization, hydrogen bond formation and strongly favourable binding 
energies (with PB and GB values in good agreement). Fragments 7A3, 4H11 and 15B11 
also ranked towards the high end of the group. At the other side of the ranking scale, 
2G5 and 11D6 did not appear to perform well since their intermolecular binding interac-
tions were significantly  less favourable than any other of the 15 fragment studies, and 
moreover, both completely left the binding site during the course of 5-ns MD runs.
Table 7.2: Fragments ranked according to their binding energies and stability plots, over the 15 5-ns MD 
simulations.
[kcal/mol]
GB 15B11 6A8 6H8 14H8 11G3 16C10 1B2 1B5 4H11 9B4 7A3 2F2 1H3 2G5 11D6
PB 7A3 6H8 4H11 16C10 9B4 2F2 1H3 15B11 1B2 6A8 1B5 11G3 14H8 11D6 2G5
ORDER 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
RMSD (complex)16C10 11G3 14H8 6H8 7A3 4H11 1H3 9B4 2F2 1B2 1B5 15B11 6A8 11D6 2G5
RMSD (DNA) 16C10 11G3 2G5 14H8 6H8 11D6 9B4 1B5 4H11 7A3 1H3 2F2 1B2 6A8 15B11
RANK 6H8 16C10 7A3 4H11 15B11 11G3 14H8 6A8 9B4 1B2 1H3 1B5 2F2 11D6 2G5
            PART 2
175
            PART 2
176
FR
A
G
-
M
E
N
T
H
B
 (d
oc
ke
d)
H
B
 (t
ra
je
ct
or
y)
 
fr
ag
m
en
t’s
 lo
ca
tio
n
R
M
SD
 [Å
]
G
B
/S
A
 sc
or
e
M
M
/P
B
(G
B
)S
A
 [k
ca
l/m
ol
]
sc
or
e
1B
5
7A
3
1H
3
9B
4
2G
5
11
D
6
6H
8
16
C
10
14
H
8
11
G
3
15
B
11
6A
8
1B
2
2F
2
4H
11
(U
C
SF
 c
hi
m
er
a)
(V
M
D
, c
ut
of
f 3
.2
 Å
)
(M
D
 5
-n
s)
G
4/
fr
ag
m
en
t
G
4 
on
ly
[k
ca
l/m
ol
]
G
B
 
PB
 
E
ne
; r
m
s
G
13
_O
4’
--
-
T1
4-
A
15
 lo
op
 →
 3
‘s
ite
2.
69
2.
32
-1
9.
24
-1
0.
58
-9
.7
1
19
; 1
9
G
8_
O
P
G
8;
 G
22
gr
oo
ve
2.
33
2.
35
-2
0.
25
-9
.2
8
-1
3.
87
12
; 1
5
G
16
_O
P
G
17
T1
4-
A
15
 lo
op
2.
44
2.
42
-2
0.
79
-8
.4
6
-1
0.
89
20
; 1
8
G
13
_O
4’
G
12
; G
13
es
ca
pe
s
2.
51
2.
27
-2
0.
41
-9
.5
1
-1
1.
37
15
; 1
5
G
16
_O
P
--
-
es
ca
pe
s
4.
55
2.
18
-1
9.
67
-2
.7
5
-1
.4
7
29
; 1
8
G
16
_O
P
--
-
es
ca
pe
s
3.
73
2.
26
-2
0.
84
-2
.6
4
-1
.9
8
29
; 2
0
G
16
_O
P
G
12
T1
4-
A
15
 lo
op
2.
32
2.
26
-2
0.
35
-1
1.
85
-1
2.
70
5;
 9
G
13
_N
2;
 G
18
_O
P
G
12
; G
13
T1
4-
A
15
 lo
op
2.
10
2.
07
-1
8.
40
-1
1.
21
-1
1.
76
10
; 2
G
12
_N
2;
 G
13
_O
3’
; A
15
_N
3
G
13
; G
17
T1
4-
A
15
 lo
op
2.
25
2.
19
-1
8.
64
-1
1.
74
-9
.0
6
17
; 7
G
12
_N
2;
 G
16
_O
P
G
12
; G
16
T1
4-
A
15
 lo
op
2.
19
2.
15
-1
8.
89
-1
1.
46
-9
.4
4
17
; 4
G
12
_N
2;
 G
13
_O
3’
; T
14
_O
P
G
12
; G
13
T1
4-
A
15
 lo
op
2.
71
2.
74
-2
0.
51
-1
2.
41
-1
0.
56
9;
 2
7
G
13
_N
2;
 A
15
_O
3’
G
18
T1
4-
A
15
 lo
op
 →
 3
‘s
ite
2.
97
2.
70
-2
0.
97
-1
2.
20
-1
0.
08
12
; 2
7
G
13
_N
2;
 G
17
_O
P
G
13
T1
4-
A
15
 lo
op
 *
2.
66
2.
60
-2
1.
08
-1
0.
83
-1
0.
37
16
; 2
3
G
16
_O
P
G
13
; T
14
es
ca
pe
s 
2.
63
2.
51
-2
2.
64
-8
.6
9
-1
1.
00
18
; 1
2
G
16
_O
P;
 G
12
_N
2
G
13
; A
15
; G
17
T1
4-
A
15
 lo
op
2.
38
2.
33
-2
4.
53
-9
.9
7
-1
2.
53
12
; 1
5
Ta
bl
e 
7.
1:
 O
ve
rv
ie
w
 o
f t
he
 re
su
lts
 o
f t
he
 c
M
Y
C
 2
1m
er
 in
 si
lic
o 
st
ud
y 
w
ith
 1
5 
sm
al
l-m
ol
ec
ul
e 
fr
ag
m
en
ts
.
H
yd
ro
ge
n 
bo
nd
s 
(H
B
) 
su
gg
es
te
d 
up
on
 d
oc
ki
ng
, a
s 
w
el
l a
s 
th
ro
ug
h 
th
e 
co
ur
se
 o
f 
th
e 
M
D
 ru
ns
 a
re
 l
is
te
d.
 T
he
 R
M
Sd
 v
al
ue
s 
fo
r 
th
e 
en
tir
e 
G
-q
ua
dr
up
le
x/
fr
ag
m
en
t 
co
m
pl
ex
es
, a
nd
 th
e 
co
m
pl
ex
-b
ou
nd
 2
1m
er
 o
nl
y 
ar
e 
su
m
m
ar
iz
ed
. R
el
at
iv
e 
bi
nd
in
g 
in
te
rm
ol
ec
ul
ar
 e
ne
rg
ie
s 
w
er
e 
ca
lc
ul
at
ed
 v
ia
 b
ot
h 
G
B
 a
nd
 P
B
 im
pl
ic
it 
so
lv
en
t 
m
et
ho
ds
. (
Th
e 
fr
ag
m
en
ts
 a
re
 li
st
ed
 a
cc
or
di
ng
 to
 th
ei
r s
tru
ct
ur
al
 si
m
ila
rit
y,
 a
nd
 c
ol
or
-c
od
in
g 
co
rr
es
po
nd
s t
o 
Fi
gu
re
 7
.3
)
Binding poses of the best ranked fragments 6H8, 16C10 and 7A3 are shown in Figure 
7.4 in detail, both upon docking, and at the end of their 5-ns MD runs (last frame of the 
5-ns trajectory was used). This finding is in accord with the experimental work, as 
fragments 6H8 and 16C10 were identified among the four best inhibitors (16C10, 11D6, 
6H8 and 14H5, Figure S7.1 in Supplementary  section), reducing c-MYC in all repeat 
experiments, with fragment 6H8 being the top hit identified both experimentally and in 
silico. It is worth mentioning, that the two best-ranked fragments are structurally very 
similar (Figure 7.1), with oxygen atoms in their di-substituted cyclohexane ring being 
either in para (6H8) or meta (16C10) positions; these were then found to be involved in 
specific hydrogen-bond formation with N2 of G12. Similarly, 2G5 and 11D6 at the very 
end of the ranking spectra are structurally alike, and together with fragment 9B4 they all 
moved away from their binding site through the course of the MD run. Structurally-
similar fragments 1H3 and 1B5 also ranked towards the lower end of the group, how-
ever fragment 7A3, which is also structurally similar to 1H3 and 1B5, performed well in 
terms of stability and binding energy. The difference may lay in an extra methyl group 
at the para position of the disubstituted cyclohexane ring, which may contribute towards 
its preferable binding properties at the G-quadruplex groove.
Figure 7.4 : Best predicted fragments 6H8, 16C10 and 7A3 shown bound to the G4-cMYC 21mer. 
The predicted binding poses of fragments upon docking are shown in panels (a, c, e), and at the end of the 
5-ns MD runs in panels (b, d,  e); Graphical representation of the G-quadruplex is corresponding to Figure 
7.2,  with the fragment shown in stick representation, and colored brown (6H8), yellow (16C10) and tur-
quoise (7A3) and by heteroatom. (Fragments’s colors also correspond to figure 7.3).  Hydrogen bonds 
formed between the fragments and 21-mer bases are shown in cyan.
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7.5 CONCLUSIONS:
An in silico study focused on fragment-based design of G-quadruplex DNA ligands tar-
geting c-MYC was performed in parallel with an experimental approach, in order to 
assess the feasibility of providing a more rapid, reliable and economic approach to find-
ing hit fragments. The 15 fragments that  were employed have been previously  screened 
and determined by NMR methods as being able to bind c-MYC G-quadruplex structure 
in vitro, and they  were shown to down-regulate cellular c-MYC in human HT1080 
osteosarcoma cells.
(I) A combination of several computational tools were applied to identification of a 
promising hit, namely (in a sequential manner) molecular docking of the fragments with 
a truncated 21-mer c-MYC G-quadruplex, explicit solvent MD simulations of the indi-
vidual proposed complexes, and their free binding energy  calculations, provided a valu-
able insight into the dynamic behavior and stability of these complexes. 
(II) The docking-proposed binding poses of the fragments with the 21-mer c-MYC were 
in excellent agreement with the experimental results, where only fragment 7A3 was 
observed bound elsewhere than the rest of the fragments.  
(III) The combined in silico approaches then led to a successful prediction of two best-
ranked fragments, 6H8 and 16C10, that were also among the best experimentally 
determined compounds, with an ability  to significantly reduce c-MYC in all repeat 
experiments. Fragment 6H8 was ranked as the best inhibitor in both experimental, and 
in silico study.
(IV) Employing multiple computational tools simultaneously in hit identification was 
shown to provide an advantage to using a single technique, such as rigid receptor dock-
ing in this case. If only docking was employed here, fragments 4H11, 2F2 or 1B2 would 
have been suggested as promising inhibitors (based on the GB/SA scores), neither of 
them being on the list of most-successful inhibitors selected experimentally.
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Supplementary information for CHAPTER 7:
Figure S7.1: c-MYC experimental data.11
The target c-MYC protein translation was investigated in presence of hit fragments by quantification of 
c-MYC expression using a c-MYC specific antibody. Combined data from five plates, at least 18 data 
points per well. Statistical significance per ANOVA (Kruskall-Wallis test; P<0.0001).  Four treatments 
significantly reduced c-MYC in all repeat experiments; these were 16C10, 11D6, 6H8 and 14H5, of 
which 6H8 was the best inhibitor.  These fragments were used to carry out further binary treatments, 
whereupon all binary treatments (125 mM of each component) induced a significant reduction (ANOVA). 
The best binary mixture was 6H8*11D6. 
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Molecular modeling and computational chemistry methods have become profoundly 
integrated into the drug discovery process over the last quarter century. Indeed, in silico 
approaches can provide various levels of insight into the drug-target (ligand-target) 
binding and recognition, which require application of different computational methods 
along the drug discovery pipeline. In the earliest stages of the drug discovery process, 
homology  modeling and molecular dynamics simulations (or Monte Carlo sampling) 
can contribute to target validation, and target's conformational sampling respectively. 
Virtual screening (structure-based or ligand-based) for potential small molecule ligands 
can be then applied at the hit identification stage, together with 3D-pharmacophore 
modeling. Free energy calculations of ligand-receptor binding are then another natural 
application of in silico approaches in drug discovery. Further explicit solvent molecular 
dynamics simulations of the receptor-ligand complexes may  be applied in the proceed-
ing stages of the pipeline to complement and rationalize experimental observations in 
the absence of structural data. Molecular modeling (and computational chemistry) 
methods may both challenge and complement current experimental techniques by pro-
viding spatial and temporal resolutions to allow for  in-depth analysis and further under-
standing of the mechanisms underlying the biological and chemical systems.270
 Molecular dynamics simulations are being increasingly mated with numerous 
experiments, as simulations may  trace system behavior over large “spatiotemporal 
domain-length scales” (i.e atomic precision, femtosecond resolution, and timescales up 
to microseconds).270 Together with the computational power, that has tremendously  in-
creased in the last two decades or so (with parallel capability  of current computer archi-
tectures), the amount of produced data (i.e trajectories) is proportionally increasing. 
However, effective post-processing analysis tools and methods that  can efficiently deal 
with the volume of the data are yet needed. There has also been a continuous improve-
ment in the simulation algorithms and parameters, but  their current limitations (i.e the 
simulation time scale that is not biochemically relevant to biomolecular dynamics, and 
the approximate nature of the biomolecular force fields) should be always kept in mind 
to avoid mis-interpretation of the simulation results. Whereas more approximate, 
empirical, methods are adequate for large biomolecular systems simulations, more deli-
cate questions that require the quantum electronic effects to be accounted for (i.e bonds 
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forming/breaking, polarization effects or charge transfer) need to be answered at higher 
level of theory, by means of quantum mechanics-based approaches.
 MD simulations served as the imaginary “spine” of this thesis, as they were ap-
plied, and purposefully tailored to all studied systems that are described here. In first 
part of the thesis, explicit solvent full atom molecular dynamics simulations of the 
STAT3βtc homodimer:DNA complex were performed, in both its phosphorylated and 
unphosphorylated form, as well as in complex-bound and latent monomeric form. Valu-
able insight into the aspects of the recognition at both protein-DNA-solvent, and 
protein-protein level was reached, together with structural explanation of experimen-
tally determined point  mutations. The modeling results provided a theoretical platform 
for X-ray studies of the unphosphorylated STAT3-DNA complex, supporting the re-
cently emerged evidence STAT3 non-canonical signaling (Nkansah et al, manuscript 
submitted for publication, 2012). A number of point mutations of the residues involved 
in protein-DNA hydrogen bond formation have been also examined experimentally, by 
means of X-ray  crystallography (Parkinson et al, work in progress), aiming to explore 
the 3D structural consequences of naturally occurring disease-related mutations. Fur-
thermore, single-site mutations of STAT3β proteins will be generated to probe the con-
formational surface of the SH2 domain, in the presence or absence of selected ligands. 
Multiple receptor conformations obtained from the MD trajectory were directly  imple-
mented into in silico approaches to the discovery of novel STAT3-STAT3 inhibitors for 
chemotherapeutic intervention, employing a comparative multiple receptor conforma-
tion molecular docking study, providing an advantage over more traditional single 
receptor conformation studies, as the dynamic aspect of the receptor behavior was in-
troduced here.
 A truly  dynamic (fully  flexible) approach to receptor-ligand binding was taken in 
the second part of the thesis. A systematic and general approach to determining all plau-
sible positions for binding a ligand to a G-quadruplex structure was developed. The 
flexibility of both the target and the ligand, as well as any conformational changes upon 
ligand binding were fully taken into consideration. Free binding energies of the vast 
number of ligand binding poses were then evaluated by means of semiempirical and 
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empirical methods, showing a very good correlation of these methods when the confor-
mationally variable ligand was considered. In the last chapter, combined  computational 
techniques were applied to fragment-based approach towards G-quadruplex stabilizing 
ligands, that was performed in parallel to ongoing experimental work. The combined in 
silico approaches led to a successful prediction of two best-ranked fragments, that were 
also among the best  experimentally determined compounds, with an ability to signifi-
cantly reduce c-MYC.
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